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Summary
Extended-spectrum beta-lactamases (ESBL) mediate resistance to 3rd generation 
cephalosporins and aztreonam in Enterobacteriaceae and pose major clinical 
problems. Screened Enterobacteriaceae were collected from PHW Microbiology 
ABM Swansea laboratory and were demonstrated phenotypically to be ESBL- 
producers by BSAC methods. Isolates were identified using the BD Phoenix™ 
Automated system and Bruker Daltonics MALDI Biotyper. 138 isolates were 
genetically defined as ESBL-producers (103 Escherichia coli, 32 Klebsiella spp., 2 
Enterobacter cloacae and 1 Citrobacter freundii) and 4 isolates (2 E. coli, 1 
Enterobacter cloacae and 1 Morganella morganii) were genetically confirmed as 
AmpC-producers.
PCR analysis revealed that the most prevalent ESBLs were CTX-M (n=133), 
predominantly Group 1 (n=128), of which 51% (66/128) contained the ZS26-CTX- 
M-15 link region, which is characteristic for epidemic E. coli strain A. PFGE 
confirmed that these isolates had a clonal relatedness to epidemic E. coli strain A. 
Allele-specific PCR revealed that all E. coli positive for ZS26-CTX-M-15 belonged 
to clone 025b-ST131 (found internationally), which has a high virulence potential 
and encompasses diverse PFGE patterns.
With the molecular epidemiology established; the sensitivity and performance of 
phenotypic screening and confirmatory assays were analysed so that optimal 
strategies to handle difficult-to-identify ESBL resistance traits could be determined. 
In this study, the sensitivity of ESBL screening increased to 100% when ceftazidime 
was used alongside cefpodoxime.
Isolates harbouring ESBL genes are often difficult to treat, as options are greatly 
limited. Susceptibility to various well-established antibiotics, along with temocillin 
and tigecycline, were investigated. Temocillin and tigecycline were effective against 
98% and 89% of all isolates tested. The carbapenems were the most active 
antibiotics with 100% of isolates susceptible to imipenem and meropenem and 99% 
susceptible to ertapenem.
Biofilm production in E. coli was also investigated. The pgaABCD gene locus was 
detected in all ESBL and AmpC-producing E. coli isolates (n=105); however, only 
38% of these produced a phenotypic biofilm.
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Chapter 1: Introduction
The introduction chapter will give a fundamental overview of the aspects involved in 
this thesis. Each results chapter with then provide more indepth information along 
with discussion points.
1.1 Enterobacteriaceae
The Enterobacteriaceae are a large heterogeneous family of Gram-negative straight 
rods, with an approximate length of 1.5 pm. They are non-spore forming bacteria that 
share many common characteristics. Generally, Enterobacteriaceae are catalase 
positive, oxidase negative organisms that can ferment many carbohydrates and 
reduce nitrate to nitrite (Mims, 1998, Brooks, 2007). They can be found with or 
without a capsule and be motile or non-motile (depending on the presence of 
flagella) (Brooks, 2007). The term Enterobacteriaceae was first established in 1937 
by Otto Rahn to describe morphologically and biochemically similar organisms 
(Bacteriology, 1981, Janda, 2006). Common genera of Enterobacteriaceae include 
Escherichia, Klebsiella, Enterobacter, Proteus, Salmonella, Shigella, Serratia, 
Citrobacter, Morganella, Yersinia, Hafnia and Providencia (Mims, 1998). In 1984, 
there were 69 recognised species of Enterobacteriaceae (Farmer et al., 1985) 
whereas now there are in excess of 170. Primarily located (often as commensal flora) 
within the intestinal tract of human and animals, Enterobacteriaceae are one of the 
most abundant facultative anaerobes of this region making up approximately 109 
CFU/g of faeces (Mims, 1998).
Enterobacteriaceae can be serotyped based upon the presence of antigens. There are 
three main antigens outlined by Edwards and Ewing (1972) and these are known as 
the O (somatic), H (flagellar) and K (capsular). The O antigen is a heat-stable 
somatic antigen consisting of a phospholipid and polysaccharide complex. This 
complex is composed of approximately 60% polysaccharides, 20-30% lipids and 
3.5-4.5% hexosamine. It is the nature of the terminal group along with the order 
found within the polysaccharide chain that determines the specificity of the O 
antigen. The H antigen or flagella are heat-labile proteins which are composed of 
flagellins. Specificity of the H antigen is determined by the amino acid content and 
order found within the flagellin (Edwards and Ewing, 1972). The flagella are
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essential for bacterial motility (Cooke, 1974). The K antigen or capsule is made up 
of polysaccharides. It can be subdivided based upon physical and chemical 
properties (Edwards and Ewing, 1972). The capsule is outside of the cell wall, 
important serologically (Cooke, 1974) and is often associated with protecting the cell 
(Johnson, 1991).
1.1.1 Escherichia coli
The Escherichia genus was discovered by Theodor Escherich (1857-1911). He first 
described the bacterium Bacterium coli commune, which was later commonly known 
as Escherichia coli (Sussman, 1985). There are 7 species found within the genus of 
Escherichia (Table 1.1) (http://www.bacterio.cict.fr). However, E. coli is the species 
of medical importance. E. coli is a Gram-negative, mobile, non-fastidious, bile 
tolerant lactose fermenting organism, which is capable of growth at temperatures up 
to 44°C (Mims, 1998).
E. coli can be divided up into four phylogenetic groups known as A, B l, D and B2. 
It is thought that groups A and B 1 are commensal-associated whereas groups D and 
B2 are associated with extraintestinal E. coli (Clermont et al., 2009, Picard et al., 
1999). E. coli is usually located in the gut of humans and animals and is often found 
to colonise the lower end of the urethra and vagina. It is an opportunistic pathogen 
which is commonly associated with urinary-tract infections, wound infections 
following surgery, hospital-acquired pneumonia, infections of the gastrointestinal 
tract (diarrheal disease), neonatal meningitis and sepsis. Transmission of E. coli may 
be via the faecal-oral route or food-borne; infection may also be endogenously 
contracted (Mims, 1998).
Using serotyping, O (somatic), H (flagellar), K (capsular) antigens can be identified, 
as described above. Additionally, E. coli also have F (fimbrial) antigens (Mims, 
1998). Fimbriae are associated with adhesion and conjugation but not motility 
(Cooke, 1974). The two main types of fimbriae found in E. coli are known as P 
fimbriae and type I fimbriae. These fimbriae are important in pathogenesis as they 
aid in the adherence of the bacteria to the host cell, thereby, permitting bacterial 
colonisation and stimulating inflammation. Additionally, colonising factors e.g. CFA 
I and II, K88 and K99 are adhesins associated with gastrointestinal tract infections
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(Mims, 1998). In some E. coli strains, the capsule may also play a role in adhesion, 
as well as providing protection from phagocytosis (Johnson, 1991). The K1 capsular 
type is associated with neonatal meningitis (Mims, 1998). The polysaccharide 
capsule, associated adhesins and exopolysaccharide production e.g. colanic acid and 
poly-0-1, 6-N-acetyl-D-glucosamine (PGA) (Wang et al., 2004) can also play a role 
in the ability of E. coli to form a biofilm (Pratt and Kolter, 1998). Biofilms are a 
strategy of bacterial survival (Hall-Stoodley and Stoodley, 2009), as they play a role 
in protection (Costerton et al., 1999) and due to a complex structure, they can 
arguably prevent antimicrobial agents from penetrating (Jefferson et al., 2005) and 
can provide protection from phagocytes. Biofilms are discussed in Chapter 8.
Other virulence factors associated with E. coli include the production of haemolysin 
(capable of lysing some blood cells), siderophores e.g. aerobactin (promotes 
bacterial growth) and serum resistance (this allows the bacteria to escape killing by 
the innate immune system as it blocks the complement cascade) (Johnson, 1991). 
Additionally, some enteric E. coli are also associated with enterotoxins e.g. in ETEC 
(enterotoxigenic E. coli), a cholera-like heat-labile toxin (LT) is produced and in 
EHEC (enterohaemorrhagic E. coli), shiga-like cytotoxin or verotoxin associated 
with haemolytic uremic syndrome is produced (Mims, 1998, Nataro and Kaper, 
1998).
Table 1.1 Escherichia species (http://www.bacterio.cict.fr)
No. Escherichia species
1. Escherichia adecarboxylata
2. Escherichia albertii
3. Escherichia blattae
4. Escherichia coli
5. Escherichia fergusonii
6. Escherichia hermannii
7. Escherichia vulneris
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1.1.2 Klebsiella spp.
Named after the German bacteriologist, Edwin Klebs (1834-1913) 
(http://www.bacterio.cict.fr), the genus Klebsiella are represented by Gram negative, 
non-motile, non-fastidious, oxidase negative, lactose fermenting encapsulated rod­
shaped bacteria which have the capability of aerobic and anaerobic respiration 
(Mims, 1998). Originally, the taxonomy of Klebsiella divided isolates into three 
species according to the disease types caused. These were K  pneumoniae, K  
ozaenae and K  rhinoscleromatis (Podschun and Ullmann, 1998). However, there 
are now 12 species and 3 subspecies listed (Table 1.1.1) 
(http://www.bacterio.cict.fr).
There are currently three classification systems used to group the Klebsiella spp. 
known as the Cowan, Barcomb and Orskov systems. Differences primarily lie with 
the classification of K. pneumoniae. The Orskov system identifies K  pneumoniae, K  
ozaenae and K. rhinoscleromatis to be subspecies of K  pneumoniae whereas the 
Cowan and Bascomb systems list them as individual species. In the UK and ex- 
Commonwealth countries, the Cowan system is used. However, in the USA and 
parts of Europe, the Orskov system is followed (Podschun and Ullmann, 1998).
Klebsiella are opportunistic bacteria, which usually colonise the intestinal tract and 
often the nasalpharynx of humans. However, Klebsiella has also been found to 
inhabit the mucosal surfaces of some animals and is also ubiquitous in the 
environment e.g. in soil and water (Mims, 1998, Podschun and Ullmann, 1998).
K  pneumoniae is thought to the most medically important species of Klebsiella and 
infection is associated with hospitalised immunocompromised patients who often 
have underlying disorders such as diabetes mellitus and chronic obstructive 
pulmonary disease. Klebsiella can cause a number of medical conditions such as 
sepsis, pneumonia, urinary-tract infections and soft tissue infections (Podschun and 
Ullmann, 1998) and the transmission of infection is usually through contact spread 
or is endogenous (Mims, 1998).
Using serotyping, two main antigens can be identified for Klebsiella spp; the O 
(somatic) and K (capsular). Surrounding the bacterium is a well developed and
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complex polysaccharide capsule, which gives it protection from phagocytosis and 
also its characteristic mucoid appearance. Also surrounding the bacterium are a 
number of pili (type 1 and type 3) adhesins, which allow the bacteria to adhere to 
host cells (Mims, 1998, Podschun and Ullmann, 1998). These virulence factors 
prepare the Klebsiella for causing infection.
Table 1.2 Klebsiella species and subspecies (http://www.bacterio.cict.fr)
No. Klebsiella species and subspecies
1. Klebsiella granulomatis
2. Klebsiella mobilis
3. Klebsiella ornithinolytica
4. Klebsiella oxytoca
5. Klebsiella ozaenae
6. Klebsiella planticola
7. Klebsiella pneumonia
Klebsiella pneumoniae subsp. ozaenae 
Klebsiella pneumoniae subsp. pneumonia 
Klebsiella pneumoniae subsp. rhinoscleromatis
8. Klebsiella rhinoscleromatis
9. Klebsiella singaporensis
10. Klebsiella terrigena
11. Klebsiella trevisanii
12. Klebsiella variicola
5
1.1.3 Other Enterobacteriaceae
As listed in 1.1, there are many genera associated with the Enterobacteriaceae 
family. In this study, E. coli and Klebsiella spp. were the main focus. However, 
Enterobacter spp., Citrobacter spp. and Morganella morganii were also 
investigated.
1.1.3.1 Enterobacter spp.
The genus name of Enterobacter was proposed in 1960 by Hormaeche and Edwards 
(Hormaeche and Edwards, 1960). Enterobacter spp. are Gram-negative, lactose 
fermenting, bile tolerant, oxidase negative rod-shaped bacteria. Enterobacter spp. 
have non-fastidious growth and can grow aerobically and anaerobically. These 
bacteria usually colonise the gastrointestinal tract of humans and animals and can 
also be found in the environment. Infection with Enterobacter spp. is associated with 
the urinary and respiratory tracts (Mims, 1998). The Enterobacter genus can be 
divided into 24 species and 2 subspecies (Table 1.3) (http://www.bacterio.cict.fr).
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Table 1.3 Enterobacter species and subspecies (http://www.bacterio.cict.fr)
No. The Enterobacter species and subspecies
1. Enterobacter aerogenes
2. Enterobacter agglomerans
3. Enterobacter amnigenus
4. Enterobacter arachidis
5. Enterobacter asburiae
6. Enterobacter cancerogenus
7. Enterobacter cloacae 
Enterobacter cloacae subsp. cloacae 
Enterobacter cloacae subsp. dissolvens
8. Enterobacter cowanii
9. Enterobacter dissolvens
10. Enterobacter gergoviae
11. Enterobacter helveticus
12. Enterobacter hormaechei
13. Enterobacter intermedius
14. Enterobacter kobei
15. Enterobacter ludwigii
16. Enterobacter nimipressuralis
17. Enterobacter oryzae
18. Enterobacter pulveris
19. Enterobacter pyrinus
20. Enterobacter radicincitans
21. Enterobacter sakazakii
22. Enterobacter soli
23. Enterobacter taylorae
24. Enterobacter turicensis
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1.1.3.2 Citrobacter spp.
The Citrobacter genus is thought to be closely related to the genera of Escherichia 
and Salmonella. Members of this genus are Gram negative, non-sporeforming, 
facultative anaerobes that are motile by the means of peritrichous flagella (Dworkin 
and Falkow, 2006, Werkman and Gillen, 1932). As the name suggests, Citrobacter 
spp. utilise citrate as their carbon source. The genus name Citrobacter and its species 
C. freundii was determined by Werkman and Gillen in 1932. These bacteria were 
found to produce trimethylene glycol from glycerol (Werkman and Gillen, 1932). 
This organism, along with C. koseri are opportunistic pathogens that have been 
isolated from urine, blood and wounds (Dworkin and Falkow, 2006). There are 11 
species of Citrobacter (Table 1.4) (http://www.bacterio.cict.fr).
Table 1.4 Citrobacter species (http://www.bacterio.cict.fr)
No. The genus Citrobacter
1. Citrobacter amalonaticus
2. Citrobacter braakii
3. Citrobacter farmeri
4. Citrobacter freundii
5. Citrobacter gillenii
6. Citrobacter koseri
7. Citrobacter murliniae
8. Citrobacter rodentium
9. Citrobacter sedlakii
10. Citrobacter werkmanii
11. Citrobacter youngae
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1.1.3.3 Morganella spp.
The Morganella spp. are Gram negative rods, which are also motile by the means of 
a peritrichous flagella. They are also capable of the deamination of phenylalanine 
and tryptophan. Morganella spp. are related to other Enterobacteriaceae such as 
Proteus and Providencia (Dworkin and Falkow, 2006).
Typically, Morganella spp. are commensal organisms that inhabit the gut of humans 
and animals. However, they may also colonise the respiratory and urinary tract. They 
are opportunistic bacteria and for example, the colonisation of urinary catheters can 
lead to urinary tract infection. Infection with Morganella spp. is associated with 
immunocompromised and in particular, hospitalised patients (Dworkin and Falkow, 
2006). There are 2 species of Morganella found within the genus and 2 subspecies 
(Table 1.5) (http://www.bacterio.cict.ff).
Table 1.5 Morganella species and subspecies (http://www.bacterio.cict.fr)
No. Morganella species and subspecies
1. Morganella morganii
Morganella morganii subsp. morganii
Morganella morganii subsp. sibonii
2. Morganella psychrotolerans
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1.2 The Gram-negative cell wall
The Gram-negative cell wall is a structure capable of protecting the cell (Beveridge, 
1999). It contains an outer membrane which has a bilayer of phospholipids and a 
number of proteins/lipoprotein structures e.g. porins along with the 
lipopolysaccharide layer (LPS). The LPS consists of components such as lipid A and 
the carbohydrate based O antigens (outlined in 1.2.1). The inner membrane 
(cytoplasmic membrane) is also made up of a bilayer of phospholipids and contains 
the penicillin binding proteins (PBPs). Between the outer and inner membrane a 2-3 
nm layer of peptidoglycan which is loosely cross linked can be found within the gel­
like matrix known as the periplasmic space (Mims, 1998, Walsh, 2003, Greenwood, 
2000, Beveridge, 1999). Peptidoglycan is a polymer consisting of glycan strands 
cross linked through short peptides (Schleifer and Kandler, 1972).
1.2.1 The lipopolysaccharide layer (LPS)
The LPS layer varies between bacteria and has many functions. It is essential for 
bacterial survival, can cause some human disease e.g. septic shock (Wang and 
Quinn, 2010) and is also responsible for preventing the entry of large hydrophilic 
molecules. However, small hydrophilic molecules have the ability to enter through 
aqueous channels and porins in the outer membrane (Mims, 1998).
The LPS layer can be divided into three main components: lipid A, O antigen and 
core polysaccharides (Wang and Quinn, 2010). Lipid A is a hydrophobic constituent 
of the LPS, which is often responsible for the toxic effects in bacteria (Raetz and 
Whitfield, 2002). The O antigen plays a protective role against the environment 
(Wang and Quinn, 2010). It consists of a polysaccharide structure and this structure 
defines the O antigen’s serological specificity. The numbers of O antigens vary from 
species to species. For example in E. coli, there are 170 O serotypes (Nataro and 
Kaper, 1998, Raetz and Whitfield, 2002). Core polysaccharides can be divided into 
two types: the inner core and outer core. The outer core acts as an attachment site for 
the O antigen and often serves as a serological specificity marker in organisms where 
no O antigen is produced. The inner core is well conserved and is associated with the 
lipid A proximal region (Raetz and Whitfield, 2002).
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1.2.2 Peptidoglycan synthesis
Peptidoglycan, also known as mucopeptide or murein, is an essential component of 
the cell wall. It protects the cell from osmotic lysis and determines the cell shape 
(Jacobs et al., 1997). Peptidoglycan is made up from alternating units of /?-l, 4- 
linked A-acetylglucosamine (NAG) and A-acetylmuramic acid (NAMA) (Schleifer 
and Kandler, 1972, Walsh, 2003, Greenwood, 2000, Mims, 1998). The first step of 
peptidoglycan synthesis (Figure 1.1) takes place in the cytoplasm and involves the 
formation of uridine diphosphate (UDP)-NAMA from UDP-NAG by the addition of 
a lactic acid moiety derived from phosphoenolpyruvate. Next, UDP-NAMA receives 
three amino acids, Z-alanine, D-glutamic acid and mesodiaminopimetic acid (or L- 
lysine in Gram positive organisms). Two Z)-alanine (D-ala) residues are formed 
from Z-alanine, via the enzymes alanine racemase and D-alanine synthetase. The D- 
ala-D-ala residue is subsequently added to the aforementioned three amino acids 
associated with the NAMA, thus forming the NAMA-pentapeptide. This is passed 
from the cytoplasmic membrane to a lipid carrier in the cell membrane whereby 
UDP-NAG transfers NAG to the NAMA-pentapeptide. This unit is then transported 
across the cell membrane where it is added to the existing peptidoglycan in the cell 
wall. Once transported, final cross-linking via transpeptidation by penicillin binding 
proteins (PBPs) takes place (Mims, 1998, Walsh, 2003, Greenwood, 2000). PBPs are 
found in most bacteria and in E. coli they are numbered 1A, IB, 2, 3, 4, 5 and 6 
(Selwyn et al., 1980) (Figure 1.2). PBPs are encoded chromosomally and mutations 
may affect their number and affinity to p-lactam antibiotics (Katzung, 1995).
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Figure 1.1 A simplified schematic diagram o f  bacterial cell wall synthesis and the 
site o f  action o f  p-lactam antibiotics. NA G -  A-acetylglucosamine, N A M A  -  
7V-acetylmuramic acid and ala -  alanine. Adapted from G reenwood (2000).
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Figure 1.2 A simplified schematic diagram o f  the Gram-negative cell wall. The outer 
membrane is a lipid bilayer with hydrophilic proteins called porins. Beneath this 
m em brane the thin peptidoglycan layer can be found sitting in the periplasmic space. 
The periplasmic space also contains P-lactamases. However, P-lactamases can also 
be found on the surface o f  the cytoplasmic m em brane whereby penicillin binding 
proteins (PBPs) can also be found. Adapted from Katzung (1995).
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1.3 p-lactam antibiotics
P-lactam antibiotics all contain a common p-lactam ring structure. Penicillins have a 
P-lactam ring that is fused to a 5 membered thiazolidine ring whereas the p-lactam 
ring in cephalosporins is fused to a 6 membered dihydrothiazine ring (Figure 1.3) 
(Greenwood, 2000, Samaha-Kfoury and Araj, 2003). The main focus of p-lactam 
antibiotics is to prevent the transpeptidation steps in the final stages of peptidoglycan 
synthesis (Mims, 1998, Katzung, 1995).
P-lactam antibiotics bind to bacterial cell receptors known as penicillin binding 
proteins (PBPs). It has been suggested that due to structural similarity between 
penicillins and cephalosporins to D-ala-Z)-ala, a component of peptidoglycan (see 
1.2.2), the CO-N bond of the p-lactam ring in the antibiotic competes with the CO-N 
bond of Z)-ala-D-ala for the active site of the PBP transpeptidase enzyme (Katzung, 
1995, Greenwood, 2000, Walsh, 2003).
Once the p-lactam antibiotic has bound to PBPs, the transpeptidase reaction is 
inhibited, as covalent penicilloyl complexes are formed between the PBPs and the P- 
lactam. As a result, the peptidoglycan lacks sufficient cross linkages (Selwyn et al., 
1980, Katzung, 1995, Mims, 1998). Additionally, autolytic enzymes or hydrolases 
are activated in some microorganisms resulting in cell lysis in isotonic conditions or 
in the formation of spheroplasts in hypertonic conditions (Samaha-Kfoury and Araj, 
2003, Mims, 1998).
1.3.1 Penicillins
Obtained from the Penicillium mould, the original preparations of penicillins were 
found to contain a mixture of closely related compounds. These compounds were 
labelled as penicillin F, G, K and X (Selwyn et al., 1980). Developments in 
manufacturing along with the properties of the compound, allowed the exclusive 
extraction of penicillin G or benzylpenicillin from Penicillium chrysogenum. The use 
of penicillin was ground-breaking in the treatment of many bacterial infections such 
as scarlet fever, bacterial endocarditis, meningococcal meningitis, puerperal sepsis, 
staphylococcal sepsis, pneumococcal pneumonia, gonorrhoea, syphilis, anthrax and 
also in the treatment of some anaerobic infections (Katzung, 1995, Walsh, 2003, 
Greenwood, 2000).
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The spectrum of activity for penicillins was broadened by the development of 
penicillin derivates i.e. the semi-synthetic modifications of side chain variants 
(Figure 1.3). This allowed the p-lactam antibiotic to have an increased potency and 
also aided in overcoming resistance (Walsh, 2003).
1.3.2 Cephalosporins
Cephalosporin antibiotics are produced by Cephalosporium fungi. It was observed 
that this fungus generated antibiotics that resembled the penicillins. From this 
fungus, cephalosporin C was obtained but never marketed. However, the common 
cephalosporin nucleus, 7-aminocephalosporanic acid, was derived from 
cephalosporin C and produced on a large scale (Katzung, 1995). From 7- 
aminocephalosporanic acid, an array of cephalosporins with different properties was 
developed. Cephalosporins are active against Gram-positive and Gram-negative 
bacteria and have an analogous mode of action to penicillins (Figure 1.3). However, 
the extra atom in the fused ring structure allowed for further semi-synthetic 
modifications (Katzung, 1995, Walsh, 2003, Greenwood, 2000).
1.3.2.1 First generation cephalosporins
The first generation cephalosporins were available circa 1975 (Greenwood, 2000). 
These compounds had narrow spectrum activity and were effective against Gram- 
positive (not methicilin resistant Staphylococcus aureus - MRSA) and some Gram- 
negative organisms. First generation cephalosporins include cefadroxil, cefazolin, 
cephalexin, cephalothin, cephapirin and cephradine (Katzung, 1995).
1.3.2.2 Second generation cephalosporins
The second generation cephalosporins were termed ‘expanded spectrum’ due to their 
activity (Walsh, 2003). These compounds were less active against Gram-positive 
organisms when compared to the activity of the first generation cephalosporins 
(Walsh, 2003, Katzung, 1995). Second generation cephalosporins were stable against 
p-lactamases and had a greater activity against Gram-negative organisms for 
example E. coli and other enterobacteria, B. fragilis and H. influenza. However, they 
have no activity against enterococci or P. aeruginosa. Second generation 
cephalosporins include cefaclor, cefamandole, cefonicid, ceforanide, cefoxitin,
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cefmetazole, cefoetan, cefuroxime, cefprozil, loracarbef and cefpodoxime (Katzung, 
1995).
1.3.2.3 Third generation cephalosporins
The third generation cephalosporins were termed ‘broad spectrum’ antibiotics 
(Walsh, 2003). These compounds had stability to many p-lactamases and improved 
activity to most Gram-negative bacteria. Some have pronounced activity against P. 
aeruginosa, for example ceftazidime. Third generation cephalosporins differed from 
their predecessors in that they were capable of reaching the central nervous system 
(Katzung, 1995). Third generation cephalosporins include cefoperazone, cefotaxime, 
ceftazidime, ceftriaxone, cefixime and moxalactam (Greenwood, 2000, Katzung, 
1995).
1.3.2.4 Fourth generation cephalosporins
The properties of fourth generation cephalosporins are similar to those of the third 
generation. These compounds have a greater activity against Gram-negative 
organisms and P. aeruginosa. Fourth generation cephalosporins include cefepime 
and cefpirome (Walsh, 2003).
With each generation of cephalosporins, greater activity against Gram-negative 
bacteria can be demonstrated. This is due to better penetration through porins of the 
Gram-negative outer membrane (determined by acyl chains), an increased affinity 
for PBP targets and a decreased catalytic efficiency towards hydrolysis by P- 
lactamases (Walsh, 2003, Greenwood, 2000).
1.3.3 Cephamycins
Cephamycins were first isolated from Streptomyces spp. in 1972 (Stapley et al., 
1972) and were found to share their antimicrobial properties with the cephalosporins 
owing to sharing the same cephem nucleus (Greenwood, 2000). Some examples of 
cephamycins include latamoxef flomoxef, loracarbef and cefoxitin (Greenwood, 
2000).
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1.3.4 Monobactams
Monobactams are based upon a monocyclic P-lactam ring structure with no 
associated fused ring system (Katzung, 1995). They are active against Gram- 
negative bacteria similarly to 3rd generation cephalosporins like cefotaxime and 
ceftriaxone but exhibit no activity against Gram-positive or anaerobic organisms 
(Katzung, 1995, Greenwood, 2000). Aztreonam is currently the only licensed 
monobactam. This compound contains the same acyl chain as that found in 
ceftazidime (Walsh, 2003).
1.3.5 Carbapenems
The carbapenems are also a group of p-lactam containing compounds, which are 
stable against most p-lactamases. This group of compounds exhibit the broadest 
spectrum of activity and so have increased activity against Gram-positive and Gram- 
negative organisms including the obligate anaerobes. Carbapenems include 
imipenem, meropenem, doripenem and ertapenem. It was found that imipenem was 
inactivated by dihydropeptidases in renal tubules and it is therefore administered 
with a dihydropeptidase inhibitor (Greenwood, 2000, Walsh, 2003, Katzung, 1995). 
The carbapenems are considered to be the antibiotics of choice for treating serious 
ESBL infection (Livermore and Hawkey, 2005, Peirano and Pitout, 2010, Dhillon 
and Clark, 2011). However, it has been noted that carbapenems should be used in 
optimal doses and restricted to appropriate patients in order to minimise resistance 
development (Edwards and Betts, 2000).
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Figure 1.3 The structure of p-lactam antibiotics. A -  penicillins, B -  cephalosporins, 
C -  carbapenems, D -  monobactams and E -  clavams. Figure reproduced from 
Walsh et al., (2003) page 38.
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1.4 p-lactamases
Often found in the periplasmic space or extracellularly (Bush, 1988) (Figure 1.2), p- 
lactamases are enzymes produced by certain bacteria that can prevent destruction by 
p-lactam antibiotics. The p-lactamase enzyme binds to the carbonyl moiety of the p- 
lactam ring, thus hydrolysing its amide bond. When the p-lactam ring is hydrolysed, 
penicillinoic acid, which is a stable product, is produced therefore inactivating the 
function of the p-lactam antibiotic (figure 1.4) (Greenwood, 2000, Katzung, 1995, 
Samaha-Kfoury and Araj, 2003, Sykes and Matthew, 1976).
The first p-lactamase was discovered in E. coli by Abraham and Chain in 1940, after 
the development of penicillin; penicillinases capable of hydrolysing penicillin were 
found in S. aureus. These .S', aureus penicillinases were thought to be the ‘scourge’ 
of penicillin during the 1950s and so prompted research into alternative solutions 
such as the development of cephalosporins (Medeiros, 1997, Selwyn et al., 1980, 
Walsh, 2003). It is now estimated that over 850 P-lactamases have been identified 
(Drawz and Bonomo, 2010).
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Figure 1.4 The inactivation of the p-lactam antibiotics by the p-lactamase enzyme. 
The figure illustrates the opening of the p-lactam ring in A — penicillins, B — 
cephalosporins and C -  carbapenems. Figure reproduced from Walsh et al., (2003) 
page 108.
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1.4.1 p-lactamase inhibitors: overcoming resistance to p-lactam antibiotics
The p-lactamase inhibitors resemble p-lactam antibiotics and are structurally based 
on a clavam scaffold or a penicillinic acid sulfone. They are poor substrates for PBPs 
and therefore usually have no clinically useful antimicrobial activity (Drawz and 
Bonomo, 2010, Bush, 1988). However, they have p-lactamase inhibitor properties 
which protect p-lactam antibiotics from inactivation. They are capable of protecting 
the antibiotic by binding to the p-lactamases and so preventing the destruction of p- 
lactam antibiotics (Mims, 1998). Enzyme inhibitors can bind either reversibly or 
irreversibly. A reversible inhibitor can bind to an enzyme in such a way that the 
enzyme activity can be restored whereas the opposite is true for an irreversible 
inhibitor. Reversible inhibitors may be less effective than irreversible inhibitors as 
they are often hydrolysed as a substrate (Drawz and Bonomo, 2010, Bush, 1988).
Clavulanic acid, derived from Streptomyces clavuligerus, has a clavam structure. 
This was the first naturally occurring bicyclic p-lactam that did not possess a 
penicillin or cephalosporin nucleus (Reading and Cole, 1977). Other examples of P- 
lactamase inhibitors are sulbactam and tazobactam. These have penicillinic acid 
sulfone structures and were designed to have similar properties to clavulanic acid i.e. 
the inhibition of class A p-lactamases (Bush, 1988, Drawz and Bonomo, 2010).
1.5 The classification of p-lactamases
There are two major schemes of classification for p-lactamases, which are 
commonly currently utilised. These are known as the Ambler molecular 
classification scheme (Ambler, 1980) and the Bush-Jacoby functional classification 
system (Bush and Jacoby, 2010).
1.5.1 The Ambler molecular classification scheme
As the name suggests, the Ambler molecular classification scheme focuses on
classifying p-lactamases at the molecular level. It uses protein homology, in
particular amino acid similarity, as a basis for determining class (Ambler, 1980).
There are four main classes within the Ambler classification scheme and these are
labelled from A to D. p-lactamases belonging to classes A, C and D all have serine at
their active site (Medeiros, 1997) whereas class B p-lactamases are known as
metallo-p-lactamases and are often associated with zinc (Paterson and Bonomo,
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2005). Class A, C and D p-lactamases share conserved amino acid homology to 
penicillin binding proteins and D-alanyl-£)-alanine peptides which are the target of 
P-lactam antibiotics (Medeiros, 1997).
Class A is the largest group of p-lactamases. These have a high protein sequence 
similarity which is thought to be derived from a single ancestral gene. Although they 
have homologous protein structure, their enzymatic properties and substrate profiles 
differ greatly. Class A enzymes have a substrate preference of penicillin. Enzymes of 
this class can be cell bound, periplasmic or secreted and derived from plasmid or 
chromosomal genes and can belong to both Gram-positive and Gram-negative 
organisms (Ambler, 1980, Ambler et al., 1991).
The class B p-lactamases, or metallo-p-lactamases, are smaller than class A p- 
lactamases and require a metal co-factor e.g. zinc. These p-lactamases are inhibited 
by metal ion chelators and are not inhibited by p-lactamase inhibitors such as 
clavulanic acid, tazobactam and sulbactam (Bush, 1998, Wang et al., 1999).
The class C p-lactamases were discovered by Jaurin and Grundstrom (1981) in an 
AmpC-producing E. coli K12 strain. It was found to have a substrate preference for 
cephalosporins and had no homology with class A (Jaurin and Grundstrom, 1981).
The class D p-lactamases were discovered in 1988 after it was noted that the OXA 
group of enzymes were found to lack structural similarities to the class A, B and C p- 
lactamases. It was thought that they had a ‘distinct evolutionary origin’ and so the 
fourth class of P-lactamases were formed within the Ambler scheme (Huovinen et 
al., 1988).
1.5.2 The Bush-Jacoby functional classification system
The Bush-Jacoby functional classification system uses functional similarities, in 
particular substrate and inhibitor profiles, to classify p-lactamases (table 1.6) (Bush 
and Jacoby, 2010). Prior to the current Bush-Jacoby classification system and 
previous versions thereof, other functional schemes were devised to classify P- 
lactamases e.g. classification schemes by Sawai, Richmond and Sykes, Sykes and 
Matthew and Mitsuhashi and Inoue. However, unlike the Bush system(s), these
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schemes did not combine functional properties i.e. substrate and inhibitor profiles 
with molecular structure (Bush et al., 1995).
The Bush-Jacoby system contains four main enzyme groups. Group 1 consists of 
cephalosporinases that are not fully inhibited by clavulanic acid, group 2 contain 
penicillinases, cephalosporinases and broad spectrum p-lactamases which are 
generally inhibited by p-lactamase inhibitors (active-site-directed), group 3 is made 
up of metallo-P-lactamases which are active against penicillins, cephalosporins and 
carbapenems and are poorly inhibited by p-lactamase inhibitors except EDTA and p- 
chloromercuribenzoate and finally, group 4 are penicilinases that are not inhibited by 
clavulanic acid (Bush, 1989a). However, differences between the 1989 and 1995 
systems arose due to the variations in TEM and SHV p-lactamases. Therefore, three 
new subgroups were added to group 2 to further diversify the former 2b subgroup. 
These were named 2be, 2br and 2bf. Extended-spectrum p-lactamases (ESBLs) were 
added to the 2be group whereas enzymes with a reduced affinity to p-lactamase 
inhibitors were added to the 2br group. 2bf represents enzymes that hydrolyse 
carbapenems but are poorly inhibited by P-lactamase inhibitors (Bush, 1989a, Bush, 
1989c, Bush, 1989b, Bush et al., 1995).
The functional classification system was reviewed once more in 2010 to incorporate 
more variations (the Bush-Jacoby system). Further subgroups were added within 
group 2. The 2ber subgroup represents ESBL TEM enzymes which are potentially 
resistant to clavulanic acid and the 2ce subgroup consists of the extended-spectrum 
carbenicillinase RTG-4 (CARB-10) with activity against cefepime and cefpirome. 
Other new additions to group 2 include 2de and 2df. The 2de subgroup consists of p- 
lactamases with extended spectrum ability to hydrolyse cloxacillin or oxacillin but 
not carbapenems whereas 2df contain p-lactamases that have the capability of 
hydrolysing carbapenems.
Additionally, subgroups were added to diversify group 1 and group 3. These new 
subgroups were named le, 3a and 3b respectively. Group le refers to variants of 
group 1 that have an increased activity towards ceftazidime. This type of variant is 
also known as an extended-spectrum AmpC or ESAC (Bush and Jacoby, 2010). 
Within group 3, 3a now refers to plasmid encoded metallo-p-lactamases e.g. VIM
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and IMP (Queenan and Bush, 2007) whereas group 3b includes metallo-p-lactamases 
which preferentially hydrolyse carbapenems over penicillins or cephalosporins 
(Segatore et al., 1993). Another difference between the current Bush-Jacoby system 
and previous versions is the removal of group 4. It was stated that these enzymes 
could potentially belong to another group within the classification system if 
characterisation is undertaken to obtain more information (Bush and Jacoby, 2010).
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1.6 Extended-spectrum p-lactamases (ESBL)
ESBLs can be defined as [3-lactamase enzymes capable of hydrolysing the 
penicillins, 1st, 2nd and 3rd generation cephalosporins and the monobactam 
aztreonam. They are unable to hydrolyze cephamycins and carbapenems. ESBLs are 
inhibited in vitro by the p-lactamase inhibitor clavulanic acid (Philippon et al., 1989, 
Paterson and Bonomo, 2005).
1.6.1 The classification of extended-spectrum p-lactamases (ESBL) and AmpC 
According to Ambler et al., (1991) ESBLs belong to molecular class A or D. TEM, 
SHV and CTX-M ESBLs are designated class A whereas, OXA ESBLs belong to 
class D (Huovinen et al., 1988, Bush and Jacoby, 2010, Paterson and Bonomo, 
2005). AmpC p-lactamases belong to the Ambler class C (Jaurin and Grundstrom, 
1981). However, classes A, C and D all have serine at their active site (Huovinen et 
al., 1988, Bush and Jacoby, 2010, Paterson and Bonomo, 2005, Jaurin and 
Grundstrom, 1981, Bradford, 2001).
The Bush-Jacoby system places ESBLs into the group 2be subgroup. This highlights 
that ESBLs are variants of group 2b enzymes such as TEM-1 and SHV-1 but have 
extended-spectrum activity (Bush and Jacoby, 2010, Bush et al., 1995). OXA 
enzymes belong to group 2d (Bush, 1989c). Using this classification system, AmpC 
p-lactamases are classified as being group 1 or group le (Bush and Jacoby, 2010, 
Bush, 1989a, Bush, 1989b, Bush et al., 1995).
1.6.2 The diversity of ESBL enzymes
The types of ESBL enzymes are diverse. In the UK, there are three main types of 
ESBL enzyme namely TEM, SHV and CTX-M. However, other rarer ESBL 
enzymes also exist.
1.6.2.1 TEM
The name TEM is derived from a Greek patient, Temoneira, from whom TEM-1 was 
first discovered in an E. coli isolate in 1965 (Paterson and Bonomo, 2005, Heritage 
et al., 1999). TEM-1 was found to have narrow-spectrum activity and was found to 
hydrolyse ampicillin at a greater rate than carbenicillin, oxacillin or cephalothin. Its
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twin enzyme, TEM-2, shares the same properties as TEM-1 but varies in isoelectric 
point (Paterson and Bonomo, 2005, Jacoby and Medeiros, 1991).
The first ESBL-TEM enzyme was found in France in 1987. Originally named CTX- 
1, it was later renamed TEM-3 (Sirot et al., 1987, Paterson and Bonomo, 2005). 
TEM-3 differs from TEM-2 by two amino acid substitutions 
fhttp://www.lahev.org/studies). However, controversially, a report by Du Bios et al., 
suggests that an ESBL-TEM enzyme was in fact possessed earlier by a Klebsiella 
oxytoca strain which was isolated in Liverpool in 1982 (Du Bois et al., 1995). An 
outbreak of TEM-1-producing K. oxytoca was treated with ceftazidime and 
subsequently, the K. oxytoca was found to be resistant. This indicates that ESBLs 
emerge as a response to selective pressure (Du Bois et al., 1995). There are currently 
190 different TEM-type p-lactamase enzymes listed and their amino acid sequences 
vary in comparison to TEM-1 or TEM-2 ('http://www.lahev.org/studies).
It has been noted that the point mutations leading to amino acid substitutions within 
the TEM-type p-lactamases are clustered within five areas of the enzyme and each 
adjacent to seven evolutionary conserved elements. These elements are located near 
to the active site and therefore increase the size available to accommodate oxyimino- 
components of cephalosporins thus allowing broad-spectrum resistance (Joris et al., 
1991, Du Bois et al., 1995, Stiirenburg and Mack, 2003).
As outlined in 1.4.2, P-lactamase inhibitors such as clavulanic acid serve to protect 
its accompanying p-lactam antibiotic e.g. penicillins from hydrolysis by 
p-lactamase enzymes (Bush, 1988). However, resistance to these p-lactamase 
inhibitors, specifically clavulanic acid, was seen in E. coli isolates in the early 1990s. 
It was believed that this was due to an overproduction of the non-ESBL TEM-1 p- 
lactamase enzyme (Reguera et al., 1991). Bacteria exhibiting TEM-type enzymes 
and which are inhibitor resistant, often do not effectively hydrolyse 3rd generation 
cephalosporins and so are not classed as ESBL. Unfortunately, a number of ESBL- 
producing TEM were found to exhibit resistance to p-lactamase inhibitors. These 
have been referred to as ‘complex mutants’ (Fiett et al., 2000, Poirel et al., 2004, 
Sirot et al., 1997). Inhibitor resistant SHV have also been discovered (Prinarakis et
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al., 1997, Manageiro et al., 2010). However, inhibitor resistant CTX-M remains to be 
seen (Ripoll et al., 2011).
1.6.2.2 SHV
The name SHV is derived from sulphydryl variable, which is a description of the 
biochemical properties of the SHV p-lactamase enzyme (Heritage et al., 1999, 
Paterson and Bonomo, 2005). In 1972, the first sulphydryl variable (SHV) P- 
lactamase was identified with the isolation of SHV-1 (Chaves et al., 2001). It was 
found to be the chromosomally encoded p-lactamase within the Klebsiella spp. 
SHV-1 was found to be a narrow-spectrum p-lactamase with the ability to hydrolyse 
penicillins (Heritage et al., 1999).
The first ESBL-SHV was isolated from isolates of K. pneumoniae (Heritage et al., 
1999) and was designated SHV-2 (Kliebe et al., 1985). It was found that the SHV-2 
enzyme had the same isoelectric point as SHV-1 (Kliebe et al., 1985). However, 
further analysis demonstrated a single amino acid substitution: a glycine to serine 
mutation at position 238 (Barthelemy et al., 1988). It was found that the cavity used 
by the P-lactam substrate of SHV-2 was of an increased size, thereby maximising the 
space used to accommodate the bulky chains of cephalosporins such as cefotaxime 
and ceftazidime (Joris et al., 1991). In doing so, there is an increased affinity during 
hydrolysis. However, as a disadvantage, the p-lactam is at an increased distance from 
the serine active site at position 70, thus decreasing enzyme activity (Heritage et al., 
1999, Huletsky et al., 1993). To compensate for this, it is thought that mutations in 
the promoter region may increase the production of ESBLs (Nuesch-Inderbinen et 
al., 1995, Heritage et al., 1999). There are currently 141 SHV enzymes listed, each 
varying in the number and type of amino acid substitutions 
(http://www.lahey.org/studies).
SHV was initially only associated with K. pneumoniae. However, the first isolation 
of SHV enzymes from bacteria other than K. pneumoniae was discovered in E. coli 
isolates. By the mobilisation of transmissible plasmids, SHV is now also found in 
other Enterobacteriaceae, for example C. diversus, K. oxytoca, M. morganii, P. 
aeruginosa and B. cepacia (Heritage et al., 1999).
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1.6.2.3 CTX-M
The name CTX-M is directly linked to the word cefotaxime signifying its 
hydrolysing ability. The ‘M’ of CTX-M is donated from the word Munich, where 
CTX-M was first isolated (Peirano and Pitout, 2010). Unrelated to TEM or SHV 
P-lactamases (Peirano and Pitout, 2010), CTX-M are presumed to be derived from 
the chromosome of the environmental bacteria Kluyvera spp. namely 
K. cryocrescens, K. ascorbata and K. georgiana. It is believed that these CTX-M 
enzymes emerged in other species via a genetic escape and mutation from this 
medically unimportant species (Poirel et al., 2002, Bonnet, 2004, Woodford et al., 
2004) by genetic mobile elements such as ISEScpl. CTX-M genes are carried on 
plasmids that are often associated with TEM-1, TEM-2, OXA-type and SHV-type 
p-lactamases (Bonnet, 2004). These plasmids are also often associated with 
resistance genes for other antibiotics e.g. aminoglycosides, chrloramphenicol and 
tetracycline (Peirano and Pitout, 2010).
There are currently 120 CTX-M enzymes listed (http://www.lahey.org/studies). 
These enzymes can be subdivided into 5 phylogenetic groups: 1, 2, 8, 9 and 25 
(Bonnet, 2004). Within each group, members have approximately >94% amino acid 
homology and <90% amino acid homology between groups (Peirano and Pitout, 
2010). For example, CTX-M group 1 includes CTX-M-1, CTX-M-3, CTX-M-10, 
CTX-M-12, CTX-M-15, CTX-M-23, CTX-M-32 and CTX-M-55 amongst others. 
CTX-M group 2 includes CTX-M-2, CTX-M-4, CTX-M-4L, CTX-M-5, CTX-M-6, 
CTX-M-7, CTX-M-20 and Toho-1 amongst others. CTX-M group 9 includes CTX- 
M-9, CTX-M-13, CTX-M-14, CTX-M-16, CTX-M-17, CTX-M-19, CTX-M-21, 
CTX-M-27 and Toho-2 amongst others. CTX-M group 25 includes CTX-M-25 and 
CTX-M-26 (Bonnet, 2004) and CTX-M group 8 includes CTX-M-8, CTX-M-40 and 
CTX-M-63 (Rossolini et al., 2008).
The CTX-M enzymes are less effective than TEM or SHV enzymes at hydrolysing 
penicillins. However, they show significant hydrolysis against cephalosporins such 
as cefepime and cefpirome (Bonnet, 2004).
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1.6.2.4 Other ESBL enzymes
Aside from TEM, SHV and CTX-M, there are an abundance of rarer ESBLs in 
existence. Examples include TLA, BES-1, BEL-1, and SFO-1. However, although 
often uncommon, OXA, PER, VEB, GES are being identified more frequently (Naas 
et al., 2008).
Not all of the OXA class of P-lactamases have ESBL properties, as some are 
incapable of hydrolysing the oxyiminocephalosporins. Needless to say, a proportion 
of OXA enzymes do pertain to have ESBL activity. For example, OXA-45 was 
found in a P. aeruginosa strain capable of hydrolysing all antibiotics except 
polymyxin B (Toleman et al., 2003). OXA enzymes are predominantly associated 
with P. aeruginosa but have also been seen in Enterobacteriaceae (Naas et al., 
2008).
Originally detected in P. aeruginosa (Nordmann et al., 1993), PER ESBLs are now 
found in E. coli, K. pneumoniae, P. mirabilis, Alcaligenes faecalis, S. enterica, 
Vibrio cholera and Acinetobacter spp. (Paterson and Bonomo, 2005). The PER-1 p- 
lactamase is capable of hydrolysing penicillin and cephalosporins. It is inhibited by 
clavulanic acid (Nordmann et al., 1993).
VEB-1, or Vietnamese extended-spectrum p-lactamase, is thought to be homologous 
with the PER-1 enzyme (Naas et al., 2008, Bradford, 2001). It demonstrates activity 
against amoxicillin, ticarcillin, piperacillin, cefotaxime, ceftazidime and aztreonam 
and is inhibited by clavulanic acid (Poirel et al., 1999). GES, BES-1, BEL-1 and 
TLA-1 all hydrolyse broad-spectrum cephalosporins and are inhibited by p- 
lactamase inhibitors (Naas et al., 2008).
1.7 AmpC
ampC genes have been found chromosomally in a number of Enterobacteriaceae 
e.g. Citrobacter freundii, Enterobacter spp., E. coli, Morganella morganii, Proteus 
rettigeri, Providencia stuartii, Serratia marcescens, Hafnia alvei and Yersinia 
enterocolitica. They are also found in other species including Acinetobacter spp., 
Aeromonas spp., Chromobacterium violaceum, Lysobacter lactemgenus, 
Ochrobactrum anthropi, Pseudomonas aeruginosa, Psychrobacter immobilis and
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Rhodobacter sphaeroides (Philippon et al., 2002). In these organisms, AmpC 
expression is regulated by AmpR (a member of the LysR transcriptional family). 
When peptidoglycan synthesis is interrupted by a P-lactam antibiotic, there is a build 
up of N-acetylglucosamine (NAG)-l,6 -anhydro-N-acetylmuramic acid (NAMA) 
oligopeptides. The NAG moiety is removed thus forming 1,6-anhydro-N- 
acetylmuramic acid tri, tetra and pentapeptides. These oligopeptides compete with 
oligopeptides of UDP-NAMA for the binding site on AmpR. Displacement of UDP- 
NAMA leads to a conformational change in AmpR and therefore activates the 
transcription of ampC. However, to prevent the overexpression of AmpC, the AmpD 
enzyme removes stem peptides from 1,6 -anhydro-N-acetylmuramic acid and N- 
acetylglucosamin-l,6 -anhydro-N-acetylmuramic acid oligopeptides thereby 
decreasing their concentration (Jacoby, 2009, Jacobs et al., 1997). Mutation in this 
pathway can cause the overexpression of chromosomal AmpC (Jacoby, 2009, 
Philippon et al., 2002, Barlow and Hall, 2002).
AmpC have been found in naturally ampC negative isolates such as E. coli, K. 
pneumoniae, K. oxytoca, Salmonella spp. and P. mirabilis. This is due to the 
transmission and acquisition of plasmid-mediated ampC genes. It is thought that K. 
pneumoniae for example, may have acquired its ampC genes from being close to an 
“ecological neighbourhood” of ampC carrying organisms e.g. other 
Enterobacteriaceae found in the intestine (Bauemfeind et al., 1999). However, it has 
been postulated that due to the position of the ampC genes within the host 
chromosome, ampC genes were not initially subject to the rapid dissemination which 
is usually demonstrated by the horizontal transmission of plasmid-borne genes 
(Barlow and Hall, 2002). Plasmid-mediated AmpC have now been discovered 
worldwide (Philippon et al., 2002).
Plasmid-mediated AmpC enzymes are named according to the resistance trait it 
exhibits e.g. CMY (cephamycin), FOX (cefoxitin), MOX (moxalactam) or LAT 
(latmoxef). Alternatively, they are so named according to the type of P-lactamase 
e.g. ACT (AmpC type), ACC (Ambler class C) or reflecting their site of discovery 
e.g. MIR-1 (Miriam Hospital in Providence) and DHA (Dhahram Hospital in Saudi 
Arabia) (Philippon et al., 2002).
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The structures of AmpC enzymes are similar to the class A p-lactamases but possess 
a slightly more open active site to accommodate the bulkier side chains found within 
the cephalosporins (Jacoby, 2009). AmpC enzymes are capable of hydrolysing 
narrow and broad spectrum cephalosporins along with the cephamycins (Thomson, 
2010). However, they are not affected by p-lactamase inhibitors such as clavulanic 
acid, sulbactam and tazobactam (Thomson, 2010, Philippon et al., 2002). Resistance 
to carbapenems has also been noted in association with AmpC enzyme production 
and it is thought that porin loss is partly responsible (Philippon et al., 2002, 
Stiirenburg et al., 2002), thus impairing the entry of antibiotics into the cell (Edwards 
and Betts, 2000).
1.8 Carbapenemases
Carbapenemases can be described as enzymes capable of hydrolysing the 
carbapenem class of p-lactam antibiotics. However, they are often able to hydrolyse 
other P-lactam antibiotics too. Carbapenemases have disseminated into a number of 
species. Using the p-lactamase classification system outlined in 1.5 and Table 1.6, 
the carbapenemases are distributed amongst Ambler class A, B and D (Queenan and 
Bush, 2007).
1.8.1 Carbapenemases found within Ambler class A
The carbapenemases that are found within this molecular class can be divided into 
chromosomal and plasmid mediated. The chromosomal carbapenemases are thought 
to be induced in response to cefoxitin and imipenem. Some examples of these are; 
SME (S. marcescens), IMI (imipenem hydrolysing p-lactamase) and NMC (not 
metallo-enzyme carbapenemase). The plasmid mediated carbapenemases are 
transferable. The KPC (K. pneumoniae carbapenemase) has now also been found in 
Enterobacter spp. and Salmonella spp. (Queenan and Bush, 2007).
1.8.2 Carbapenemases found within Ambler class B
As outlined in 1.5.1, the metallo-p-lactamases belong to Ambler class B and have
zinc as opposed to serine in their active site (Bush, 1998, Wang et al., 1999). Some
examples of Ambler class B carbapenemases include: IMP (active on imipenem),
VIM (Verona integron-encoded metallo-p-lactamase), SPM (Sao Paolo metallo-p-
lactamase), GIM (German metallo-P-lactamase), SIM (Seoul imipenemase)
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(Queenan and Bush, 2007) and NDM-1 (New Delhi metallo-[3-lactamase) 
(Kumarasamy et al., 2010, Yong et al., 2009).
1.8.3 Carbapenemases found within Ambler class D
Within the Ambler class D, the OXA p-lactamases are found. These are enzymes 
capable of hydrolysing oxacillin (Huovinen et al., 1988). Carbapenemases of the 
OXA class of p-lactamases are usually associated with Acinetobacter baumannii e.g. 
OXA-23 (Queenan and Bush, 2007, Perez et al., 2010).
1.9 The epidemiology of ESBLs in the UK
Initially, ESBLs in the UK were mostly mutants of TEM and SHV. Despite a 
number of outbreaks, ESBL-producing Enterobacteriaceae were not common. These 
ESBLs were predominantly found in nosocomial Klebsiella spp. (Potz et al., 2006). 
In 2001, the UK saw the first emergence of CTX-M-9 in a K. oxytoca strain 
(Alobwede et al., 2003). However, the first CTX-M related outbreak was seen in 
2001 in a hospital in Birmingham with CTX-M-26 producing K. pneumoniae 
(Brenwald et al., 2003). CTX-M, particularly CTX-M-15, is now the most 
predominant UK ESBL type (Munday et al., 2004, Peirano and Pitout, 2010), 
followed by CTX-M-14 (Woodford et al., 2006). Canton and Coque (2006) 
demonstrated that CTX-M enzymes were at endemic levels in Europe, Canada, 
South America, Asia, Africa and Australia (Canton and Coque, 2006). The 
epidemiology of ESBLs are discussed in Chapter 3.
The spread of E. coli harbouring CTX-M-15 is unexplained although suggestions 
have been put forward. It is thought that CTX-M-15 derives from India where it is 
the predominant CTX-M genotype. Therefore, it has been suggested that CTX-M-15 
has spread through travelling and migration (Ensor et al., 2006, Warren et al., 
2008a). A prospective Swedish study conducted in 2007 investigated the link 
between travel and ESBL colonisation. Volunteers were screened pre and post travel 
for ESBLs. Isolates harbouring ESBLs, particularly CTX-M types were found to 
colonise 24% of volunteers who were negative pre-travel. All travellers who had 
been to India were subsequently colonised with CTX-M-15 producing bacteria. 
Therefore these findings suggest that the ESBLs were acquired at the specific travel 
destination (Tangden et al., 2010).
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Domestic animals have been suggested as a reservoir for ESBLs. For example, a 
study by O’Keefe et al. (2010), documented the presence of CTX-M (CTX-M-14 
and CTX-M-15) and SHV-12 genes in dogs and cats suffering urinary tract 
infections (UTIs). Additionally, food animals can often act as a source of antibiotic- 
resistant organisms e.g. Campylobacter jejuni and Salmonella enterica, which can 
lead to gut colonisation. S. enterica is often a reservoir for CTX-M in food animals, 
such as poultry. Studies by Warren et al., (2008a) and Dhanji et al., (2010) found that 
chicken meat from Brazil and Argentina harboured CTX-M-2; although this enzyme 
is not common in the UK it is prevalent in Argentina, which could suggest that the 
genotype found in poultry reflects the genotype prevalence of the country of origin. 
However, Warren et al., (2008a) also analysed the prevalence of CTX-M in UK 
poultry and found that it harboured CTX-M-1 as opposed to CTX-M-15. It was 
suggested that this finding reflected the restrained use of antibiotics such as cefitiofur 
and enrofloxacin in UK poultry production (Warren et al., 2008a). The link between 
CTX-M and poultry has also investigated in Italy and Denmark. Bertolaia et al 
(2010b), identified CTX-M-1, CTX-M-12 and CTX-M-32 in Italian broiler flocks 
and E. coli harbouring CTX-M-1, CTX-M-2 and CTX-M-9 has been documented in 
Danish chickens (Bortolaia et al., 2010a). A study by Calbo et al., (2011) found that 
a single strain of SHV-1 and CTX-M-15-producing K. pneumoniae had caused 
infection within all wards of a hospital in Spain. However, after screening healthcare 
staff and the ward environment, no colonisation with this strain could be determined. 
Therefore it prompted an investigation into food bome transmission. It was found 
that the kitchen surfaces and food were contaminated, and that a number of food 
handlers were in fact, faecal carriers of the strain (Calbo et al., 2011). A study by 
Rodriguez-Bano et al., (2008) found that faecal carriers were often associated with 
patients (in particular those who were male or had a urinary catheter) with 
community-associated UTIs caused by ESBL-producing E. coli. In their study, UTIs 
caused by ESBL-producing E. coli derived from host flora in 50% of cases. It was 
suggested that person to person transmission or acquisition from a common source 
was likely in aiding the spread of ESBLs (Rodriguez-Bano et al., 2008). In addition, 
there are a number of factors associated with the acquisition of ESBLs. These can be 
divided into hospitalised and non-hospitalised and are outlined in Table 1.7 
(Colodner et al., 2004).
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In a hospital environment during an outbreak, infection control measures are put into 
place. Typically, these include isolation of the colonised patient, the use of gloves 
and aprons (barrier nursing), stringent hand washing and appropriate use of 
antibiotics. However, in a study by Calbo et al., (2011) in which an outbreak of K. 
pneumoniae harbouring SHV-1 and CTX-M affected all wards of a hospital, these 
infection control measures did not stop the outbreak. It was thought that by imposing 
these infection control measures that the horizontal transmission and wider 
dissemination of this strain could be prevented (Calbo et al., 2011).
The control of ESBL infection and the accurate detection of ESBLs are important as 
ESBLs are often associated with complications and a high mortality rate. Therefore, 
the correct treatment is imperative to ensure adequate patient care and to avoid a 
fatal outcome (Rodriguez-Bano et al., 2006, Sturenburg and Mack, 2003).
Table 1.7 Factors associated with ESBL colonisation in hospitalised and non­
hospitalised patients. Adapted from Colodner et al., (2004).
Hospitalised patients Non-hospitalised patients
Length of hospital stay Previous hospitalisation
Time in ICU
Severity of illness Underlying diseases e.g. diabetes, heart
disease, genitourinary, neurological
disease and malignancies
Intubation and mechanical ventilation
Urinary or arterial catheterisation
Previous exposure to antibiotics Use of antibiotics in the last 3 months
UTI Recurrent UTI
Older age
Male gender
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1.9.1 Epidemic E. coli Strains A-E
In the UK, five major epidemic E. coli strains have been identified based upon their 
different PFGE banding patterns. These strains are labelled A-E and all harbour 
CTX-M-15 (Lau et al., 2008a). However, epidemic E. coli Strain A has been found 
nationally and will therefore be focussed on in this study.
1.9.1.1 Epidemic E. coli Strains A
In the UK, E. coli Strain A has been located in Shropshire, Ulster and parts of the 
South of England. However, the most prolific outbreak was seen in Shropshire 
during the latter part of 2002. During this time, 28 out of 105 patients died due to 
infection with E. coli with CTX-M-15. These fatalities brought about changes in 
antibiotic policies whereby a restriction was placed on the usage of quinolones and 
3rd generation cephalosporins. The usage of carbapenems, particularly ertapenem, 
was increased in the treatment of patients suspected of or proven to have ESBL 
infection. GPs were also advised to prescribe trimethoprim as a first line treatment of 
urinary-tract infections. CTX-M-15-positive E. coli was also found in stool samples 
which could imply that CTX-M-15 is transferred through the food chain (Livermore 
and Hawkey, 2005).
Analysis of Strain A by Woodford et al., (2004) revealed that an insertion sequence, 
IS26, was found within the terminal inverted repeat of the IS£cpl-like elements, 
which was positioned upstream of the CTX-M-15 allele therefore suggesting that 
IS26 separated CTX-M-15 from its promoter region. The IS26 element was found to 
be flanked by 8 bp direct repeats of ISEcpl DNA, which is consistent with 
duplication after a transposition event (Woodford et al., 2004). This suggests that 
\SEcpl is involved in the dissemination of CTX-M-15 (Poirel et al., 2003).
1.9.2 International clone 025b-ST131
025b-ST131 belongs to the B2, subgroup 1 phylogenetic group of E. coli and is 
associated with a specific O antigen, 025b. It also has the multilocus sequence type 
(MLST) 131 (Clermont et al., 2009). It is thought that the predominance of this 
specific sequence type ST131, particularly in urinary-tract infections, is due to the
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ability to overcome host defence mechanisms by the acquisition of virulence factors 
(Lau et al., 2008b).
This clone encompasses the UK’s epidemic E. coli strains A-E (Lau et al., 2008a) 
along with other ESBL types and includes isolates with diverse PFGE patterns 
(Clermont et al., 2009). The typing and characterisation of E. coli isolates are 
outlined in Chapter 5.
1.10 Laboratory detection of ESBLs
ESBL detection in the laboratory currently involves a two-step procedure whereby 
Enterobacteriaceae are firstly screened for ESBL production and then confirmed as 
ESBL producers. In the UK, guidelines for susceptibility testing are outlined by the 
British Society for Antimicrobial Chemotherapy whereby coliform isolates are 
screened using a cefpodoxime (CPD) disc at a concentration of 10pg (BSAC, 2009). 
If the isolate is found to be resistant to cefpodoxime ESBL status is confirmed 
routinely using a synergy test with clavulanic acid protected cefpodoxime discs. The 
presence of an ESBL can be confirmed where the zone of inhibition for the 
cephalosporin plus clavulanic acid is > 5mm larger than the cephalosporin alone. 
The isolate is then usually identified to the species level e.g. using API 20E. 
However, this test is currently only recommended for E. coli and Klebsiella spp. 
(Black et al., 2005). The detection of ESBLs is detailed more extensively in Chapter 
4.
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Figure 1.5 The detection o f  ESBLs within the clinical laboratory using a phenotypic 
screening and confirmation method with the cephalosporin cefpodoxim e (C PD ) and 
its augmented counterpart (CPDCV).
1.11 Project aims
The molecular epidemiology o f  ESBL-producing Enterobacteriaceae in Swansea 
will be investigated in order to give an insight into the current epidem iology o f  the 
area, which will enable a comparison to be made to the rest o f  the UK and other parts 
o f  the world. Accurate surveillance and ESBL detection allows for adequate and 
appropriate treatment regimens to be selected. Treatment options for infections with 
ESBL-producing organisms are limited, as ESBLs are often harboured alongside 
other resistance genes and are often also associated with clonal spread. The 
inappropriate treatment o f  infection with ESBL-producers can be associated with a 
higher mortality rate (Rodriguez-Bano et al., 2006). Therefore, briefly, the aims o f  
this project included (the aims are outlined in more detail in each results chapter):
•  Deduce the molecular epidemiology o f  ESBLs by the use o f  PCR 
amplification and DNA sequencing.
•  Deduce the sensitivity o f  current phenotypic screening and confirmation
• Evaluate the BD Phoenix Automated System and Mast A m pC  and ESBL 
Detection set for the detection o f  ESBL and AmpC.
methods.
3 9
• Typing and characterisation to deduce any strain and or clonal relatedness 
within the E. coli and Klebsiella spp. populations by using PFGE and PCR 
based methodologies.
• Evaluate the use of temocillin and tigecycline along with other antibiotics.
• Evaluate the use of Matrix Assisted Laser Desorption Ionisation-Time of 
Flight mass spectrometry in the rapid identification of Enterobacteriaceae.
• To identify the pgaABCD locus in 3 different E. coli populations, to establish 
biofilm production phenotypically and to identify any correlation between 
biofilm formation and ESBL production.
• To evaluate the clinical epidemiology of ESBL-producing 
Enterobacteriaceae.
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Chapter 2: Materials and Methods
2.1 Bacterial Strains
Enterobacterial strains were obtained from the Public Health Wales (PHW) 
Microbiology Abertawe Bro-Morgannwg (ABM) University Healthboard, Swansea 
laboratory (Singleton Hospital), UK. Four-hundred and fifty-two isolates were 
phenotypically screened using cefpodoxime and of which, 164 isolates were retained 
for further characterisation, including:
• 117 E. coli isolates (102 from urine, 9 from blood, 3 from wound and 3 from 
faeces). 81/117 (69%) were hospital-associated and 36/117 (31%) were GP- 
associated.
• 38 Klebsiella spp. (33 from urine, 3 from blood and 2 from wound). 26/38
(6 8 %) were hospital-associated and 12/38 (32%) were GP-associated.
• 9 other Enterobacteriaceae (5 from urine, 1 from blood and 3 from wound).
6/9 (67%) were hospital-associated and 3/9 (33%) were GP-associated.
E. coli strain A was a kind gift from the Health Protection Agency (HPA), Colindale, 
London, UK.
E. coli strains B-E were kind gifts from Dr. Mathew Upton, Manchester University, 
UK.
E. coli K12 was obtained from Dr. Alyson Bexfield, Swansea University, UK.
E. coli isolates sensitive to cefpodoxime (CPD) were kindly isolated by Michelle 
Reid from urine samples at the PHW Microbiology Laboratory, Singleton Hospital, 
ABM University NHS Trust, Swansea, UK.
NCTC 10418 was obtained from the PHW Microbiology ABM Swansea laboratory, 
Singleton Hospital, UK.
E. coli BL21 was purchased from Novagen, UK
Bovine E. coli isolates were obtained from Professor Martin Sheldon, Swansea 
University, UK (Sheldon et al., 2010).
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Bacteria were stored in Microbank™ vials (Pro-Lab Diagnostics) and Glycerol 
(Sigma-Aldrich, UK). Glycerol stocks were made by using 300pl of liquid culture 
and 300pl of glycerol. All were stored at -80°C.
2.1.1 General Bacterial Growth Conditions
Enterobacterial isolates (that were screened to be resistant/intermediately resistant to 
cefpodoxime) were collected from the PHW Microbiology ABM Swansea 
laboratory, and were sub-cultured onto Cystine-Lactose-Electrolyte Deficient 
(C.L.E.D) agar or Luria Bertani (LB) agar and incubated at 37°C for 24 hours before 
use.
For liquid cultures, 2 colonies were suspended in 5ml LB/EC broth and incubated 
overnight at 37°C and aerated with 200 revolutions per minute (rpm).
2.2 Growth Media
2.2.1 Agar
Cystine-Lactose-Electrolyte Deficient (C.L.E.D) agar (Oxoid, UK)
Developed by Mackey and Sandys in 1966, C.L.E.D medium was found to support 
the growth of potential urinary pathogens. It is a non-inhibitory medium deficient in 
electrolytes therefore being capable of preventing Proteus spp. from swarming. The 
addition of cystine allowed the growth of cystine dependent coliforms. The addition 
of Bromothymol blue allows for a colour change depending on lactose-fermenting 
ability. Lacose fermenting bacteria produce yellow colonies whereas non-lactose 
fermenting bacterial colonies remain blue (Mackey and Sandys, 1966).
Iso-sensitest agar (Oxoid, Cambridge, UK)
Developed from Oxoid’s sensitest media, iso-sensitest agar was designed specifically 
for antimicrobial testing and to overcome the limitations faced by Muller Hinton 
media.
Luria-Bertani Agar
LB was made using the recipe of Sambrook et al., (1989). 1% w/v bacto tryptone 
(Oxoid, Cambridge, UK), 0.5% yeast extract (Oxoid, Cambridge, UK), 1% Sodium
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Chloride (Fisher Scientific) and 2% agar (Oxoid, Cambridge, UK) were dissolved in 
dFhO and autoclaved. The agar was cooled and aseptically poured into agar plates 
(10mm x 90mm) and allowed to set.
2.2.2 Broth 
Luria-Bertani Broth
LB was made using the recipe of Sambrook et al., (1989). 1% w/v bacto tryptone 
(Oxoid, Cambridge, UK), 0.5% yeast extract (Oxoid, Cambridge, UK) and 1% 
sodium chloride (Fisher Scientific) were dissolved in dH2 0  and autoclaved before 
use.
Tryptic Soy Broth (Oxoid, UK)
30g TSB powder was dissolved in 1L dFLO and autoclaved before use.
EC Broth (Oxoid, UK)
EC broth was developed by Hajna and Perry (1943) to increase the selectivity of 
bacteria found within the coliform group and in particular, E. coli. It is a selective 
medium containing Bile salts No. 3 which enhance the growth of coliforms while 
inhibiting the growth of faecal streptococci.
37g of EC broth powder was dissolved in 1L of dFbO and autoclaved before use.
2.3 Chemicals and Reagents
Tris HC1 (C4H, ,N 03HC1) Fisher Scientific, UK
Tris Base (C4H 11NO3) Fisher Scientific, UK
Sodium Chloride (NaCl) Fisher Scientific, UK
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific, UK
Magnesium Chloride (MgCb) Fisher Scientific, UK
Dichlorodiphenyltrichloroethane (DDT, C 14H9CI5) Sigma-Aldrich, UK
Potassium Chloride (KC1) Fisher Scientific, UK
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Di-sodium hydrogen phosphate (Na2HPC>4) 
Potassium di-hydrogen phosphate (KH2PO4)
Fisher Scientific, UK
Fisher Scientific, UK
Alpha-4-cyano-hydrocycinnamic acid (HCCA, C10H7NO3) Sigma-Aldrich, UK
Tri-fluoro-acetic-acid (TFA, CF3CO2H)
Sodium N-lauryl sarcosine (CisFbsNNaCh)
Sigma-Aldrich, UK 
Sigma-Aldrich, UK
Formic Acid (CH2O2)
Acetonitrile (CH3CN)
Ethanol (C2H5OH)
D-Glucose (C6H]2 0 6 )
Sucrose (C12FI22O1])
Sodium meta-periodate (NaI04)
Picric Acid (C6H3N3O7)
Acetic Acid (C2H4O2)
Formaldehyde (CH2O)
Crystal Violet (C25H30CIN3)
Ethidium Bromide (EtBr, C2iH2oBrN3) 
SensiMix™
5Ox Sybr Green
6X Tri Track Loading Dye Solution 
lOObp Molecular DNA marker 
1Kb Molecular DNA marker 
50 -  1000 Kb Pulse marker
Fisher Scientific, UK
Fisher Scientific, UK
Fisher Scientific, UK
Fisher Scientific, UK
Fisher Scientific, UK
Sigma-Aldrich, UK
Fisher Scientific, UK 
Sigma-Aldrich, UK 
Sigma-Aldrich, UK
Quantace, UK 
Quantace, UK 
Fermentas, UK 
Promega, UK 
Promega, UK 
Sigma-Aldrich, UK
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Sybr Safe® Invitrogen, UK
Primers Invitrogen, UK
Deoxynucleotide Triphosphates (dNTPs) Promega, UK
Agarose Melford, UK
Low Melt Point (LMP) Agarose Biorad, UK
Certified™ Molecular Biology Agarose Biorad, UK
Glycerol Sigma-Aldrich, UK
Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) 
Matrix Preparation
Matrix for MALDI-TOF was prepared by saturating 15mg of alpha-4-cyano- 
hydrocycinnamic acid (HCCA) in 500pl of 100% acetonitrile and 500pl of 5% tri-
was stored in the dark.
Bouin’s fixative
Bouin’s fixative was made by mixing 11.25ml of Picric Acid, 3.75ml of 40% 
Formaldehyde and 0.75ml of Acetic acid.
Crystal Violet
0.05g of Crystal Violet powder was dissolved in 100ml of dL^O.
2.3.3 Buffers
50X Tris-acetate-EDTA (TAE)
2M Tris Base (pH 8.0) (Fisher Scientific), 1M glacial acetic acid (Fisher Scientific) 
and 0.05 M EDTA was made up to 1L with water.
IX Tris-acetate-EDTA (TAE)
20ml 50X TAE was made up to 1L with dH2 0 .
fluoro-acetic-acid (TFA) before ultra-sonicating for 10 minutes. The matrix solution
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1M Tris HC1 (pH 7.5)
2.36g of Tris base and 12.70g Tris HC1 was dissolved in 100ml of dHiO before 
being autoclaved before use.
5M Sodium Chloride (NaCI)
146.1 g NaCl was dissolved in 500ml of d ^ O .
1M Magnesium Chloride (MgCh)
20.3g of MgCb was dissolved in 1 0 0 ml of dT^O.
0.5M Ethylenediaminetetraacetic acid (EDTA)
93.06g Na4EDTA was dissolved in 400ml dH2 0 . The pH was adjusted to 7.5 before 
adding an additional 1 0 0 ml of dH2 0 .
SE Buffer
15ml 5M NaCl and 50ml of 0.5M EDTA were made up to 1L with dH2 0 . 
Tris-EDTA (TE) Buffer
10ml 1M Tris HC1 (pH 7.5) and 20ml 0.5M EDTA (pH 7.5) were made up to 1L 
with dH2 0 .
Proteinase K Buffer
1L of 0.5M EDTA (pH 7.5) was added tolOg Na-lauryl sarcosine before adjusting to 
pH to 9.
0.5x Tris-Borate-EDTA (TBE)
100ml of 10X TBE (Biorad) was made up to 2L with dH2 0 .
Phosphate Buffered Saline (PBS)
3.2g NaCl, 0.08g KC1, 0.576g Na2HP04 and 0.096g KH2P 0 4 were dissolved in 
400ml dH20 .
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Buffer D
lx Buffer D was made using a recipe supplied by Promega. 6 mM Tris HC1, 6 mM 
MgCb, 150mM NaCl and ImM DDT were mixed and the volume made up to 20ml 
with dt^O. The pH was adjusted to 7.9.
Buffer B
Supplied by Promega, UK.
PCR lOx Buffer 
Supplied by Invitrogen, UK.
2.3.3.1 Buffers supplied by Qiagen, UK
Genomic DNA extraction:
Buffer ATL 
Buffer AL 
Buffer AW1 
Buffer AW2 
PCR Purification:
Buffer PB 
Buffer PE
2.3.4 Antibiotics
2.3.4.1 Antibiotic discs
Antibiotic discs are commercially available filter paper discs impregnated with the 
following antibiotics:
Cefpodoxime (CPD), ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), 
cefuroxime (CXM), cefepime (CPM) and cefpirome (CFP) (Mast, Merseyside, UK).
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All antibiotic discs were supplied at a concentration of 30pg. However, cefpodoxime 
was used at a concentration of lOpg.
Discs containing amoxicillin and clavulanic acid known as co-amoxiclav or 
augmentin (AUG) (30 pg + 10 pg) and antibiotic discs (as described previously) 
with the addition of 10 pg clavulanic acid (CV) per disc were also utilised.
2.3.4.2 E-test strips
E-test strips are commercially available plastic strips impregnanted with an antibiotic 
at various concentrations. Temocillin and tigecycline antibiotics were utilised 
(ABBiodisk, bioMerieux).
2.3.4.3 Mast® AmpC and ESBL Detection set
A commercially available AmpC and ESBL detection set comprising of 4 discs. 
Each disc contained lOpg of cefpodoxime, lOpg of cefpodoxime plus ESBL 
inhibitor, lOpg of cefpodoxime plus AmpC inhibitor and lOpg of cefpodoxime plus 
ESBL inhibitor and AmpC inhibitor respectively (Mast, Merseyside, UK).
2.4 Identification of Bacteria
2.4.1 BD Phoenix Automated Microbiology System
The BD Phoenix is a diagnostic system utilised in the rapid identification and 
antimicrobial susceptibility of organisms. The BD Phoenix panel (NMIC/ID) is split 
into two portions. One side determined bacterial identification (ID) and the other 
side deduced Antimicrobial Susceptibility Testing (AST) (BD, 2009).
Bacterial Identification (ID)
This portion of the BD Phoenix panel consisted of 51 wells, of which, 45 contained 
dried biochemical substrates. A series of fluoregenic, chromogenic and conventional 
biochemical tests were employed. The ability for the organism to utilise, degrade, 
hydrolyse or reduce each substrate was detected in order to determine its 
identification (BD, 2009).
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Antimicrobial Susceptibility Testing (AST)
This portion of the BD Phoenix panel consisted of 85 wells, of which, 84 contained 
dried antimicrobial agents with a range of two-fold doubling concentrations. 
Antimicrobial susceptibility testing was based upon the principle of the 
microdilution method whereby the turbidity of bacteria was measured at each 
antimicrobial concentration. However, the BD Phoenix system utilised a redox AST 
indicator which allowed for the measurement of bacterial growth as well as bacterial 
tubidity (BD, 2009).
The following antimicrobial agents are contained within the BD Phoenix panel:
Amikacin, amoxicillin/clavulanate, ampicillin, aztreonam, cefotaxime, cefoxitin, 
ceftazidime, cefuroxime sodium, cephalexin, ciprofloxacin, colistin, ertapenem, 
gentamicin, imipenem, levofloxacin, meropenem, nitrofurantoin, 
piperacillin/tazobactam, tobramycin, trimeth/sulfamethoxazole (DIN) and 
trimethoprim.
A 0.5 McFarland suspension was made in Identification (ID) broth using a BD 
PhoenixSpec™ nephelometer. Of which, 25 pi was aliquoted into BD Antibiotic 
Susceptibility Testing (AST) indicator broth along with one freefalling drop of AST 
indicator solution. The inoculated ID broth and BD Antibiotic Susceptibility Testing 
(AST) indicator was added to the appropriate sections of the BD Gram negative 
Phoenix panel (NMIC/ID) and placed into the BD Phoenix analyser. The BD 
Phoenix panel was incubated at 35°C and was systematically read by the instrument 
at 20 minute intervals. Results could be obtained up to 16 hours later. In order the 
detect ESBL, the Xpert system uses a screening technique and generates rules based 
upon antibiotic susceptibility (BD, 2009).
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2.4.2 Bruker Dalton ics MALDI Biotyper - Matrix-Assisted Laser 
Desorption/Ionization-Time of Flight/Mass Spectrometry (MALDI-TOF/MS)
Matrix Assisted Desorption/ionization-time of flight (MALDI-TOF) 
massspectrometry was performed with the Bruker Daltonics Microflex LT system 
(Bruker Daltonics, Germany).
The principles of MALDI-TOF are as follows. A laser beam is fired at the target 
plate thus causing the sample (which is overlayed with MALDI-TOF HCCA matrix) 
to ionise. The MALDI-TOF HCCA matrix protects the sample from complete 
degradation by absorbing most of the laser energy. Ionising the sample caused it to 
become vapourised. With the assistance of a strong electric field, the molecules enter 
a time of flight tube where they could be separated dependent on their mass to 
charge ratio (Stults, 1995). MALDI-TOF was first utilised for the identification of 
bacterial species in the 1990s (Holland et al., 1996).
In order to run MALDI-TOF, samples were prepared via two methods -  a direct 
smear method or by ethanol-formic-acid extraction.
The target plate was placed in the Bruker microflex series MALDI-TOF whereby a 
spectrum could be achieved after 240 shots with a Nitrogen laser. The spectra were 
compared to the Bruker BioTyper database in order to determine the identification of 
the organism.
2.4.2.1 Direct Smear Method
Using an inoculating loop, a bacterial colony was picked from an overnight plate 
culture and was thinly applied to the MALDI-TOF standard steel target plate. 
Depending on species, one colony of bacteria was sufficient to cover three sample 
spots of the steel target plate. The samples were overlayed with 2pl of MALDI-TOF 
matrix solution.
2.4.2.2 Ethanol-formic-acid extraction
To prepare samples via ethanol-formic-acid extraction, approximately 3-5 colonies
of bacteria was resuspended in 150pl of deionised water before adding 450pl of
ethanol. The suspension was centrifuged at maximum speed for 2 minutes and the
supernatant was discarded. The tubes were inverted and allowed to dry to ensure
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complete removal of ethanol. The pellet was resuspended in 30pl of 70% formic 
acid. After a 10 minute incubation period, 30pl of 100% acetonitrile was added and 
the suspension vortexed before further centrifugation at maximum speed for 2  
minutes. One microlitre of the supernatant was pipetted onto the MALDI-TOF target 
plate. The target plate was left to air dry at room temperature before overlaying with 
2pl of MALDI-TOF matrix solution.
2.5 ESBL susceptibility tests
2.5.1 Inoculation of Medium for Antibiotic Tests
For antibiotic testing, British Society for Antimicrobial Chemotherapy (BSAC) 
regulations were followed (BSAC, 2008). A colony of bacteria was added to 2ml of 
sterilised deionised water to create a suspension with a turbidity of 0.5 McFarland. 
This suspension was spread in a lawn fashion over iso-sensitest agar before the 
appropriate antibiotics were applied.
2.5.2 Synergy Test
The synergy test is a phenotypic assay used to determine the presence of an ESBL. 
The principle is based upon the formation of synergy between a cephalosporin and a 
cephalosporin with clavulanic acid. ESBL production is determined when there is a 
difference of >5mm between the zone of inhibition of the cephalosporin and its 
augmented counterpart.
The cephalosporins cefpodoxime (CPD), ceftazidime (CAZ), cefotaxime (CTX), 
cefepime (CPM) and cefpirome (CFP) along with their augmented counterparts (CV) 
were divided into two batches (in their respected pairs) and dispensed on two 
inoculated agar plates along with cefuroxime (CXM) and cefoxitin (FOX). The discs 
were applied approximately 20-30mm apart and incubated for 24 hours at 37°C.
2.5.3 Disc Approximation test
The Disc Approximation test is another phenotypic disc assay based upon the 
principle of demonstrating synergy. ESBL production can be confirmed when there 
is a distortion of the zone of inhibition between the cephalosporins and augmentin.
51
A disc of augmentin (AUG) was placed in the centre of an inoculated Iso-sensitest 
agar plate. CPD, CAZ, CTX were then applied 20-30mm apart in a triangular fashion 
around the augmentin disc. A second plate was set up using CFP and CPM. Plates 
were incubated for 24 hours at 37°C.
2.5.4 E-test
Iso-sensitest agar plates were inoculated as described in 2.5.1. Once the surface was 
dry, an E-test strip was applied using sterile forceps. Plates were incubated at 37°C 
for 18-24 hours before MIC readings were noted and interpreted.
2.5.5 Mast® AmpC and ESBL Detection set method
Iso-sensitest agar plates were inoculated as described in 2.5.1. Once the surface was 
dry, the four discs contained within the set were applied using sterile forceps. Plates 
were incubated at 37°C for 18-24 hours before being interpreted according to 
manufacturer’s guidelines (Chapter 4).
2.6 Molecular Biology
2.6.1 Enzymes
NheI (lOU/pl) (Promega, Southampton, UK)
A restriction enzyme used to cleave at the following site:
Gt CTAGC 
C GATCa G
Xbal (lOU/pl) (Promega, Southampton, UK)
A restriction enzyme used to cleave at the following site:
Tt CTAGA 
A GATCiT
DdeI (10U/pl) (Promega, Southampton, UK)
A restriction enzyme used to cleave at the following site:
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Ct TNAG 
G ANTa C
Taq Polymerase (5U/pl) (Invitrogen)
Utilised in PCR reactions, Taq polymerase is a heat stable enzyme isolated from 
E. coli cells expressing a Thermus aquaticus DNA polymerase gene.
Proteinase K (lOOmg/ml)
Isolated by Ebeling et al., (1974) from Tritirachium album, Proteinase K is a serine 
protease capable of aiding in the prevention of nucleic acid degradation.
All enzymes were stored at -20°C
2.6.2 DNA Extraction
2.6.2.1 Crude DNA extraction
500pl of sterile deionised water was inoculated with two colonies from an overnight 
plate. The DNA was then extracted from bacterial cells by heating the suspension at 
95°C for 10 minutes. The suspension was then centrifuged at 12, 000 rpm for 2 
minutes.
2.6.2.2 Genomic DNA extraction using Qiagen Kit
Genomic DNA was extracted from bacteria using the Qiagen DNeasy Blood & 
Tissue kit.
lml of an overnight liquid culture was centrifuged at 7500 rpm for 10 minutes. The 
supernatant was discarded and the pellet was resuspended in 180pl Buffer ATL. 
20pl of Proteinase K (supplied with Qiagen kit) was added and the suspension 
vortexed before incubating for 2 hours at 56°C. 200pl of Buffer AL (supplied with 
Qiagen kit) and 200pl of 100% ethanol were added. The suspension was thoroughly 
vortexed and pipetted into a DNeasy Mini spin column contained within a 2ml 
collection tube. The DNeasy mini spin column and its contents were centrifuged at 
8000 rpm for 1 minute before discarding the flow through. The collection tube was 
replaced and 500pl of Buffer AW1 was added before centrifuging again at 8000 rpm 
for 1 minute -  this step was repeated with the addition of Buffer AW2. To elute, the
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DNeasy Mini spin column was placed in a clean 1.5ml microcentrofuge tube and 
1 OOpl of dP^O was directly added to the DNeasy membrane and centrifuged at 8000 
rpm for 1 minute.
2.6.3 General PCR
PCR was carried out on all suspected ESBL-producers using a Corbett Rotorgene 
and BioRad Tetrad. The PCR master mix for one reaction consisted of 12.5pi 2x 
SensiMix™, 0.5pl each primer (lOpM), 0.75pl 50x Sybr Green and 2pl crude DNA 
extract. Nuclease free water (NFH2O) was added to make the total volume of master 
mix equal 25 pi. To detect CTX-M and ampC genes respectively, multiplex PCR 
methods were used. Therefore, all the necessary primers were added together in one 
PCR reaction to determine which CTX-M group was present.
2.6.3.1 Primers used
List of primers used in PCR reactions:
Table 2.1 Primers used in Multiplex reaction for identifying CTX-M groups 
(Woodford et al., 2006)
CTX-M
Group
Primers Expected 
Amplicon size 
(bp)
Annealing
Temperature
(°C)
1 5 ' -AAAAATCACTGCGCCAGTTC-3 '  
5 ' -AGCTTATTCATCGCCACGTT-3 '
415bp
2 5 '  -CGACGCTACCCCTGCTATT-3'  
5 ' -CCAGCGTCAGATTTTTCAGG-3'
552bp
8 5 ' -TCGCGTTAAGCGGATGATGC-3 '  
5 ' - AACCCACGATGTGGGTAGC-3 '
6 6 6 bp 52°C
9 5 ' -CAAAGAGAGTGCAACGGATG-3' 
5 ' -ATTGGAAAGCGTTCATCACC-3 '
205bp
25/26 5 '  -GCACGATGACATTCGGG-3 '
5 ' -AACCCACGATGTGGGTAGC-3 '
327bp
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Table 2.2 Primers used to identify presence of SHV genes (Nuesch-Inderbinen et al.,
1996)
SHV Primers Expected 
Amplicon 
size (bp)
Annealing
Temperature
(°C)
1 5 ' -GCCCGGGTTATTCTTATTTGTCGC-3' 1017bp 49°C
2 5 ' -TCTTTCCGATGCCGCCGCCAGTCA-3'
Table 2.3 Primers used to identify presence of TEM genes (Wiegand et al., 2007)
TEM Primers Expected 
Amplicon 
size (bp)
Annealing
Temperature
(°C)
T1 5 ' -ATTCTTGAAGACGAAAGGGCCTC-3 ' lOOObp 55 °C
T3 5 ' -TTGGTCTGACAGTTACCAATGC-3 '
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Table 2.4 Primers used in a multiplex PCR to identify the presence of AmpC genes
(Perez-Perez and Hanson, 2002)
AmpC Expected Annealing
Amplicon Temperature 
size (bp) (°C)
MOXMF
MOXMR
5 ' -GCTGCTCAAGGAGCACAGGAT - 3 '  
5 ' -CACATTGACATAGGTGTGGTGC-3'
520bp
CITMF
CITMR
5 ' -TGGCCAGAACTGACAGGCAAA-3 '  
5 ' -TTTCTCCTGAACGTGGCTGGC-3'
462bp
DHAMF
DHAMR
5 ' -AACTTTCACAGGTGTGCTGGGT-3' 
5 ' -CCGTACGCATACTGGCTT-3/
405bp 64°C
ACCMF
ACCMR
5 ' - AACAGCCTCAGCAGCCGGTTA-3 '  
5 ' -TTCGCCGCAATCATCCCTAGC-3'
346bp
EBCMF
EBCMR
5 ' -TCGGTAAAGCCGATGTTGCGG-3' 
5 ' -CTTCCACTGCGGCTGCCAGTT-3'
306bp
FOXMF
FOXMR
5 ' -AACATGGGGTATTCAGGGAGATG-3' 
5 ' -CAAAGCGCGTAACCGGATTGG-3 '
190bp
Table 2.5 Primers used for sequencing to type genes belonging to CTX-M group 1
(Sturenburg et al., 2004b)
CTX-M Primers Expected Annealing
Group 1 Amplicon Temperature
size (bp) (°C)
F 5 7 -TCTTCCAGAATAAGGAATCCC-3' 
R 5 ' -CCGTTTCCGCTATTACAAAC-3 '
909bp 58°C
Table 2.6 Primers used for sequencing to type genes belonging to CTX-M group 9 
(Eckert et al., 2006)
CTX-M Primers Expected Annealing
Group 9 Amplicon Temperature
size (bp) (°C)
M9 Upper 5 ' -ATGGTGACAAAGAGAGTGCA-3' 
M9 Lower 5 ' -CCCTTCGGCGATGATTCTC-3'
lOOObp 52°C
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Table 2.7 Primers used for sequencing to type genes belonging to CTX-M group 
25/26. Designed using Primer 3 (http://frodo.wi.mit.edu/primer3/).
CTX-M Primers Expected Annealing
Group Amplicon Temperature (°C)
25/26 size (bp)
F 5 ' -GCGATGTTAATGACGAGAGC-3' 806bp
R 5 ' - AACCGTCGGTGACAATTCTG-3 '
2.6.2.2 General Reaction Conditions
Amplification conditions comprised of initial incubation step at 95°C for 15 minutes 
followed by 35 cycles of denaturation at 95°C for 20 seconds, annealing for 20 
seconds (temperatures shown in the appropriate Table) and a final extension at 72°C 
for 1 minute.
2.6.2.3 Restriction-Fragment Length Polymorphism (RFLP) Analysis of SHV 
positive PCR Products
RFLP analysis was carried out on all SHV positive isolates (PCR product 
approximately lOOObp) using the method developed by Nuesch-Inderbinen et al., 
(1996). A reaction mix consisting of 2pl DNA, 0.5pl of Buffer, 0.5pl of the 
restriction enzyme Nhel (lOU/pl) and 2pl of dH2 0  was incubated at 37°C for 2 
hours. A second mix with additional dH2 0  in place of restriction enzyme was set up 
alongside as a control.
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2.6.3 CTX-M-15IS! 6 PCR
Table 2.8 Primers used to amplify the junction between IS2.6 and the CTX-M-15 
allele (Woodford et al., 2004)
CTX-M-15 Primers Expected Annealing
IS26 Amplicon 
size (bp)
Temperature
(°C)
F 5 ' -GCGGTAAATCGTGGAGTGAT- 
3 '
400bp 52 °C
R 5 ' -AATCGGCAAGTTTTTGCTGT- 
3 '
PCR cycling conditions consisted of 94°C for 5 minutes followed by 30 cycles of 
94°C for 25 seconds, 52°C for 40 seconds 72°C for 50 seconds and a final extension 
at 72°C for 6  minutes.
2.6.4 025b-ST131 PCR
025b-ST131 PCR (Clermont et al., 2009) was carried out on all E. coli isolates to 
determine the presence of an intercontinental clone, 025b-ST131. In this allele- 
specific PCR, two primer sets are used (see table 2.9).
A PCR master mix for one reaction consisted of 8.25pl of NFH2O, 2pl of lOx buffer 
(Invitrogen, UK), 0.5pl of dNTP mix (Promega, UK), 1.5mM MgCh (Invitrogen, 
UK), 20 pmol of each 025pabBspe primer, 12 pmol of each trpA primer, 0.25pi of 
Taq polymerase (Invitrogen, UK) and 2pl of DNA bringing the total volume up to 
2 0 pl.
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Table 2.9 Primers used to identify members of the intercontinental clone 025b- 
ST131 (Clermont et al., 2009)
025b-ST131 Primers Expected 
Amplicon 
size (bp)
Annealing
Temperature
(°C)
trpA.F
trpA.R
5 ' -GCTACGAATCTCTGTTTGCC-3' 
5 ' -GCAACGCGGCCTGGCGGAAG-3'
427bp 65°C
025pabBspe.F
025pabBspe.R
5 ' -TCCAGCAGGTCTGGATCGT-3' 
5 ' -GCGAAATTTTTCGCCGTAC-3'
347bp
The published amplification conditions comprised of 94°C for 4 minutes followed by 
30 cycles of 94°C for 5 seconds, 65°C for 10 seconds and 72°C for 5 minutes. 
However, using these conditions on the Biorad Tetrad yielded no positive 
amplification products therefore, the method was optimised. Four experiments were 
set up in parallel. Each experiment had a different annealing time. The conditions 
were as follows:
94°C for 4 minutes, 30 cycles of 94°C for 20 seconds/30 seconds/40 seconds/1 
minute, 65°C for 10 seconds and 72°C for 5 minutes. E. coli BL21 was used as a 
control isolate, as it is negative for pabB mutations. It was found that a 20 second 
annealing time was suitable for the specific nature of this PCR as a longer annealing 
time generated false-positive results.
2.6.4.I. Digestion of positive pabB  products
In order to identify that the products generated by pabB primers were not due to non­
specific binding, enzymatic cleavage of the amplification product was carried out. A 
pabB gene sequence was analysed using NEBcutter V2.0 to determine a suitable 
enzyme along with digested fragment size. Cleavage with the restriction enzyme 
DdeI was employed. A reaction mix consisting of 2pl DNA, 0.5pl of Buffer, 0.5pl of 
the restriction enzyme Dde I (lOU/pl) and 2pl of dH2 0  was incubated at 37°C for 2 
hrs. A second mix with additional dHiO in place of restriction enzyme was set up 
alongside as a control.
Upon digestion, positive fragments were cleaved to 216 bp and 131 bp.
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2.6.4.2 pabB Primers
Primers were designed using Primer3 (http://frodo.wi.mit.edu/primer3/) to amplify a 
larger region of the pabB gene in order to confirm the presence of mutations in
selected positive fragments.
Table 2.10 Primers used to amplify the pabB gene
pabB Primers Expected Annealing
Amplicon Temperature
size (bp) (°C)
F 5 ' -ATGCCGATCATCCGTATAAGC-3' 
R 5 ' -TGGCCTGATTAAGCTGAAGG-3'
597bp 65°C
2.6.5 pgaABCD  PCR
Table 2.11 Primers used to identify the presence of the pgaABCD gene locus (Cerca 
et al., 2007).
The pgaABCD gene locus was found to be associated with the promotion of surface 
binding, intercellular adhesion through the production of poly-p-1, 6 -N-acetyl-D-
glucosamine. This is thought to be an important factor associated with E. coli biofilm 
formation (Wang et al., 2004).
pgaABCD Primers Expected 
Amplicon 
size (bp)
Annealing
Temperature
(°C)
pgaA F 
pgaA R
5 ' -GGCTTTGAAACTTCTTACTGC-3' 
5 ' -CCTGTTTATCTTGCCCGGCC-3'
2 0 0 bp 50°C
PgaC F 
pgaC  R
5 ' - ATGATTAATCGCATCGTATCG-3 '  
5 ' -CATCGGTTCCACAATATATGC-3'
550bp
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PCR cycling conditions consisted of 94°C for 5 minutes followed by 32 cycles of 
94°C for 30 seconds, 50°C for 30 seconds 72°C for 45 seconds and a final extension 
at 72°C for 5 minutes.
2.6.6 Agarose Gel Electrophoresis
PCR reaction products or DNA fragments were separated by agarose gel 
electrophoresis. 1-3% (w/v) agarose gels in TAE were made and submerged in TAE 
electrophoresis buffer. DNA samples were mixed with one fifth their volume of 6  x 
DNA loading buffer and NFH2O, then loaded into wells in the gel formed by 
insertion of the appropriate comb prior to gel solidification. Electrophoresis was 
carried out at 90V for 30 minutes (1-2%) or at 110V for approximately 1 hour (3%). 
Amplification products were then stained and visualised using SybrSafe® and UV 
light. The size and concentration of DNA fragments were estimated by co- 
electrophoresing 7pl Promega lOObp DNA Ladder as size standards. A permanent 
record of agarose gels was obtained by photographing the SybrSafe® stained gels 
illuminated with incident UV light on a Bio-Doc It UV Transilluminator system.
2.6.7 DNA Purification -  QIAquick PCR Purification Kit
PCR products were purified using the QIAquick PCR purification kit.
lOOpl of PB buffer was added to 20pl of PCR product. Once mixed, the sample was 
applied to a QIAquick spin column and centrifuged at 13,000 rpm for 30 seconds in 
order to bind the DNA. The flow-through was discarded and 750pl of Buffer PE was 
added before centrifuging at 13,000 rpm for 30 seconds. After the washing with 
Buffer PE, the flow-through was discarded once more and residual ethanol was 
removed by centrifuging the column at 13,000 rpm for 1 minute. The column was 
placed into a clean 1.5ml microcentrifuge tube and DNA was eluted using 30pl of 
H2O and centrifuging at 13,000 rpm for 1 minute.
2.6.8 DNA Sequencing
PCR products were purified as described in 2.6.7 before being quantified using a 
NanoDrop spectrophotometer. The purified DNA was diluted to a specific 
concentration in 15jnl as stated by MWG Operon. The samples, along with 2pmol of 
each primer were sent to MWG operon for sequencing. The results were analysed
61
using Basic Local Alignment Search Tool (BLAST), ClustalX (Thompson et al., 
1997) and Bioedit (Hall, 1999).
2.6.9 Pulsed Field Gel Electrophoresis (PFGE)
2.6.9.1 Sample preparation
2-3 colonies of bacteria were suspended in 5ml of LB broth and incubated overnight 
at 37°C. 1.6ml of culture was aliquoted into microcentrifuge tubes and centrifuged 
for 2 minutes at 12,000 rpm. The pellet was resuspended in 1ml of SE buffer and the 
procedure was repeated twice. 125 pi of washed bacterial suspension was added to 
125pl of 1.6% Low Melt Point (LMP) agarose before loading approximately lOOpl 
of the mixture into Biorad PFGE plug moulds and leaving at 4°C for 10-30 minutes 
to set.
The agarose plugs were removed from the moulds and placed into 20ml universal 
tubes. One mililitre of Proteinase K lysis solution was pipetted into each tube and 
allowed to incubate overnight at 56°C. The Proteinase K lysis solution was removed 
and the agarose plugs were washed four times with 10ml of TE Buffer for 1 hour 
with shaking. The TE buffer was discarded and the agarose plugs were equilibrated 
in 800pl of lx Buffer D (Promega, UK) for 1 hour at room temperature. The 
restriction buffer solution was removed and replaced with lOOpl of fresh Buffer D 
and 4pl o fXbal (lOU/pl) (Promega, UK).
2.6.9.2 Gel preparation
Two litres of 0.5x TBE was cooled at 4°C and 160ml was used to make a 1% (w/v) 
agarose gel using Certified™ Molecular Biology Agarose. The gel was allowed to 
set for approximately 30 minutes before placing each agarose mould into the wells. 
Molecular markers (Sigma Aldrich pulse-field DNA marker -  50-1000Kb) were 
placed at each end of the gel and a layer of LMP was pipetted onto each sample well.
2.6.9.3 PFGE Settings
The remaining 0.5x TBE buffer was placed into the CHEF-DR® III Variable Angle 
System and allowed to circulate at 75L/minute. The buffer was equilibrated to 14°C 
before placing the gel inside the tank.
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Settings:
Block 1: 5 seconds initial switch, 15 seconds final switch -  run time 10 hours.
Block 2: 15 seconds initial switch, 60 seconds final switch -  run time 13 hours.
6.0 V/cm, angle 120°.
The current was maintained between 115 and 135 V by adding or subtracting the 
appropriate volume of 0.5x TBE buffer.
Once the PFGE was complete, the gel was removed from the tank and stained in 1% 
Ethidium bromide for 20 minutes with shaking. The Ethidium bromide solution was 
removed and the gel was destained in 400ml of deionised water for 1-3 hours. After 
destaining the gel, the PFGE profile was visualised using UV light on a Bio-Doc It 
UV Transilluminator system.
2.7 Biofilm Assay
Overnight liquid cultures were diluted with fresh media in a ratio of 1:100 and 200pl 
aliquots were inoculated into the wells of 96-well tissue culture plate (Nunc, 
ThermoFisher Scientific, Denmark). Each sample was added in triplicate. After 
incubation at 37°C for 18-24 hours, the media was carefully removed and the wells 
were washed three times with PBS (200pl per well). 150pl of Bouin’s Fixative was 
added to each well and left for 15 mins in order to fix adherent bacteria. The fixative 
was removed and the plate was washed once more in PBS (200pl per well). The 
plate was allowed to airdry at room termperature and later stained with crystal violet. 
The optical density of the biofilm was measured at 600 nm using a FLUOstar 
Optima plate reader (BMG, Germany).
63
Chapter 3: Molecular characterisation and epidemiology of ESBL- 
producing Enterobacteriaceae isolated from the PHW Microbiology 
ABM Swansea laboratory
3.1 Introduction
P-lactam antibiotics are ‘front line antibiotics’ which account for approximately 50% 
of antibiotics used worldwide (Barlow and Hall, 2002). All P-lactam antibiotics are 
composed of a p-lactam ring fused to either a five or six-membered ring 
(Greenwood, 2000). p-lactam antibiotics function as bacterial cell wall synthesis 
inhibitors, which incorporate into the cell wall of the bacteria to bind to penicillin 
binding proteins (PBPs). PBPs are enzymes responsible for the final stages of 
peptidoglycan synthesis. Additionally, inhibition of PBPs causes the activation of 
cell wall hydrolases to stimulate the autolysis mechanism, thus resulting in cell lysis 
(Mims, 1998, Samaha-Kfoury and Araj, 2003). Certain bacteria possess an enzyme 
that can prevent the destruction caused by P-lactam antibiotics. The P-lactamase 
enzyme hydrolytically cleaves the p-lactam ring of the antibiotic thus inactivating its 
function (Samaha-Kfoury and Araj, 2003, Katzung, 1995, Greenwood, 2000).
The first plasmid-mediated p-lactamase in E. coli, TEM-1, was isolated in Greece in 
1965 (Bradford, 2001). Due to its transferable capabilities e.g. plasmids or 
transposons, TEM-1 has been found in other Enterobacteriaceae and other bacterial 
species such as Pseudomonas spp. and Neisseria gonorrhoeae (Bradford, 2001). In 
1972, the first sulfhydryl variable (SHV) p-lactamase was identified with the 
isolation of SHV-1 (Chaves et al., 2001). SHV-1 which is commonly chromosomally 
encoded in K. pneumoniae also spreads via plasmids and is now additionally 
common in E. coli (Bradford, 2001). According to Bush et al., these non-ESBL 
enzymes belong to the classification group 2 b which states that they have a spectrum 
of activity whereby penicillins and some cephalosporins can be hydrolysed (Bush, 
1989b).
The first report of a plasmid-mediated P-lactamase capable of hydrolysing broad- 
spectrum cephalosporins was published in 1983 (Paterson and Bonomo, 2005). 
Kliebe et al (1985), described plasmid-mediated resistance to broad-spectrum
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cephalosporins in Klebsiella ozaenae isolates. Sequencing showed that this enzyme 
differed to SHV-1 as there was a glycine to serine mutation at position 238 which 
conferred extended spectrum properties. Owing to this difference, the enzyme was 
named as SHV-2 (Kliebe et al., 1985). Soon after, more variants of TEM-1 and 
SHV-1 with the ability to hydrolyse broad-spectrum cephalosporins were discovered 
and so the phrase ‘extended-spectrum (3-lactamase’ was coined to describe this 
phenomenon (Philippon et al., 1989, Paterson and Bonomo, 2005). Since the 
discovery of TEM-1 and SHV-1, over 190 TEM and 141 SHV variants have been 
identified (www.lahev.org/studies).
Described as CTX-M owing to its ability to hydrolyse cefotaxime, a non-TEM, non- 
SHV ESBL found in E. coli was isolated simultaneously in Germany and Argentina 
in 1989 (Bonnet, 2004, Canton et al., 2008). Found to only have a 40% homology to 
TEM and SHV enzymes (Tzouvelekis et al., 2000), CTX-M enzymes emerged via a 
genetic escape and mutation from the medically unimportant Kluyvera spp. (Poirel et 
al., 2002, Bonnet, 2004, Woodford et al., 2004). Approximately 120 CTX-M 
variants have since evolved (www.lahev.org/studies) and it is now the most common 
ESBL type (Munday et al., 2004). CTX-M, specifically CTX-M-9 was first isolated 
in the UK in 2001 (Alobwede et al., 2003) and during the same year, the UK had its 
first ESBL outbreak caused by a CTX-M-26 producing K. pneumoniae in 
Birmingham (Brenwald et al., 2003). However in 2003, CTX-M outbreaks caused by 
CTX-M-15 (Mushtaq et al., 2003) were being reported. CTX-M-15 is now the most 
common CTX-M type in the UK (Munday et al., 2004). Aside from TEM, SHV and 
CTX-M, there are also minor or rarely identified ESBL types such as PER, VEB and 
OXA (Naas et al., 2008).
Another class of important p-lactamases detected in this study are the AmpC p- 
lactamases. Like ESBL enzymes these p-lactamases mediate resistance to 
cephalosporins, oxyiminocephalosporins and aztreonam (Barlow and Hall, 2002); 
however they are not inhibited by clavulanic acid (Bush, 1989a). The transfer of an 
ampC gene via a plasmid can assist in the spread of multiresistant E. coli, K. 
pneumoniae as well as other Enterobacteriaceae (Bauemfeind, 1999). AmpC 
production (either plasmid mediated or inducible chromosomal) can often be
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difficult to distinguish from ESBL production (Thomson, 2001) especially if an 
organism produces both ESBL and AmpC enzymes. Identification of the p- 
lactamase type can be mistaken phenotypically (Perez-Perez and Hanson, 2002).
Variants of p-lactamases have been selected for by the selective pressure caused by 
the use and overuse of antibiotics in the treatment of patients (Bradford, 2001). 
Already in 1985, after the discovery of SHV-2, Kliebe noted that the use of broad- 
spectrum cephalosporins should be handled carefully and warned that resistance 
should be monitored (Kliebe et al., 1985).
The objective of this study was to deduce the molecular epidemiology of ESBLs by 
the use of PCR amplification and DNA sequencing.
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3.2 Results
3.2.1 Screening for ESBL using Cefpodoxime Synergy
Four hundred and fifty-two enterobacterial isolates were collected from the PHW 
Microbiology ABM Swansea laboratory in Singleton Hospital. Isolates were 
screened for ESBL production using cefpodoxime (CPD) and cefpodoxime plus 
clavulanic acid (CPDCV).
Using BSAC guidelines (BSAC, 2007), isolates are said to be resistant to 
cefpodoxime when the zone of inhibition is <19mm. Susceptible isolates have a 
zone of inhibition of >20mm. Of the 452 isolates, 157 isolates were completely 
resistant to cefpodoxime, of which, 141 isolates were found to have a positive 
synergy result with cefpodoxime and cefpodoxime plus clavulanic acid. Seven 
isolates that were classified as susceptible with zones of inhibition of between 
>20mm and <25mm and with no cefpodoxime synergy were also collected. 
Therefore in total, 164 isolates were retained for molecular characterisation and 
further phenotypic analysis.
3.3 Prevalence of ESBL and AmpC-producing Enterobacteriaceae
3.3.1 TEM PCR and sequencing analysis
blajEM specific PCR (Wiegand et al., 2007) revealed that 64 out of 164 potential 
ESBL-producing isolates (45%) were found to be TEM positive thus generating a 
1000 bp amplicon (Fig. 3.1).
To deduce ESBL TEM-status, DNA sequencing (MWG Operon) was carried out on 
the PCR amplification products in order to identify single point-mutations that can 
lead to amino acid substitutions. Using ClustalX (Thompson et al., 1997) the DNA 
sequences obtained were aligned and exported into BioEdit (Hall, 1999) where they 
were translated into amino-acid sequences for further analysis. In this study, TEM- 
33 (L69M), TEM-116 (I84V, V184A) and TEM-52 (K104E, T185M, S238G) were 
found alongside TEM-1. A representation of these results can be seen in Figure 3.2.
Currently, the Lahey Clinic has the amino acid substitutions listed for approximately 
190 different TEM enzymes (www.lahev.org/studiesV Using these guidelines, 8
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TEM  positive amplicons were defined as ESBL (Table 3.1). In total 6 T E M -1 16 
(75%), 1 TEM -33 (12.5%) and 1 TEM -52 (12.5%) were distributed am ongst 5 E. 
coli isolates (3 T E M -1 16, 1 TEM-33 and 1 TEM -52), 2 K. pneumoniae (2 T E M -1 16) 
and 1 Citrobacter freundii (1 T E M -1 16). TEM-1 (non-ESBL) was found in 56 
isolates (88%) and o f  which, 36 (64%) were found in E. coli, 18 (32%) were found 
in Klebsiella spp. and 2 (4%) were found in other Enterobacteriaceae namely C. 
freundii and Enterobacter cloacae.
M 1 2 3 4 5 6  7 8  9 10 11 12 13
1OOObp-
500bp-
Figure 3.1. Agarose gel showing blaTEM specific PCR. Lanes 2-13 have a positive 
product o f  approximately 1000 bp. M -100 bp DNA marker. Lane 1: negative 
amplification control.
Table 3.1. Prevalence and distribution o f  blajem genes found by DNA sequencing 
within 64 TEM -producing isolates
T E M -1 16 TEM -33 TEM -52 TEM-1
E. coli (n=41) 3 1 1 36
Klebsiella spp. (n=20) 2 18
Other (n=3) 1 2
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3.3.2 SHV RFLP and sequencing analysis
38 out of 164 potential ESBL producing isolates (23%) were identified as positive by 
PCR for the blasuv gene by amplification of a 1017 bp amplicon. Positive 
amplification products were distributed amongst 5 E. coli (13%), 31 Klebsiella spp. 
(82%) and 2 E. cloacae (5%).
To determine ESBL status, RFLP analysis was carried out using NheI (Nuesch- 
Inderbinen et al., 1996).
In some SHV genes, this restriction site occurred through the formation of point- 
mutations and in turn led to a glycine to serine amino acid substitution at position 
238. Of the 38 SHV-positive PCR products, 5 (13%) were cleaved with Nhel to 
770bp and 247bp and were deduced SHV-ESBL positive. The 5 ESBL-SHV genes 
were found within 2 E. coli (40%), 2 K. pneumoniae, (40%) and 1 E. cloacae (20%) 
isolates.
At present the Lahey Clinic has listed approximately 141 different SHV enzymes 
(www.lahev.org/studies') and therefore the Nhe I methodology is not applicable for 
the identification of all SHV-ESBLs anymore. In order to identify the specific SHV 
genes found in this study, all 38 positive PCR amplification products were sent for 
DNA sequencing. The DNA sequences were analysed using ClustalX and BioEdit as 
described in section 3.3.1. A representation of these results can be viewed in figure 
3.4, in which DNA sequences have been aligned to highlight amino acid 
substitutions between different SHV genes. In total, 33 non-ESBL SHV genes were 
found. The non-ESBL SHV genes consisted of SHV-1, SHV-11 (L35Q) (Nuesch- 
Inderbinen et al., 1997) and SHV-89 (L35Q, Ml29V) (Li et al., 2009). In total, 10 
SHV-1 (26%), 17 SHV-89 (45%) and 6  SHV-11 (16%), were identified in 3 E. coli 
(1 SHV-1, 1 SHV-89, 1 SHV-11), 29 Klebsiella spp. ( 8  SHV-1, 16 SHV-89, 5 SHV- 
11) and 1 E. cloacae (1 SHV-1). The presence of SHV-2 (G238S) was confirmed by 
DNA sequencing in the 5 aforementioned Nhel cleavable ESBL-SHV isolates (Table 
3.2).
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Figure 3.3 Agarose gel showing SHV-RFLP results. +/- denotes the presence or
absence o f  N h e l .  Isolates 3 and 5 are SH V -ESBL positive as the 1000 bp fragment 
was cleaved to 770 bp and 247 bp. M -  100 bp DNA marker.
Table 3.2 Prevalence and distribution o f  blasuw genes found by DNA sequencing 
within 38 SHV-producing isolates
ESBL-SHV genes Non-ESBL SHV genes
SHV-2 SHV-1 SHV-89 SHV-11
E. coli (n=5) 2 1 1 1
Klebsiella spp. (n=31) 2 8 16 5
Other (n=2) 1 1
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3.3.3 CTX-M PCR and Sequence Analysis
3.3.3.1 CTX-M PCR Results
A multiplex PCR system was devised by Woodford et al. (2006) in order to allow 
the rapid identification of 5 CTX-M phylogenetic groups. Prior to this multiplex 
system, the characterisation of CTX-M alleles would often require two individual 
PCR runs firstly with universal primers and secondly with specific primers. Due to 
the increasing prevalence of CTX-M ESBLs, rapid identification facilitated CTX-M 
monitoring (Woodford et al., 2006).
Using this system, 138 out of 164 potential ESBL-producing isolates (81%) were 
initially found to be positive for a CTX-M gene (Figure 3.2) and were distributed 
within 102 E. coli (77%), 32 Klebsiella spp. (24%) and 5 other isolates (3%) 
specifically 4 E. cloacae and 1 C. freundii. 128 isolates were positive for a CTX-M 
group 1 gene (92%) and were found within 96 E. coli (75%), 30 Klebsiella spp. 
(23%) and 2 E. cloacae (2%) isolates. In addition, 5 E. coli isolates (4%) were 
positive for CTX-M group 9 genes, 4 isolates (2 K. pneumoniae, 1 E. cloacae and 1 
C. freundii) (3%) were positive for CTX-M group 25/26 genes and 1 E. cloacae 
isolate (1%) was found to possess CTX-M group 2 genes. However, to ensure that 
the results obtained with this multiplex PCR system were accurate, PCR using the 
primers in a simplex fashion and later DNA sequencing was carried out (described in 
section 3.3.3.2). Upon doing this, the previously demonstrated CTX-M group 2 gene 
and 4 CTX-M group 25/26 genes were deemed false positive results (see in Figure 
3.5) and so therefore making a total of 133 isolates positive for CTX-M genes.
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M l  2 3 4 5 6 7 8 9 M
400bp- 
200bp-
Figure 3.5 Agarose gel showing the prevalence o f  CTX -M  genes obtained from 
CTX-M  specific multiplex PCR. Lanes 1, 4, 5, 7, 8 - group 1 (415 bp); lane 2 - group 
25/26 (327 bp); lane 3 -  group 9 (205 bp); lane 9 - group 8 (552 bp);, M -  100 bp 
DNA marker.
Table 3.3 Prevalence o f  blacix-u genes found by multiplex PCR and confirmed using 
simplex PCR and sequencing within 164 potential ESBL-producing isolates.
C T X -M
Positive
C T X -M  G ro u p  
1 9
E. coli (n=l 17) 101 96 5
Klebsiella spp. (n=38) 30 30
Other (n=9) 2 2
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3.3.3.2 CTX-M Sequence Analysis
To further characterise isolates with a positive CTX-M PCR product, DNA 
sequencing was carried out using primers that amplify a larger proportion of the gene 
of interest.
3.3.3.2.1 CTX-M Group 1 Sequence Analysis
DNA amplification products positive for a CTX-M group 1 gene (a selection of 48 
E. coli and 16 Klebsiella spp. isolates) were sequenced using primers as described by 
Stiirenburg et al. (2004a). Table 3.4 outlines the prevalence of CTX-M genes found 
in this study. 38/43 (8 8 %) E. coli isolates were positive for CTX-M-15, 2/43 (5%) 
were positive for CTX-M-1, 2/43 (5%) were positive for CTX-M-32 and 1/43 (2%) 
were positive for CTX-M-55. Sequencing revealed that 16 out of 16 (100%) of 
Klebsiella spp. with a positive CTX-M group 1 PCR product contained CTX-M-15. 
When compared to the DNA sequence of CTX-M-1, CTX-M-15 has an A to C 
mutation at position 138, T to C mutation at 239, T to C mutation at 313, G to T 
mutation at 315, G to A mutation at 349, G to T mutation at 427, T to G mutation at 
582, T to C mutation at 609 and A to G mutation 725. CTX-M-55 shares all of these 
mutations except for the T to C mutation at position 239. CTX-M-32 only has one 
DNA mutation when compared to CTX-M-1 -  an A to G mutation at position 325 
(Figure 3.6).
Table 3.4 Prevalence of CTX-M group 1 genes found within a selection of E. coli 
and Klebsiella spp.
CTX-M Group 1 Genes
CTX-M-15 CTX-M-1 CTX-M-32 CTX-M-55
E. coli (n=43) 38 2  2  1
Klebsiella spy. (n=16) 16 0  0  0
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3.3.3.2.2 CTX-M Group 9 Sequence Analysis
PCR amplification products positive for CTX-M group 9 were sent for DNA 
sequencing (MWG Operon) with primers of Eckert et al., (2006). The DNA 
sequences were analysed by initially performing a BLAST search to identify the 
most homologous sequences and then aligning using ClustalX and BioEdit. Out of 5 
positive CTX-M group 9 E. coli isolates, 2 CTX-M-14 (40%), 2 CTX-M-14b (40%) 
and 1 CTX-M-27 (20%) were identified (Table 3.5). When compared to the DNA 
sequence of CTX-M-14, CTX-M-27 has a G to A mutation at position 372, A to G 
mutation at position 702 and A to G mutation at position 725; whereas, CTX-M-14b 
has a G to A mutation at position 570 (Figure 3.7).
Table 3.5 Prevalence of CTX-M group 9 genes found by DNA sequencing within 
E. coli.
CTX-M Group 9 Genes 
CTX-M-14 CTX-M-14b CTX-M-27
E. coli (n=5) 2 2 1
3.3.3.2.3 CTX-M Group 25/26 Sequence Analysis
As amplification of the CTX-M group 25/26 genes could not be achieved by 
singleplex PCR, primers were designed using Primer3 
(http://frodo.wi.mit.edu/primer3A) in order to amplify a larger portion of the gene for 
analysis. However, no positive amplification was yielded using these primers. 
Therefore the positive amplification products generated through the multiplex PCR 
system were sent for DNA sequencing.
A BLAST search revealed that 2 of these PCR products from Klebsiella spp. isolates 
were sorbose-specific phosphotransferase enzyme IIB components also known as the 
phosphotransferase system (PTS) sorbose-specific EIIB component. The PTS system 
is a major carbohydrate active-transport system which phosphorylates and
79
translocates sugars (in this instance sorbose) across the cell membrane (Bramley and 
Komberg, 1987).
The remaining 2 amplification products from isolates of E. cloacae and C. Jreundii 
had homology to an “uncultured bacterium pJM6  unknown genes”.
The positive PCR products generated could have arisen from non-specific annealing 
within the multiplex PCR system. These isolates could not be assigned a CTX-M 
subgroup and were so deemed false positive.
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3.3.4 Amp C prevalence
A multiplex PCR methodology devised by Perez-Perez and Hanson (2002) was used 
in order to detect family-specific plasmid-mediated ampC genes. The detection and 
differentiation o f  Am pC enzymes from ESBL enzymes is necessary for surveillance, 
epidemiology and infection control issues (Perez-Perez and Hanson, 2002).
Therefore in this study, this PCR system was used to determine genes associated 
with the ampC class o f  (3-lactamases. In order to ensure that false-positive results 
were not obtained through the use o f  the multiplex PCR system, singleplex PCR was 
carried out on isolates which generated positive amplification products with the 
multiplex system. O f  the 164 isolates collected, 5 isolates (3%) had ampC genes 
present. One C. freundii isolate was positive with C IT  primers, 1 
M. morganii was positive with IViOX, 1 E. cloacae was positive with EBC and 2 E. 
coli isolates were positive for FOX primers. The CIT, M OX and EBC primers 
encode various specific target sequences (Table 3.6).
M 1 2 3  4
500bp- 
300bp-
100bp-
Figure 3.8 Agarose gel showing ampC specific multiplex PCR. Lane l - positive for 
EBC (302bp); lane 2 - positive for CIT (462bp); lane 3 positive for M O X  (520bp); 
lane 4 positive for FOX (I90bp). M -lOObp DNA marker.
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Table 3.6 Prevalence of ampC gene families and their respective target genes.
ampC gene family Target genes
E. coli (n=2) FOX FOX-1 to FOX-5b
E. cloacae (n=l) EBC MIR-1T ACT-1
C.freundii (n=l) CIT LAT-1 to LAT-4, CMY-2 to 
CMY-7, BIL-1
M. morganii (n=l) MOX MOX-1, MOX-2, CMY-1, 
CMY- 8  to CMY-11
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3.3.5 General summary of ESBL and AmpC prevalence in Enterobacteriaceae
Using primers specific for CTX-M group 1 79% of E. coli, 76% of Klebsiella spp. 
and 11% of other Enterobacteriaceae selected for this study gave positive 
amplification. Of these CTX-M group 1 positive isolates, 92% (54/59) of the E. coli 
and Klebsiella spp. tested were found carry CTX-M-15.
Detection of CTX-M group 9 genes by PCR generated 5 positive amplification 
products, all within E. coli. Therefore 4% of all E. coli in this study were positive for 
CTX-M group 9. The most common CTX-M group 9 types found were CTX-M-14 
and CTX-M-14b.
In this study, only 1 isolate of E. coli was found to possess a TEM ESBL gene 
(TEM-52) alone. In addition, the non-ESBL TEM-1 was found alone in 9 E. coli 
isolates, 3 Klebsiella spp. and 3 other Enterobacteriaceae. Two SHV-2 enzymes 
were found independently of other ESBL genes amongst 1 E. coli and 1 Klebsiella 
spp. isolates. The non-ESBL SHV-1 was found alone in 1 E. coli isolate whereas 
SHV-11 was found in 1 Klebsiella spp. The remaining TEM or SHV non-ESBL 
genes were all found in conjunction with a CTX-M gene. However, 8/12 genetically 
ESBL or AmpC negative E. coli, 3/6 genetically ESBL or AmpC negative Klebsiella 
spp., and 2/4 genetically ESBL or AmpC negative other Enterobacteriaceae 
possessed TEM-1. 1/6 genetically ESBL or AmpC negative Klebsiella spp. 
harboured SHV-11.
Four ampC genes were found alone in this study. These were distributed amongst 2 
E. coli and 2 other Enterobacteriaceae isolates.
Eight isolates were found to possess multiple ESBL and ampC genes. These are 
described in section 3.3.6.
Within 22 isolates, of which 5 isolates had a positive synergy test with cefpodoxime, 
no genetic ESBL or AmpC mechanism could be ascertained. 10% E. coli, 16% 
Klebsiella spp. and 4% other Enterobacteriaceae isolates did not give positive 
amplification with any of the primers used in this study.
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3.3.6 Multiple ESBL and AmpC-producing Enterobacteriaceae 
After conducting TEM, SHV, CTX-M and AmpC PCR, 8  isolates were found to 
harbour more than one ESBLlampC gene (Table 3.8). Four out of 105 (3%) ESBL 
and AmpC-producing E. coli were found to have a TEM gene, of which, 3 (75%) 
were TEM-116 and the remaining 1 (25%) was TEM-33. All were associated with a 
CTX-M group 1 gene. One of these four E. coli isolates harboured 3 p-lactamase 
genes: CTX-M group 1, TEM-116 and SHV-2. Two of 32 (6 %) ESBL-producing 
Klebsiella spp. were found to contain two ESBL genes. Both (100%) were K. 
pneumoniae isolates carrying TEM-116. However, one isolate was found to harbour 
a CTX-M group 1 gene, whereas the other harboured SHV-2. Two of the 5 (40%) 
other ESBL/AmpC-producing Enterobacteriaceae specifically C. freundii and E. 
cloacae, were found to harbour multiple genes. The C. freundii was TEM-116 and 
MOX positive whereas, the E. cloacae harboured CTX-M group 1 and SHV-2 genes.
Table 3.8 Prevalence of multiple ESBLlampC genes within Enterobacteriaceae
ESBL Type
CTX-M TEM SHV AmpC
E. coli Group 1 TEM-33
E. coli Group 1 TEM-116
E. coli Group 1 TEM-116
E. coli Group 1 TEM-116 SHV-2
K. pneumoniae Group 1 TEM-116
K. pneumoniae TEM-116 SHV-2
C. freundii TEM-116 MOX
E. cloacae Group 1 SHV-2
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3.4 Discussion
ESBLs were first reported in 1983 and until 2001 ESBLs in the UK were rare and 
mostly mutants of TEM and SHV which were predominantly found in Klebsiella 
spp. (Potz et al., 2006). However, the emergence of CTX-M since 2001 (Alobwede 
et al., 2003) has led to CTX-M becoming the most predominant ESBL type in the 
UK (Munday et al., 2004). This study provides an insight into the current 
epidemiology of ESBL-producing Enterobacteriaceae in Swansea, South West 
Wales. The molecular characterisation of isolates allows for the prevalence of ESBL 
and ampC genes within a particular area to be determined. The monitoring of ESBL 
enzyme types is fundamental in tracking changes within ESBL epidemiology i.e. 
emergence and dissemination of prevalent genes.
In this study, a multiplex PCR system was used to detect CTX-M genes belonging to 
5 different phylogenetic groups namely CTX-M group 1, group 2, group 8 , group 9 
and group 25/26 (Woodford et al., 2006). Although this method provided a rapid 
identification of CTX-M genes, it was found to have reliability limitations. 
Fragments resembling group 2 and group 25/26 genes were amplified using the 
multiplex system but were later deduced to be false-positives. However, Woodford 
et al., (2006) utilised the primers on control isolates harbouring CTX-M groups 
25/26 and 2 which had been previously sequenced. In their study, 633 isolates were 
analysed by this multiplex PCR system to find that no isolates harboured CTX-M 
group 25/26 genes and only 3 isolates were found to be CTX-M group 2.
The predominant ESBL genotype found was CTX-M. CTX-M-type enzymes were
also prevalent in a study conducted in London and the South East of England by Potz
et al., (2006). In Potz’s study, CTX-M (phylogenetic groups not specified) was
found in 50.7% of E. coli, 81.5% of Klebsiella spp. and 4% of Enterobacter spp. A
study by Warren et al., (2008b) conducted in Shropshire between 2003 and 2006
demonstrated that 8 6 % of ESBLs carried by E. coli were CTX-M, particularly CTX-
M-15. This was also demonstrated by Tarrant et al., (2007) whereby CTX-M-15 was
found in 70% of isolates from the South West of England. Results in this chapter
demonstrate that CTX-M group 1 was found in 92% of isolates, comparable to
figures recorded by Woodford et al., (2004) in whose study 95% (279/291) of
isolates had a CTX-M group 1 gene. CTX-M group 1 was also prevalent during a
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‘Cornish outbreak’ between 2004 and 2005. During this outbreak, 65% (45/69) E. 
coli isolates were found to possess CTX-M group 1 genes. This outbreak strain was 
found to be different by PFGE to any of the UK’s 5 epidemic E. coli strains, A-E 
(Woodford et al., 2007b).
A report by Canton and Coque (2006) demonstrated that CTX-M enzymes were at 
endemic levels in Europe, Canada, South America, Asia, Africa and Australia 
(Canton and Coque, 2006). In Europe, the rate of ESBL carriage is generally 
increasing with CTX-M and TEM ESBLs being the most prevalent enzymes (Coque 
et al., 2008a): CTX-M-15 enzymes are now the most commonly reported ESBL in 
Europe (Peirano and Pitout, 2010). Nordic countries maintain the lowest ESBL rates 
(Coque et al., 2008a). The rate of ESBLs in Europe is less than in South America 
and Asia (Dhillon and Clark, 2011).
Rates of ESBLs in South America are some of the highest in the world (Dhillon and 
Clark, 2011). There, prevalence of ESBL in Klebsiella spp. ranges from 45%-51% 
and in E. coli isolates from 8.5% to 18%. CTX-M is the predominant type of enzyme 
(Turner et al., 1999, Winokur et al., 2001) with CTX-M-2 and CTX-M-9 being most 
prevalent (Villegas et al., 2008).
In Africa, especially North Africa, CTX-M also appears to be the most prevalent 
ESBL type whereas it is suggested that TEM and SHV ESBLs are more frequent in 
South Africa (Bell et al., 2002, Dhillon and Clark, 2011). However, Egypt was found 
to be the African country with the highest rate of ESBLs with 72% of isolates 
exhibiting resistance to 3rd generation cephalosporins (Borg et al., 2006).
Rates of ESBLs are high in Asia and across the region variation in prevalence and 
ESBL types occur (Bell et al., 2002, Dhillon and Clark, 2011). Rates were found to 
be particularly high in China with 40% of E. coli and 20-60% of Klebsiella spp. 
demonstrating an ESBL profile (Bell et al., 2002). CTX-M-14 and CTX-M-9 were 
found to be the most common enzymes in China (Hawkey, 2008). A study carried 
out in India demonstrated ESBL rates to be at 48% (Tankhiwale et al., 2004) and a 
CTX-M genotype notably CTX-M-15 was the most prevalent (Ensor et al., 2006). 
CTX-M enzymes, particularly CTX-M-15, were also found to be most common in E. 
coli and Klebsiella spp. isolates in Australia (Zong et al., 2008).
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In the USA, TEM and SHV ESBLs were once the most predominant ESBL type 
(Comaglia et al., 2008, Livermore et al., 2007). However, it is thought that CTX-M- 
15 is, by now, the most commonly found ESBL genotype. This is comparable to the 
ESBL epidemiology of Canada whereby CTX-M-producing Klebsiella spp. have 
been reported (Melano et al., 2006). It was proposed that the spread of CTX-M from 
Canada to the USA was a potential threat (Dhillon and Clark, 2011).
In this study, CTX-M-15 was found to be the most common ESBL genotype in 
Swansea with 92% of sequenced E. coli and Klebsiella spp. possessing this gene. As 
mentioned above, CTX-M-15 enzymes are now the most commonly reported ESBL 
in Europe (Peirano and Pitout, 2010) and CTX-M-15 has also been reported in 
Canada (Pitout et al., 2007, Pitout et al., 2005a, Boyd et al., 2004), Asia (Ensor et al., 
2006, Hawkey, 2008), Africa (Gangoue-Pieboji et al., 2005), South America 
(Villegas et al., 2008) and Australia (Zong et al., 2008).
The previously recorded changes in ESBL epidemiology can be clearly supported by 
this study. As previously mentioned, TEM and SHV were once the most frequently 
found ESBLs in the UK before the emergence of CTX-M. In this study, only one 
isolate of E. coli was found to possess a TEM gene independent of any other ESBL 
genes and only two isolates (1 E. coli and 1 Klebsiella spp.) were found to harbour 
SHV-2 as a sole ESBL gene.
In this chapter, 8  isolates were found to possess more than one ESBL lampC gene 
suggesting the acquisition of plasmids with multiple-ESBL genes present. In a study 
by Woodford et al., (2006) 1 isolate (1/633) was found to possess a CTX-M group 1 
gene alongside a CTX-M group 9 gene. However, in a study by Romero et al., 
(2007) multiple ESBLs were found more frequently. Out of 154 isolates, 7.8% were 
found to possess CTX-M and TEM genes, 4.6% possessed TEM and SHV genes, 
4.6% possessed CTX-M, TEM and SHV genes and 1.3% possessed CTX-M and 
SHV genes (Romero et al., 2007). Additionally to note, AmpC production (either 
plasmid mediated or inducible chromosomal) can be difficult to distinguish from 
ESBL enzymes. If an organism is an ESBL and AmpC-producer, then identification 
of the p-lactamase type can be mistaken phenotypically thus potentially leading to 
the incorrect usage of antibiotics for treatment (Perez-Perez and Hanson, 2002).
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In this study, 4 isolates were found to possess an ampC gene independent of an 
ESBL gene. The findings of positive PCR amplifications by EBC primers in E. 
cloacae and CIT primers in C. freundii are not unexpected as these isolates are the 
source for EBC and CIT ampC groups. However, the presence of MOX in 
M. morganii suggested a plasmid^acquisition of ampC genes as the expected AmpC 
group associated with M. morganii is DHA (Perez-Perez and Hanson, 2002). In this 
thesis, ampC amplification products were not sequenced and so could be seen as a 
limitation as false positive results could arise through PCR. In addition, to the 4 
isolates harbouring ampC genes, 1 isolate had an ampC gene in conjunction with a 
TEM-116 gene. A study by Kao et a l, (2010) found that ampC genes were 
commonly found in association with a TEM gene. 26/52 E. coli isolates possessed an 
ampC and TEM combination (Kao et al., 2010).
Additionally, the presence of ESBL genes is linked to antibiotic resistance. For 
example, isolates producing TEM and SHV enzymes are usually resistant to 
ceftazidime but exhibit variable resistance to cefotaxime whereas isolates harbouring 
CTX-M are often resistant to cefotaxime and exhibit variable resistance to 
ceftazidime (Livermore and Brown, 2001). It has also been described that CTX-M- 
15-producing isolates are more resistant to ESBL inhibitor combinations e.g. 
piperacillin/tazobactam (Livermore and Hawkey, 2005) and that epidemic E. coli 
strain A is more susceptible to gentamicin (Woodford et al., 2004).
The numbers of ESBLs are continuously expanding and, as described, have been 
detected across the world. The concern with the vast spread of CTX-M genes lies 
with its impact on the clinical setting. With such an increase in CTX-M prevalence, 
treatment options become limited, and so even minor infections like UTI may 
require the use of carbapenems (Livermore and Hawkey, 2005, Peirano and Pitout, 
2010, Dhillon and Clark, 2011). As a result of this increased selective pressure, the 
next threat, in the form of increasing rates of carbapenemases, in on the horizon 
(Livermore, 2009).
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Chapter 4: Evaluation of phenotypic screening and confirmatory 
assays for detection of ESBL-producing Enterobacteriaceae
4.1 Introduction
Extended-spectrum (3-lactamase (ESBL) producers are problematic amongst 
multidrug resistant Enterobacteriaceae as they can hydrolyse extended-spectrum P- 
lactam antibiotics including 1st, 2nd, 3rd generation cephalosporins and the 
monobactam aztreonam. This leads to antibiotic resistance therefore causing 
problems as cephalsporins are key to many clinical antibiotic treatment regimens. 
There are many types of ESBL and their prevalence is increasing world-wide 
(Paterson and Bonomo, 2005, Bonnet, 2004, Livermore and Hawkey, 2005, 
Bradford, 2001).
In the clinical setting, the detection of ESBL is essential as complication and death 
can arise when ESBL-associated infections are treated with cephalosporins, to which 
they are resistant or even susceptible to in vitro. It is imperative to treat ESBL 
infections with the appropriate agents (Paterson et al., 2001, Crowley, 2001, 
Sturenburg and Mack, 2003).
The detection methods employed must be sensitive and accurate as ESBL-producers 
can often appear susceptible to extended-spectrum cephalosporins at a standard 
inoculum size of 105 (Spencer et al., 1987, Jacoby and Medeiros, 1991). Also 
important to note is the need for a rapid and reliable turnaround time which is cost- 
effective.
4.1.1 Laboratory detection of ESBL producing organisms
ESBL detection in the PHW Microbiology ABM Swansea laboratory currently 
involves a two-step procedure whereby Enterobacteriaceae are firstly screened for 
ESBL production and then confirmed as ESBL producers in line with national 
recommendations e.g. those produced by BSAC. Coliform isolates are screened 
using a cefpodoxime (CPD) disc at a concentration of lOpg. If the isolate is found to 
be resistant to cefpodoxime then it is identified using API 20E in parallel to carrying 
out a synergy test. If the synergy test is found to be positive then the isolate can be
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confirmed as ESBL. However, this test is currently recommended for E. coli and 
Klebsiella spp. only (Black et al., 2005).
4.1.1.1 Screening for ESBL
The choice of antibiotics used for ESBL screening is important since different ESBL 
enzymes confer different levels of resistance amongst the cephalosporins in vitro. 
The BSAC recommends that all Enterobacteriaceae are screened for ESBL using an 
indicator cephalosporin as part of primary susceptibility testing (Andrews, 2004). 
Cefpodoxime tends to be used as the indicator of choice, as TEM and SHV are 
resistant to ceftazidime but exhibit variable resistance to cefotaxime whereas 
CTX-M are resistant to cefotaxime and exhibit variable resistance to ceftazidime. 
However in some situations, ceftazidime and cefotaxime can be used instead of 
cefpodoxime. If the tested organism is found to be resistant to the indicator 
cephalosporin then the isolate will undergo confirmation testing (Livermore and 
Brown, 2001).
BSAC produce disc susceptibility testing guidelines for determining whether 
Enterobacteriaceae are sensitive, intermediate or resistant to each antibiotic. Briefly, 
an iso-sensitest agar plate is swabbed with a 0.5 McFarland inoculum of the test 
organism. This step is important as the inoculum should give semi-confluent growth. 
The antibiotic discs are dispensed onto the inoculated agar and the plate is incubated 
at 37°C for 18 hours. After this time has elapsed, the diameters of the zones of 
inhibition are measured in millimetres and can therefore be interpreted. Table 4.1 
outlines the susceptibility profile for each indicator cephalosporin tested in this study 
based upon its zone of inhibition (BSAC, 2007).
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Table 4.1 Interpretation of susceptibility based upon the zone of inhibition created 
when tested with various cephalosporins.
Zone of Inhibition (mm)
Cephalosporin Concentration Resistant < Intermediate Sensitive >
Cefpodoxime (CPD) lOgg 19 2 0
Ceftazidime (CAZ) 30gg 29 30
Cefotaxime (CTX) 30gg 29 30
Cefepime (CPM) 30gg 26 27-31 32
Cefpirome (CFP) 30gg 24 25
Cefuroxime (CXM) 30gg 19 2 0
Cefoxitin (FOX) 30gg 19 2 0
4.1.1.2 Confirmation of ESBL
The production of an ESBL enzyme is confirmed phenotypically via three different 
methods.
4.1.1.2.1 Synergy testing
This disc test involves the comparison of the zones of inhibition between an 
indicator cephalosporin and its augmented (i.e. with clavulanic acid) counterpart 
(Figure 4.1). The presence of an ESBL can be confirmed where the zone of 
inhibition for the cephalosporin plus clavulanic acid is > 5mm larger than the 
cephalosporin alone.
In 2000, M’Zali et al. calculated a ratio of the diameter of the zone of inhibition with 
or without clavulanic acid using the formula:
Cephalosporin/clavulanic acid > 1.5 
Cephalosporin
Therefore, a ratio of > 1.5 can also confirm the presence of an ESBL (M’Zali et al., 
2 0 0 0 ).
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15 mm
Figure 4.1 Principles o f  the synergy test. Synergy can be seen between each 
cephalosporin and clavulanic acid augmented counterpart, as there is a clear 
difference o f  >5m m  between the diameters o f  the zones o f  inhibition. Antibiotics 
used: cefpodoxime (CPD), ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), 
cefuroxime (CXM), cefepime (CPM ) and cefpirome (CFP) along with the respective 
augmented discs -  clavulanic acid (CV).
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4.1.1.2.2 Disc Approximation Test
The Disc Approximation Test utilises co-amoxiclav (amoxicillin-clavulanic acid) as 
a source o f  clavulanic acid. The co-amoxiclav disc is placed in the centre o f  an 
inoculated agar plate surrounded by discs containing cephalosporins alone e.g. 
cefpodoxime, ceftazidime, cefotaxime at a distance o f  25-30 mm apart (Fig 4.2) 
(Thomson and Sanders, 1992). ESBL presence is confirmed where there is a 
distortion to the zone o f  inhibition between the cephalosporin and co-am oxiclav 
discs.
Distance 20-30 mm
Figure 4.2 Representation o f  the Disc Approximation Test. Co-amoxiclav (AUG) 
has created a distortion and expansion in the zones o f  inhibition around the indicator 
cephalosporins. However, no distortion is seen between co-am oxiclav and 
cefpodoxime (CPD). Antibiotics used: cefpodoxime (CPD), ceftazidime (CAZ), 
cefotaxime (CTX), cefepime (CPM ) and cefpirome (CFP) along with the co- 
amoxiclav (AUG).
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4.1.1.2.3 ESBL E-test
The ESBL E-test utilises a plastic strip impregnated at one end with a cephalosporin
e.g. ceftazidime with a concentration range o f  0 .2 5 -1 6 mg/L. Its c lavulanic acid
counterpart e.g. ceftazidime with 4mg/L clavulanic acid with a concentration range
o f  0 .0 6 4 -4 mg/L is found on the opposite end. The respective MIC can be read from
the scale where the ellipse o f  the inhibition zone cuts the strip. ESBL production is 
confirmed if the ratio o f  the MIC o f  cephalosporin alone to the MIC o f  cephalosporin 
plus clavulanate is >8 (Cormican et al., 1996). The deformation o f  the zone o f  
inhibition ellipse or the formation o f  a ‘phantom zo n e’ o f  inhibition is also 
characteristic o f  ESBL production (Stiirenburg et al., 2004b).
T E M - 5 2
C T X  C A Z
Figure 4.3 The ESBL E-test. The indicator cephalosporin is found at the upper half  
o f  the E-test strip in this case, CT is cefotaxime and TZ is ceftazidime. The lower 
half o f  the E-test strip contains the indicator cephalosporin plus clavulanic acid. Both 
are within an MIC gradient. In this example, a TEM -52 producing E. coli has a 
ceftazidime reading o f  >32pg/m l and a ceftazidime plus clavulanic acid reading o f  
0.125pg/ml. As the ratio between the two concentrations are >8, which is >  three 
MIC dilution steps, the isolate is confirmed to be ESBL producing. Reproduced from 
Stiirenburg and Mack (2003).
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4.1.1.3 Detection of ESBL in strains harbouring inducible AmpC
In the clinical laboratory, the presence of an inducible AmpC may hinder the 
detection of ESBL production in strains harbouring both AmpC and ESBL enzymes. 
AmpC is poorly inhibited by clavulanic acid thus it allows the AmpC (3-lactamase to 
attack the cephalosporin. This process can disguise synergy caused by the inhibition 
of the ESBL therefore preventing its detection. To overcome this problem, cefepime 
or cefpirome may be used. These antibiotics are stable to inducible AmpC and are 
therefore not hydrolysed as successfully (Tzouvelekis et al., 1999).
4.1.2 Phenotypic detection of AmpC
Currently in clinical laboratories, plasmid-mediated AmpC (3-lactamases are not 
routinely screened for (Black et al., 2005). However, all Enterobacter spp., C. 
freundii, Serratia spp., Providencia spp., and M. morganii (not isolated from urine 
samples) are recommended to be reported as resistant to all 3rd generation 
cephalosporins, as they all possess chromosomal ampC genes which can be induced 
by certain (3-lactam antibiotics (Livermore et al., 2001). In many clinical isolates of 
these species ampC expression becomes derepressed leading to resistance to all 
cephalosporins with exception of 4th generation cephalosporins and carbapenems.
There are methods available to phenotypically determine AmpC production. Four 
examples have been illustrated below. Of these, three use cefoxitin as an indicator as 
its susceptibility profile can be used to predict the inducibility of AmpC enzymes 
(Moritz and Carson, 1986). However, in this study the Mast® AmpC and ESBL 
Detection set was evaluated. This is a commercially available phenotypic kit which 
is also described here.
4.1.2.1 Cefoxitin/cefotaxime antagonism
This method is a modified Disc Approximation Test (Sanders et al., 1982). A 30pg 
disc of cefoxitin is placed 25-30mm away from a 30pg disc of cefotaxime on an Iso- 
sensitest agar plate inoculated using BSAC guidelines. AmpC presence can be 
inferred when there is an antagonism between the two discs i.e. if the zone of 
inhibition radius between cefoxitin and cefotaxime is smaller by 4mm than the zone 
of inhibition produced by cefotaxime alone. Alternatively, antagonism can be
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identified by a ‘blunting’ of the cefotaxime zone of inhibition adjacent to the 
cefoxitin disc (Livermore and Brown, 2001).
4.1.2.2 Boronic acid disc test
In 2005, both Brenwald et al. and Coudron discussed the use of benzo(b)thiophene- 
2-boronic acid (Boronic acid) in combination with a cephalosporin to determine 
AmpC production. Boronic acid is an AmpC inhibitor (Beesley et al., 1982). Using 
BSAC guidelines, iso-sensitest agar is inoculated and discs containing a 
cephalosporin, cephalosporin plus clavulanic acid (clavulanic acid induces AmpC), 
either with or without Boronic acid, are placed on the surface and allowed to 
incubate overnight. A positive result is defined as a difference of > 5mm in the zone 
of inhibition around the combined disc in comparison to the cephalosporin alone 
(Brenwald et al., 2005) The method utilised by Coudron differs in that cefotetan 
(CTT) is used along with phenylboronic acid (Coudron, 2005). Cefotetan is a strong 
inducer of ampC p-lactamases.
4.1.2.3 Mast® AmpC and ESBL Detection Set
This method is capable of detecting the presence of an ESBL, AmpC or a 
combination of both. The detection set comprises of four discs; A, B, C and D. The 
discs contain lOpg of cefpodoxime, lOpg of cefpodoxime plus ESBL inhibitor, lOpg 
of cefpodoxime plus AmpC inhibitor and 10pg of cefpodoxime plus ESBL inhibitor 
and AmpC inhibitor, respectively. The diameters of the zones of inhibition (Z) are 
measured and a series of calculations (Table 4.2) performed to deduce the presence 
of ESBL, AmpC or both as recommended by the manufacturer.
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Table 4.2 Zone calculations to determine presence of ESBL and/or AmpC
Interpretation Zone calculation Result
ESBL positive ZB -Z A and Z D -Z C > 5mm
ZD - ZB and ZC - ZA < 5mm
AmpC positive Z B -Z A and Z D -Z C < 5mm
ZD - ZB and ZC - ZA > 5mm
ESBL and AmpC positive Z D -Z C > 5mm
Z B -Z A < 5mm
AmpC and ESBL negative All zones differ by < 2mm
4.1.3 ESBL detection using semi automated systems
In order to decrease laboratory turnaround time and provide a cost-effective result, 
semi automated systems are routinely used to identify bacteria and to provide 
antimicrobial susceptibility testing (Wiegand et al., 2007). Some of these 
commercially available instruments also have algorithms capable of detecting ESBL 
e.g. BD Phoenix, Vitek (bioMerieux, France), MicroScan Walkway System 
(Siemens, Germany) and Sensititre ARIS (Automatic Reading and Incubation 
System). In this study the BD Phoenix Automated System was used and the Phoenix 
Xpertsystem evaluated with respect to ESBL identification. The methodology is 
detailed in Chapter 2. However, bacterial identifications provided by the BD 
Phoenix Automated System were compared with identifications using the Bruker 
Daltonics MALDI-Biotyper system. Results of this evaluation are outlined in detail 
in Chapter 7.
In facing the changing epidemiology of ESBL-types encountered in 
Enterobacteriaceae it is necessary to validate the performance of the diagnostic 
armamentarium with recent molecularly confirmed isolates. The aims of the 
experiments described in this chapter therefore included:
• Bacterial species identification by the BD Phoenix Automated System
99
• Detection of ESBL using the BD Phoenix Xpert System and rule 1505
• Sensitivity of ESBL screening using indicator cephalosporins (a comparison 
of BSAC and HPA QSOP51 guidelines)
• Sensitivity of confirmation using indicator cephalosporins (a comparison of 
the Synergy Test and Disc Approximation Test)
• Sensitivity of cefoxitin for the detection AmpC
• The evaluation of the Mast® AmpC and ESBL Detection set.
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4.2 Results
4.2.1 Bacterial species identification
In order to identify the Enterobacteriaceae collected from the PHW Microbiology 
ABM Swansea laboratory, the BD Phoenix Automated system and Bruker Daltonics 
MALDI Biotyper were used (latter results reported in Chapter7).
4.2.1.1 Identification of isolates by BD Phoenix automated system
The BD Phoenix Automated System was used to provide an identification of the 
Enterobacteriacae collected. The BD Phoenix system and method utilised are 
described in Chapter 2 section 2.4.1. One hundred and sixty-four isolates were 
subjected to identification by this semi-automated system and the identifications are 
shown in Table 4.3.
Table 4.3 Bacterial identification using BD Phoenix Automated System
Identification by BD Phoenix Number of isolates (n=164)
E. coli 117
Klebsiella pneumoniae 30
Klebsiella pneumoniae ssp. ozaenae 4
Klebsiella oxytoca 4
Enterobacter cloacae 6
Citrobacter freundii 1
Citrobacter koseri 1
Morganella morganii 1
o
library
4.2.1.2 Identification of ESBL by BD Xpert System (BD Phoenix)
Using antimicrobial susceptibility testing (AST) results, the BD Xpert system was 
able to deduce ESBL production. The BD Xpert System delegates rules depending 
on the resistance profile produced.
Table 4.4 BD Xpert system rules
Rule Definition
1505 “Isolate is confirmed positive for Extended-Spectrum Beta-Lactamase
(ESBL). Consultation with an infectious disease practitioner is 
recommended. ”
106 “Screening tests suggest a possible Extended-Spectrum Beta-Lactamase
(ESBL) producer. Confirmatory testing is recommended before reporting 
results for penicillins, extended-spectrum cephalosporins or aztreonam” 
1433 “Isolate exhibits unusual resistance to third generation cephalosporins.
Additional confirmatory testing for possible ESBL or AmpC 
hyperproduction is recommended before reporting results fo r  beta- 
lactams
Table 4.5 outlines the BD Phoenix rules found within the 164 isolates tested. 88.4% 
(145/164) of all isolates were delegated rule no. 1505, 3.1% (5/164) generated rule 
no. 106, 1.2% (2/164) generated rule no. 1433 and 7.3% (12/164) had no ESBL 
related rule associated to their resistance profile. 84% (138/164) of isolates were 
molecularly confirmed as ESBL (see Chapter 3). Of these 138 isolates, 134 
generated rule no. 1505 suggesting an overall sensitivity of 97% in detecting ESBL, 
for the BD Phoenix system. However, if the other species of Enterobacteriaceae are 
disregarded from this figure so that only ESBL E. coli and Klebsiella spp. are 
counted, then the sensitivity of the BD Phoenix automated system increases to 99%.
93% (109/117) of all E. coli generated rule no. 1505. 4% (5/117) generated rule no. 
106 and 3% (4/117) generated no ESBL related rule. 8 8 % (103/117) E. coli were 
molecularly confirmed to be ESBL-producing, of which, 102 (99%) were ascribed as 
rule no. 1505. One (1%) molecularly confirmed E. coli isolate (CTX-M-32) was 
delegated rule no. 106 by the BD Xpert System. The BD Xpert System generated
1 0 2
rule no. 106 for 2 AmpC producing E. coli, which were found independently of an 
ESBL gene.
95% (36/38) of all Klebsiella spp. generated rule no. 1505 by the BD Xpert System. 
5% (2/38) of Klebsiella spp. did not have any ESBL related rule. However, one 
Klebsiella spp. possessed rule 2004 and another Klebsiella spp. generated rule 1503. 
These are p-lactamase related rules and are as follows: rule no. 2004 
“Enterobacteriaceae, resistant to any second generation cephalosporins, are 
resistant to first generation cephalosporins, because they are likely to have potent 
beta-lactamase. ” and rule no. 1503 ‘'‘When K1 hyperproduction phenotype (a pattern 
o f intermediate or resistant to aztreonam) is detected in Klebsiella oxytoca, an 
interpretation o f  susceptible fo r  beta-lactams, except carbapenems, cephamycins, 
fourth generation cephalosporins, ceftazidime, or moxalactam should be changed to 
resistant. ” 82% (31/38) Klebsiella spp. were molecularly confirmed as ESBL, all of 
which (100%) were delegated rule no. 1505.
Rule no. 1505 was generated in seven non-molecularly confirmed E. coli isolates and 
4 Klebsiella spp.
Apart from E. coli and Klebsiella spp., rule no. 1505 was not generated in any other 
species. However, an alternative rule, 1433 was generated in 3/9 remaining 
Enterobacteriaceae isolates (all of which were E. cloacae). 67% (2/3) were 
molecularly confirmed as ESBL-producers. Although possessing rule no. 1433, the 
remaining isolate (33%) was not genetically confirmed as carrying ESBL or AmpC.
One isolate generated rule no. 106. This isolate was identified as 
E. cloacae and was genetically confirmed to be an AmpC-producer. The BD Xpert 
system did not generate a rule for the second genetically confirmed AmpC- 
producing isolate.
In conclusion it appears that the BD Phoenix Xpert system screened and confirmed 
ESBL presence in the molecularly confirmed E. coli and Klebsiella spp. with high 
sensitivity.
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Table 4.5 Detection of ESBL-producing organisms based on specific rules generated 
by BD Xpert System (BD Phoenix)
BD Phoenix Rule
No ESBL or
1505 106 1433 AmpC rule
Total (n=164) 145 5 2 1 2
All E. coli (n=l 17) 109 4 4
Molecular ESBL E. coli (n=103) 1 0 2 1
E. coli IS26 Postive (n=6 6 ) 6 6
E. coli IS26 Negative (n=37) 36 1
AmpC positive E. coli (n=2) 2
All Klebsiella spp. (n=38) 36 2
Molecular ESBL Klebsiella spp. (n=32) 32
All Other (n=9) 1 3 5
ESBL Other (n=3) 2 1
AmpC Other (n=2 ) 1 1
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4.3 Sensitivity of ESBL screening using BSAC and HPA QSOP 51 guidelines
The choice of inhibitor cephalosporin is crucial in screening for presence of ESBL. 
The sensitivity of screening has been analysed using two sets o f guidelines -  BSAC 
and HPA QSOP51. The only difference between these guidelines is the adjustment 
of ceftazidime breakpoints. BSAC list a screening breakpoint of 17mm and the HPA 
QSOP51 guidelines propose increasing the breakpoint to 21mm. The screening 
results for all isolates along with all molecularly confirmed ESBL and AmpC 
isolates using BSAC guidelines and HPA QSOP 51 guidelines are outlined in tables 
4.6 and 4.7.
Using cefpodoxime, 157/164 (96%) of all isolates were found to be resistant giving 
an overall sensitivity of 99% when taking all molecularly confirmed ESBL carriers 
as a baseline for true positives. The sensitivity of screening for ESBL-producing E. 
coli was 99% whereas it was 100% sensitive for Klebsiella spp. and other 
Enterobacteriaceae. Cefotaxime was the next most sensitive indicator cephalosporin, 
with an overall sensitivity of 91% for all molecularly confirmed ESBL isolates. 
Cefotaxime was found to have a better sensitivity in detecting ESBL-carrying 
Klebsiella spp. (100%) than E. coli (8 8 %). Two different guidelines were utilised in 
the evaluation of ceftazidime; BSAC and HPA QSOP51. Using BSAC guidelines, a 
sensitivity of 36% was achieved for all molecularly confirmed ESBL isolates 
whereas this increased to 41% using HPA QSOP51 guidelines. Sensitivity for 
ESBL-producing E. coli isolates was 18% using BSAC guidelines and this 
percentage increased to 25% using HPA guidelines. An difference of 4% in 
sensitivity was demonstrated between the two guidelines for Klebsiella spp.; 84% 
sensitivity with BSAC and 8 8 % sensitivity with HPA QSOP51 guidelines. The 
sensitivity of cefepime screening was also quite poor, with an overall sensitivity of 
48% for molecularly confirmed ESBL isolates. However, it was found to be more 
sensitive at screening ESBL-producing Klebsiella spp. (84%) than E. coli isolates 
(37%). Using cefpirome, a screening sensitivity of 69% was achieved for all 
molecularly confirmed ESBL isolates. Again it was also found to be more sensitive 
at screening for ESBL-producing Klebsiella spp. (8 8 %) than E. coli isolates (67%)
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In summary, cefpodoxime and cefotaxime are the most suitable indicator 
cephalosporins as a sensitivity of 99% and 91% was attained.
Using a combination of ceftazidime and cefotaxime gave overall sensitivities for 
molecularly confirmed ESBL-producing isolates of 91% and 92% using BSAC and 
HPA QSOP51 guidelines, respectively. However by using a combination of 
cefpodoxime and ceftazidime along with the HPA QSOP51 guidelines, gave 100% 
sensitivity of ESBL screening. Using BSAC guidelines meant that a sensitivity of 
99% was achieved. This pattern is followed throughout as more disc combinations 
are investigated. For example, using a 3, 4 or 5 disc combination would give either a 
99% or 100% sensitivity depending on the guidelines followed.
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4.3.3 Sensitivity of cefoxitin screening for AmpC detection
Coudron et al. used cefoxitin as an initial screening method for the detection of 
AmpC. A zone diameter of <18mm is used as a breakpoint for determining 
resistance (Coudron et al., 2000, Manchanda and Singh, 2003). However, BSAC 
utilise a breakpoint of <19mm (BSAC, 2009) and it is this measurement that is used 
in this study.
Table 4.8 Cefoxitin resistance amongst molecularly confirmed ESBL and AmpC
Cefoxitin Susceptibility
Resistant Susceptible
ESBL E. coli (n=103) 9% 91%
AmpC E. coli (n=2) 1 0 0 % 0 %
ESBL Klebsiella spp. (n=32) 25% 75%
Others ESBL (n=2) 1 0 0 % 0 %
Others AmpC (n=2) 1 0 0 % 0 %
Others ESBL and AmpC (n=l) 1 0 0 % 0 %
Total (n=142) 17% 83%
As outlined in Table 4.8, it is clear that amongst the ESBL-producing 
Enterobacteriaceae; cefoxitin resistance is low i.e. 9% for ESBL E. coli and 25% 
with Klebsiella spp. This has been noted before as an indicator for presence of ESBL 
in this species when there was a discrepancy between 3rd generation cephalosporin 
resistance paired with cefoxitin susceptibility in these species (Stiirenburg and Mack, 
2003). However, it is interesting to mention that all of the molecularly confirmed 
AmpC were in fact completely resistant to cefoxitin.
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4.4 Sensitivity of ESBL confirmation using Synergy and Disc Approximation 
tests
4.4.1 Sensitivity of the Synergy Test in confirming ESBL in molecularly 
confirmed isolates
Figure 4.1 provides an example of how the synergy test is applied to confirming 
ESBL within Enterobacteriaceae. This figure displays synergy between all of the 
indicator cephalosporins and their respective clavulanic acid counterparts for this 
particular isolate.
However, by looking at the confirmatory assay, it is also important to note how 
effective each cephalosporin is, both individually and in combination, at successfully 
confirming the presence of an ESBL. Results are compiled in tables 4.9 and 4.10
Using cefpodoxime, 138/164 (84%) of all isolates gave a positive synergy test and of 
these 132/138 (96%) molecularly confirmed ESBL-producing isolates were positive 
by synergy thereby giving a sensitivity of 96%. Cefpodoxime was 97% sensitive at 
confirming ESBL in E. coli and 94% in Klebsiella spp. Using cefotaxime, an overall 
sensitivity for molecularly confirmed ESBL-producing isolates was 77% and similar 
sensitivities were observed for E. coli and Klebsiella spp.; 77% and 78%, 
respectively. The use of ceftazidime gave an overall sensitivity of 71% for 
confirming molecularly confirmed ESBL isolates. Ceftazidime was more sensitive at 
confirming ESBL in Klebsiella spp. (94%) than E. coli (64%). Cefepime and 
cefpirome had a poorer sensitivity for confirming ESBLs as overall for all 
molecularly confirmed ESBLs, sensitivities of 51% and 62% were found. However a 
difference could be ascertained between molecularly confirmed ESBL-producing E. 
coli and Klebsiella spp. (Table 4.9).
When using combinations of cephalosporins, it might be possible to confirm a 
greater number of ESBLs. For E. coli, the combination of cefpodoxime and 
cefotaxime meant that all ESBLs would be confirmed. As expected, neither of the 
AmpC producing E. coli demonstrated synergy using cephalosporin combinations. 
Combining cefpodoxime and ceftazidime confirmed 100% of Klebsiella spp. For all 
other Enterobacteriaceae, combinations of cephalosporins maintained a sensitivity 
of 67%.
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In summary, the most suitable two disc approach for confirming the presence of 
ESBL was found either with cefpodoxime and cefotaxime or cefpodoxime and 
cefotaxime as synergy was exhibited in 98% of all the molecularly confirmed ESBL- 
producing Enterobacteriaceae. However, the addition of ceftazidime achieved 99% 
sensitivity. The combination of cefotaxime and ceftazidime as advocated by the 
CLSI was inferior in sensitivity for ESBL confirmation in the strain collection 
investigated in this thesis.
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4.4.2 Sensitivity of the Disc Approximation Test in confirming ESBL in 
molecularly characterised isolates
Figure 4.2 demonstrates a typical positive Disc Approximation Test. Distortion and 
expansion of the zones of inhibition is observed between the indicator 
cephalosporins and the central co-amoxiclav disc. Even though there is no zone of 
inhibition around cefpodoxime in this example, it is possible to state that synergy has 
still occurred due to the distortion and zone created in between the cefpodoxime and 
co-amoxiclav discs.
As with the Synergy Test, it is important to look at which indicator cephalosporins, 
both individually and in combinations, are the most sensitive at confirming ESBL 
status for the Disc Approximation Test.
The results are outlined in Table 4.11 and 4.12. Using cefpodoxime, 98/134 of 
molecularly confirmed ESBL-producing isolates exhibit distortion around the zone 
of inhibition, thereby giving a sensitivity of 73%. For E. coli and Klebsiella spp., 
sensitivities of 75% and 69% were found, respectively. Two molecularly confirmed 
ESBL-producing E. cloacae isolates were positive for distortion giving a sensitivity 
of 67%. In addition one AmpC-producing E. cloacae isolate was positive. Using 
cefotaxime, cefepime and cefpirome, overall sensitivities of 96% were achieved and 
all gave 100% sensitivity at confirming ESBL in Klebsiella spp. However, for 
ceftazidime, an overall sensitivity of 95% was found for molecularly confirmed 
ESBL-producing isolates as it confirmed ESBL in 94% of Klebsiella spp. Therefore, 
for the Disc Approximation Test, cefpodoxime is not the best indicator 
cephalosporin of choice (73%).
When using combinations of cephalosporins, it is possible to increase the sensitivity 
for confirming ESBL. For E. coli, the combination of cefpodoxime, ceftazidime, 
cefotaxime and cefepime increased sensitivity to 98%. However, for Klebsiella spp., 
the sensitivity can be increased to 1 0 0 % with a combination of cefpodoxime and 
cefotaxime or ceftazidime. The sensitivity for the other Enterobacteriaceae remained 
at 67% regardless of combinations.
In summary, the best two-disc approach for confirming sensitivity when using the
Disc Approximation Test is achieved through the use of either cefpodoxime and
120
ceftazidime or ceftazidime and cefotaxime, with sensitivities of 96%. By using four 
or five discs, the sensitivity increased to 98%.
121
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4.5 Mast AmpC and ESBL Detection Set
In order to evaluate the Mast® AmpC and ESBL Detection Set, an additional number 
of organisms were obtained from the PHW Microbiology ABM Swansea laboratory 
as the number of AmpC-producing Enterobacteriaceae collected in this thesis were 
few. In total 10 isolates were collected including 2 E. coli, 3 Klebsiella spp., 2 
Serratia marcescens, 2 C. Jreundii and 1 E. cloacae. PCR for TEM, SHV and CTX- 
M were carried out on all 10 isolates. However, no positive amplification for ESBL 
genes was found. Using the multiplex PCR for ampC genes described in Chapter 3, 6  
of these isolates were found to be positive; 3 Klebsiella spp. gave positive 
amplification for the FOX primers whereas 1 E. cloacae and 2 C. Jreundii were 
positive with the CIT primers. They were therefore included as AmpC-producers in 
this section of study. As the remaining 2 E. coli and 2 S. marcescens were not 
molecularly characterised, they were not counted in this evaluation or in table 4.13. 
However, by using the Mast® AmpC and ESBL Detection Set, these isolates were 
phenotypically AmpC positive.
The Mast® AmpC and ESBL Detection Set was used on a subset of 64 
Enterobacteriaceae. Of these 53 were ESBL, 10 were AmpC-producers and 1 
contained both an ESBL and AmpC. The set detected ESBL (sensitivity 98%) and 
AmpC (sensitivity 100%) in E. coli, Klebsiella spp. and other Enterobacteriaceae, 
with the exception to detect the presence of ESBL in one C. Jreundii isolate 
harbouring TEM-166 and an ampC gene. In fact no phenotypic test used within this 
study was able to confirm the presence of ESBL in this particular isolate.
Table 4.13 Evaluation of Mast® AmpC and ESBL Detection set
Mast® Disc Result
ESBL AmpC ESBL+AmpC
ESBL E. coli (n=32) 100% (32)
AmpC E. coli (n=2) 1 0 0 % (2 )
ESBL Klebsiella spp. (n=19) 100% (19)
AmpC Klebsiella spp. (n=3) 100% (3)
ESBL Other (n=2) 1 0 0 % (2 )
AmpC Other (n=5) 100% (5)
ESBL+AmpC Other (n=l) 0 % (0 ) 1 0 0 % ( 1) 0 % (0 )
All (n=64) 98% (53) 1 0 0 % (1 1 ) 0 % (0 )
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4.6 Discussion
The quick and effective detection of ESBL producing Enterobacteriaceae is critical 
for patient treatment and for initiating correct infection control procedures to prevent 
the spread of infection (Stiirenburg and Mack, 2003). With changes in molecular 
epidemiology and the emergence of new enzyme types, it is vital that continuous 
monitoring of current methods is undertaken.
The phenotypic screening and confirmation methods used in the detection of ESBL 
raise the question of whether the indicator cephalosporins currently used are still 
effective or not. By carrying out testing on a collection of molecularly confirmed 
ESBL, the sensitivity can be deduced in order to decide on which cephalosporin or 
indeed combinations of cephalosporins are the most suitable.
BSAC recommends that cefpodoxime is used as an indicator of choice (BSAC, 
2007, BSAC, 2009) as variable resistance to cefotaxime and ceftazidime is seen 
(Livermore and Brown, 2001). This is particularly advisable since in this study it 
was found that the majority of ESBL enzymes are CTX-M and hence have a greater 
activity against cefotaxime. Table 4.7 shows that the additional use of ceftazidime 
(with HPA QSOP 51 guidelines) alongside cefpodoxime would detect 100% of 
ESBL-producing Enterobacteriaceae. With regards to ESBL confirmation, 
cefpodoxime is also the indicator cephalosporin of choice stipulated by BSAC, but 
for the Synergy Test the addition of cefotaxime would increase sensitivity from 96% 
to 98%. The further addition of ceftazidime would increase sensitivity to 99%. When 
using the Disc Approximation test, cefpodoxime is not the most suitable indicator 
cephalosporin at confirming ESBL as a sensitivity of only 73% was achieved. On 
average, for the remaining cephalosporins both individually and in combination a 
sensitivity of 95-96% is found. However, four discs are required to achieve 98% 
sensitivity. The Disc Approximation Test is simple and easy to carry out; however, 
the interpretation of results is subjective. This has been commented on previously 
(Vercauteren et al., 1997, Brown et al., 2000).
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The laboratory detection of ESBL can often be problematic due to the presence of 
AmpC enzymes. In this study, one C. Jreundii isolate was found to possess TEM-116 
and an ampC gene. Unfortunately, the isolate was negative to all phenotypic ESBL 
tests and would have therefore been overlooked as an ESBL carrier in the clinical 
setting. None of the AmpC-producing Enterobacteriaceae were phenotypically 
misidentified as ESBL. The Mast® AmpC and ESBL Detection Set was evaluated as 
a commercial kit which allowed for the detection of both AmpC and ESBL (both 
individually and in combination). In this study, the kit was effective at confirming 
presence of ESBL or AmpC with an overall sensitivity of 98%. However, the 
aforementioned C. Jreundii proved to be a challenge as the ESBL was not detected 
with this method also. This is because cefpodoxime is not a suitable indicator 
cephalosporin in this instance. A study by Ingram et al., (2011) found a sensitivity of 
96% (71/74) and specificity of 98% (169/172) when using this detection set whereas 
it achieved 83.3% sensitivity in a study by Coyle et al., (2011).
The capability of the BD Phoenix Automated System to detect ESBL in the clinical 
laboratory is well established (Leverstein-van Hall et al., 2002, Stiirenburg et al., 
2003, Sanguinetti et al., 2003, Wiegand et al., 2007). Results in this chapter show 
that the BD Phoenix Automated System had 99% sensitivity at detecting ESBL, 
which is directly comparable to the BD Phoenix results found by Wiegand et al. in 
2007. Leverstein-van Hall et al. (2002) had 89% sensitivity for identifying ESBLs 
whereas Sanguinetti et al. (2003) and Stiirenburg et al. (2003), achieved 100% 
sensitivity for identifying ESBLs.
Although the population of AmpC-producing Enterobacteriaceae is small (n=4), the 
BD Phoenix generated rule no. 106 for 3 of these isolates. Thus it is difficult to state 
whether there are any problems associated with AmpC detection using the BD 
Phoenix. However, a collection of 22 isolates which were not molecularly 
characterised as ESBL or AmpC provided some interesting results whereby rule nos. 
1505 (found in 7 non-molecularly confirmed E. coli, 4 Klebsiella spp.), 106 (1 E. 
coli isolate) and 1433 (1 E. cloacae) were obtained. Of these 13 isolates, only 4 of 
the E. coli and 4 Klebsiella spp. had positive phenotypic ESBL tests (Synergy Test 
and Disc Approximation Test) thereby possibly suggesting that isolates with a BD
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Phoenix rule and positive confirmatory phenotypic tests may contain ESBL genes 
that are atypical and rarer. For the remaining 4 E. coli and 1 E. cloacae, which did 
not have positive phenotypic confirmatory ESBL tests and were not molecularly 
confirmed as ESBL-carriers, the BD Phoenix could have flagged false-positive 
ESBL results. Specificity of ESBL detection was also a problem noted in the study 
reported by Wiegand et al., (2007). However, the strain collection in this thesis did 
not contain enough cephalosporin resistant, ESBL-negative isolates to properly 
evaluate the specificity of the BD Phoenix for ESBL detection.
In summary, analysis of the methods employed in this study give an indication of 
suitable ESBL detection strategies. It is clear that for ESBL screening, the addition 
of ceftazidime using HPA QSOP 51 guidelines could improve sensitivity to 100% 
as found in this chapter. For the confirmation of ESBL, although the Disc 
Approximation Test is simple to use, the subjectivity of interpretation could 
potentially lead to error. Therefore, the use of the Synergy Test with appropriate 
cephalosporins (to maximise sensitivity) is usually recommended. However, using 
cefpodoxime alone for confirmation has a high sensitivity of 96%, which could be 
improved to 100% by additionally using cefotaxime in combination. Adding further 
additional cephalosporins in combination would probably be considered 
unacceptable by most clinical microbiology laboratories.
The commercial AmpC and ESBL Detection Set was shown to be 98% effective 
overall and proved to be an adequate detection system for AmpC with a sensitivity of 
100%. Only few independent evaluations have been performed of this assay, which 
indicated similar promising results (Ingram et al., 2011). However, an increased 
number of ESBL and AmpC producing Enterobacteriaceae would need to be 
evaluated and ideally such a collection should also contain challenge organisms 
without any of the two resistance mechanisms despite cephalosporin resistance to 
assess the specificity of the test.
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Chapter 5: Typing and characterisation of ESBL isolates
5.1 Introduction
Antibiotic resistance is an ongoing problem as limitations are faced with regards to 
treatment options (Paterson et al., 2000). ESBLs are often associated with multidrug 
resistances (Livermore and Hawkey, 2005) and thus subsequently pose greater 
treatment limitations. This problem is emphasised more so when clonal 
dissemination occurs. Courvalin et al., (2001) describes clonal dissemination as 
being “due to chromosome replication, plasmid conjugation to replicative transfer 
and gene migration with replicative transposition” (Courvalin and Trieu-Cuot, 
2001).
Clonal dissemination can be associated with the spread of virulence factors as well 
as multidrug resistances (Coque et al., 2008b, Clermont et al., 2009). The ability to 
accurately identify strains and clones capable of causing infection is paramount to 
epidemiological surveillance and public health decisions. There are many methods 
for identifying genetic relatedness. However, discrepancies can occur when the 
results are not reproducible between laboratories. Therefore, molecular typing with 
good discrimination has been developed to overcome this problem (Maiden et al., 
1998) and has been subsequently used in the context of infections caused by MRSA, 
E. coli 0157: H7 and vancomycin-resistant enterococci (Enright and Spratt, 1999).
5.1.1 Pulsed-field gel electrophoresis and PCR based methods
The determination of clonal relatedness between isolates is a key component of 
disease outbreak investigation and epidemiological studies. Molecular techniques 
such as pulsed-field gel electrophoresis (PFGE) along with PCR based methods are 
now commonly executed.
5.1.1.1 Determination of clonal relatedness by pulsed-field gel electrophoresis
Developed by Schwartz and Cantor (1984), PFGE was used to separate high 
molecular weight DNA. The principle of PFGE is the digestion of chromosomal 
DNA by a restriction enzyme. The DNA is then resolved by electrophoresis with 
alternately pulsed electrical fields. In doing so, the banding patterns generated by
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PFGE give a highly specific ‘fingerprint’ for the organism, thus allowing the 
discrimination of strains for molecular genotyping. The PFGE banding pattern can 
be interpreted to deduce strain relatedness using specific guidelines i.e. those 
published by Tenover (1995). Tenover’s guidelines set criteria (Table 5.1) that allow 
the recognition and analysis of strain relatedness in isolates which may have 
undergone genetic mutations leading to subsequent banding differences e.g. the loss 
of larger fragments into two smaller fragments.
PFGE is frequently used for the monitoring of E. coli 0157: H7 (Tartof et al., 2005) 
and methicillin resistant Staphylococcus aureus (MRSA). However, despite its 
efficient discriminatory ability, PFGE is a time consuming, labour intensive 
procedure (Gautom, 1997).
Table 5.1 Tenover’s criteria for interpreting PFGE (Tenover et al., 1995).
Category No. of genetic 
differences
No. of fragment 
differences
Epidemiological
interpretation
Indistinguishable 0 0 Part of the outbreak
Closely related 1 2-3 Probably part of the 
outbreak
Possibly related 2 4-6 Possibly part of the 
outbreak
Different >3 >7 Not part of the outbreak
5.1.1.2 PCR for the detection of clonal relatedness to CTX-M-15 IS26 (UK 
epidemic strain A)
A CTX-M-15 insertion sequence 26 (IS26) PCR developed by Woodford et al., 
(2004) was used to identify a CTX-M-15 IS26 link-region sequence which is specific 
to epidemic E. coli strain A (Figure 5.1). Using specific primers for this region, a 
400bp amplicon was generated upon positive amplification. The development of this
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PCR allows for the rapid identification o f  E. coli strain A. This is especially 
important for screening during an infection outbreak (W oodford et al., 2004).
A Y 4 6 2 2 3 8
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Figure 5.1 Positioning o f  CTX-M -15 IS26 primers. Primers (highlighted in blue) 
span the IS26 and CTX-M -15 link region which is characteristic o f  UK epidem ic E. 
coli strain A.
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5.1.2 Multilocus sequence typing (MLST)
Multilocus sequence typing (MLST) was developed by Maiden et al. in 1998 in 
order to identify virulent lineages of N. meningitidis and to overcome reproducibility 
issues faced with other typing methods (Maiden et al., 1998). The principles of 
MLST involve the determination of an allelic profile by the sequence analysis of 
seven or more housekeeping genes. The allelic profile defines the sequence type 
(ST). The sequence data obtained can be used to compare genetic relatedness. Clonal 
relationships can be visualised by various dendrograms or eBURST plots (Enright 
and Spratt, 1999, Maiden et al., 1998). This information gives an understanding into 
the population biology of important pathogens e.g. E. coli and S. aureus (Lau et al., 
2008b). There are two different MLST typing schemes for E. coli. The scheme used 
to identify the sequence type ST131 frequently mentioned in this chapter was 
developed by Mark Achtmann and colleagues using 7 housekeeping genes including 
adk (adenylate kinase), fumC  (fumarate hydratase), gyrB (DNA gyrase), icd 
(isocitrate dehydrogenase), mdh (malate dehydrogenase), purA (adenylosuccinate 
synthetase), and recA (ATP/GTP binding motif) (Wirth et al., 2006, Lau et al., 
2008b). The other typing scheme is proposed by the Institute Pasteur and uses 8  
housekeeping genes including dinB (DNA polymerase), icdA (isocitrate 
dehydrogenase), pabB (p-aminobenzoate synthase), polB (polymerase PolII), putP  
(proline permease), trpA (tryptophan synthase subunit A), trpB (tryptophan synthase 
subunit B), uidA (beta-glucuronidase)
(http://www.pasteur.fr/recherche/genopole/PF8 /mlst/primers Ecoli.html).
This second scheme is of importance for this chapter as an allelic variant in the pabB 
gene, which is part of this MLST scheme, is used for rapid detection of the 025b- 
ST131 clone by PCR (see below; Clermont et al., 2009).
5.1.2.1 Allele-specific PCR for the detection of clonal relatedness to 025b-ST131
Allele-specific PCR takes advantage of the many single nucleotide polymorphisms 
(SNPs) found within genomes. With such a high frequency, SNPs can be 
advantageously used as markers for genetic studies (Brookes, 1999).
In this study, allele-specific PCR was used within the pabB gene to rapidly identify 
members of the E. coli 025b-ST131 clone. Two primer sets were used. trpA primers
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amplified a 427 bp section of the trpA gene and were used as a control to ensure that 
the DNA was of sufficient quality but also, to ensure the PCR was functioning 
correctly. The pabB primers amplified a 347bp fragment of the pabB  gene and 
contained single nucleotide mutations at the 3’ end. These mutations are specific for 
E. coli belonging to B2 subgroup I isolates containing O type 25b and so positive 
amplification should only occur if these mutations are present (Figure 5.4) (Clermont 
et al., 2009).
The aim of this chapter was to type and further characterise and to deduce any strain 
and/or clonal relatedness within the E. coli and Klebsiella spp. populations by using 
PFGE and PCR-based methodologies.
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5.2 Results
5.2.1 Screening isolates for CTX-M-15 ZS26
Out o f  128 Enterobacteriaceae isolates positive for CTX-M  group 1, 66 isolates 
(51%) generated a positive amplification product (400 bp) with primers specific for 
CTX-M -15 IS26 (Figure 5.2). All o f  these isolates were identified as E. coli. 
Therefore, out o f  96 E. coli isolates positive for C TX -M  group 1, 69%  gave a 
positive PCR result. Positive amplification was not found in any other 
Enterobacteriaceae species. Additionally, as a control, this PCR was carried out on 
epidemic E. coli strains A-E. Only strain A gave a positive amplification (Figure 
5.3).
M 1 2 3 4 5
400bp- 
200bp-
Figure 5.2 Gel electrophoresis o f  the CTX-M -15 IS26 link-region. Positive 
amplification products are 400 bp in size. M, 100 bp molecular ladder; Lanes 1 and 3 
CTX-M -15 IS26 negative; Lanes 2, 4 and 5 CTX-M -15 IS26 positive.
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M A B C D E M 
SOObp- 
400bp- 
300bp-
Figure 5.3 Prevalence o f  the CTX-M -15 1S26 link region within epidemic 
E. coli strains A-E. M, 100 bp molecular ladder; Lanes A-E represent epidemic 
E. coli strains A-E.
5.2.2 Detection of E. coli 025b-ST131 using allele-specific PCR
To identify members o f  the intercontinental clone E. coli 025 b -S T 1 3 1 ,  a PCR 
developed by Clermont et al. (2009) and capable o f  identifying single-nucleotide 
polymorphisms (SNP) within the pabB gene was used.
100 (3 isolates could not be revived at this stage) ESBL-producing E. coli isolates 
were screened to identify members o f  025b-S T 131 . A selection o f  40 cefpodoxime- 
sensitive E. coli isolates obtained from urine samples were additionally screened as a 
control.
Eighty out o f  100 E. coli isolates (80%) yielded positive amplification by PCR with 
primers specific for the pabB mutation, generating a 347bp amplicon (Figure 5.4). 
O f  these, 100% o f  E. coli isolates (n=63) positive for CTX-M -15 IS26 and 46%  o f  E. 
coli (n=37) isolates negative for CTX-M -15 IS26 generated positive amplification 
products with this PCR. Within the CTX-M -15 IS26 negative E. coli, one isolate 
harbouring CTX-M -27 was positive for the pabB mutation. Eight out o f  40 non- 
ESBL control E. coli isolates (20%) gave a positive pabB amplification product.
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M 8 9  A B C D E  
R eference  Strains
Figure 5.4 Prevalence o f  amplification products positive for pabB single-nucleotide 
polymorphisms (SNPs). In this instance, amplification o f  the pabB gene is a specific 
determinant o f  025b-S T 131 . M, lOObp molecular ladder; Lanes 1, 4, 8, 9 CTX -M - 
15 IS26 negative isolates; Lanes 2, 3, 5, 6, 7, CTX-M -15 IS26 positive isolates. 
Reference strains epidemic E. coli A-E.
5.2.2.1 DNA sequencing of pabB positive amplicons
A sub-section of each group (10 E. coli isolates positive for CTX-M-15 ZS26 and 10 
E. coli isolates negative for CTX-M-15 IS16) were sent for DNA sequencing to 
confirm the sensitivity of this PCR and to validate the accuracy of the assay. All 20 
isolates sequenced revealed the SNPs within the pabB gene therefore confirming that 
these isolates belong to the 025b-ST131 intercontinental clone (Figure 5.5).
DNA sequencing was also carried out on the 8  control E. coli isolates, which had 
generated a positive PCR product of 347bp. SNPs could not be detected in 4 (50%) 
isolates. Therefore, they were considered to be PCR false-positives. However, SNPs 
were detected in the other 4 (50%) isolates, suggesting that these isolates were 
related to the intercontinental clone (Table 5.2).
Table 5.2 Prevalence of isolates positive for a single-nucleotide polymorphism
(SNP) within the pabB gene.
pabB positive
All ESBL positive E. coli (n=100) 80 (80%)
E. coli IS26 positive (n=63) 63 (100%)
E. coli IS26 negative (n=37) 17(46%)
Control ESBL negative E. coli (n=40) 4(10%)
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5.3 Detection of clonal relationships using Pulsed Field Gel Electrophoresis 
(PFGE)
5.3.1 Clonal relatedness by PFGE within E. coli
Pulsed field gel electrophoresis (PFGE) was carried out on 139 Enterobacteriaceae 
isolates in order to determine clonal patterns. The results were analysed in 
concordance with guidelines outlined by Tenover et al. (1995). Within the E. coli 
population (n=102) a distinct clonal pattern (Figure 5.6) could be distinguished 
within the CTX-M group 1 isolates (n=96). Using these guidelines, isolates that had 
been depicted as being CTX-M-15 IS26 positive by PCR (see section 5.2) could be 
termed ‘closely related’ and ‘possibly related’ as 54 isolates had 2-3 band differences 
and 12 isolates had 4-6 band differences when compared to epidemic E. coli strain A 
(Table 5.3). By Tenover’s epidemiological interpretation, isolates with a 2-3 band 
difference are defined as ‘probably part of the outbreak’ and isolates with a 4-6 band 
difference are defined as ‘possibly part of the outbreak’. This suggests that the 
CTX-M-15 IS26 positive E. coli isolates collected at Swansea had a closely related 
genetic background to that of E. coli strain A.
A second ‘closely related’ clone could be identified within 5 (5%) E. coli isolates 
(Figure 5.7). This was unrelated to any of the major UK epidemic strains A-E. The 
remaining 31 (31%) E. coli isolates were unrelated and had unique PFGE patterns.
Table 5.3 Comparison of E. coli obtained at Swansea to epidemic E. coli strain A by 
PFGE
No. of fragment differences compared to epidemic E. coli
Strain A
0 2-3 4-6 >7
E. coli (n=6 6 ) 0 54 12 0
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M 1 2 3 4 5 6 7 8 9 10 1 112 13 14 15 16 17
388 kb-
242.5 kb- 
194 kb-
145.5kb-
97 kb-
48.5 kb-
IS26 Positive Epidemic £. coli /526Negative 
Strains A-E
Figure 5.6 PFGE gel illustrating clonal relatedness between E. coli isolates from this 
study and epidemic E. coli strains A-E using Xba\. M, molecular marker; lanes 1-6 
E. coli IS26 positive; lanes 7 and 8 E. coli strain A; lanes 9 and 10 E. coli strain B; 
lanes 11 and 12 E. coli strain C; lane 13 E. coli strain D; lane 14 E. coli strain E; 
lanes 15-17 E. coli IS26 negative (unique banding patterns).
♦ ^  fli
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M 1 2  3 4
388 kb-
242.5 kb- 
194kb-
145.5kb-
97 kb-
48.5 kb-
Figure 5.7 PFGE gel illustrating clonal relatedness between E. coli isolates using 
Xba\. A “closely related’ clone was identified in 5 E. coli isolates (four o f  which are 
shown here). This clone is unrelated to any o f  the UK epidemic E. coli strains A-E. 
M, molecular marker; lanes 1-4 E. coli isolates demonstrating a ‘closely rela ted’ 
pattern.
5.3.2 C lona l  re la ted  ness w ith in  Klebsiella spp. by P F G E
Within the Klebsiella spp. (n=32), two distinct clones (Figure 5.8) could be 
identified using Tenover’s guidelines (Tenover et al., 1995). Both clones were 
associated with K. pneumoniae, o f  which, 18 (58%) belonged to ‘clone I ’ and 2 (6%) 
belonged to ‘clone IF (Table 5.4). Additionally, 12 (38%) Klebsiella spp. isolates 
had unique PFGE banding patterns.
Table 5.4 Identification o f  clonal ly related Klebsiella spp. by PFGE.
C lo n e  I C lone  II U n re la ted
K pneumoniae (n = 3 1) 18 2 11
K. oxytoca (n= 1) 1
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388 kb-
242.5 kb- 
194 kb-
145.5kb- 
97 kb-
48.5 kb-
Figure 5.8 Clonal relatedness between isolates o f  Klebsiella spp. using Xba\. M, 
molecular marker; lanes 1-4 clone I; lanes 5 and 6 clone II; lanes 7 and 8 examples 
o f  unrelated banding patterns.
Clone I Clone II Unrelated
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5.4 Discussion
The further characterisation and typing of isolates allows for a better understanding 
of the genetic variability and pathogenicity of bacterial isolates. It also allows 
tracing and the tracking of outbreaks and changes in molecular epidemiology.
Primers developed by Woodford et al., (2004) were used to amplify the CTX-M-15 
7526 link region, which is found in epidemic E. coli strain A. Strain A was first 
reported in the UK in 2003 after an epidemic E. coli outbreak in Shropshire 
(Woodford et al., 2004). However, strain A has also been found in Ulster and in 
areas of Southern England (Livermore and Hawkey, 2005). Upon screening all CTX- 
M group 1 Enterobacteriaceae isolates, 51% were found to possess this region, 
which were exclusively E. coli. This percentage changes to 6 8 % (66/96) when 
comparing CTX-M-15 7526-producing E. coli to all E. coli possessing a CTX-M 
group 1 gene. However, after aligning several CTX-M group 1 gene sequences in 
ClustalX, the reverse primer region was not conserved just for CTX-M-15 implying 
that several CTX-M group 1 genes paired with the 7526 element would be amplified. 
This is possible as the IS26 sequence is found on a mobile element. However, all 
CTX-M-15 IS26 positive E. coli isolates in this thesis followed up by CTX-M gene 
sequencing were revealed to carry CTX-M-15. In contrast a study conducted by 
Shahid (2010) found that CTX-M-15-producing Citrobacter spp. isolates generated 
the same 400bp amplicon when the CTX-M-15 7526 PCR was used. Woodford et al., 
(2004) stated that this PCR is not an indicator of clonal relatedness but an additional 
aid in characterising E. coli strain A.
Within this study, it can be deduced that a large proportion of CTX-M group 1
positive E. coli isolates (69%) are ‘closely related’ and ‘possibly related’ to one of
the UK’s epidemic E. coli strains, notably strain A as deduced by PFGE, which is
consistent with the presence of CTX-M-15 7526 in these isolates. However looking
at the larger picture, by further analysing these isolates it can be said that 1 0 0 % of
the positive CTX-M-15 IS26 isolates are in fact related to an intercontinental clone,
025b-ST131. This clone, which encompasses the UK’s epidemic E. coli strains A-E
(Lau et al., 2008a) amongst other ESBL types, takes into consideration isolates with
diverse PFGE patterns (Clermont et al., 2009). In order to question the validity of the
PCR assay used to identify members of the 025b-ST131 clones, a selection of 40
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non-ESBL E. coli isolates obtained from urine samples were screened. SNPs or 
isolates with a positive pabB amplification product were found in a total 4 out of 40 
(10%) isolates. Leflon-Guibout (2008), discussed that this clone had been found in 
7% of non-ESBL producing E. coli isolates obtained from faecal samples in Paris. A 
further study conducted by Clermont et al., (2009) analysed the frequency of 025b- 
ST131 in non-ESBL producing E. coli isolates obtained from UTI, of which 3% 
were found to be positive. Therefore, Clermont et al., (2009) has predicted that 1.5% 
of UTI are caused by E. coli associated with the 025b-ST131 clone.
In the Northwest of England, ST131 was found within 13.3% of E. coli and of 
which, 35% harboured CTX-M-15. A study conducted in the Calgary region of 
Canada demonstrated that the prevalence of ST131 associated E. coli isolated from 
blood had increased from 5% in samples collected between 2000-2003 to 41% in 
samples collected from 2004-2007 (Pitout et al., 2009b). ST131 positive isolates 
have also been found to be prevalent in the USA and Norway with 35% and 20% of 
isolates being positive for this sequence type, respectively (Naseer et al., 2009, 
Johnson et al., 2010b).
ST131 positive isolates have been found to have an increased resistance to 
antibiotics. A study by Johnson et al. (2010b) revealed that isolates were more 
resistant to levofloxacin, cefazolin, gentamicin and ampicillin. Johnson et al. (2010a) 
noted in their study that ST131 was associated with >50% of multidrug resistant 
isolates (Johnson et al., 2010a). In addition, it has been suggested that the ST131 
group has a highly virulent potential. Ender et al. (2009) reported a clinical case 
whereby an adult woman contracted emphysematous pyelonephritis, renal absess, 
bacteraemia and septic shock two weeks after visiting her hospitalised father who 
was suffering with pyelonephritis. E. coli harbouring ST131 and CTX-M-15 was 
isolated from both individuals. It was revealed that even though she had limited 
contact with her father clinical evidence suggested that transmission had occurred 
either through host to host contact or from a common external source (Ender et al., 
2009).
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Carbapenemases have also been found to be associated with the ST131 clone. Morris 
et al. (2011) reported of a KPC-2 carbapenemase in an E. coli isolate belonging to 
the ST131 clone. It was isolated along with a K. pneumoniae isolate from the urine 
of an 84 year old woman who was a resident in a care home in Ireland. The woman 
had no recent foreign travel and had not been admitted to hospital within 6  months 
prior to the isolation of the organisms. Both isolates were found to be carbapenemase 
producers and harboured TEM-1 and CTX-M-15. The K. pneumoniae isolate was 
additionally SHV-12 positive (Morris et al., 2011). Peirano and collegues (2011) 
found that an E. coli isolate isolated from the urine of a 40 year old paraplegic man 
harboured the NDM-1 carbapenemase and was positive for the ST131 clone. It was 
revealed that the man had travelled from the USA to New Dehli, India, for a surgical 
procedure. He presented with symptoms 3-4 months later. The combination of 
carbapenemases and the ST131 clone poses a great concern for the future treatment 
of community associated infections (Peirano et al., 2011). Pitout et al. (2009b) noted 
that the ST131 sequence type was an important cause in community onset 
bacteraemia.
The 025b-ST131 clone has also spread from human to animal as Pomba et al., 
(2009) demonstrated its presence in a dog (Pomba et al., 2009). It has also been 
detected in municipal wastewater treatment plant effluents. Dolejska et al. (2011) 
collected 26 E. coli isolates. Of these, 19 were 025b-ST131 and 17 were found to be 
CTX-M-15 7526 positive. It has been suggested that the conditions e.g. pH, 
temperature, nutrient concentrations and high bacterial biomass found in the plant 
effluents were ideal for gene transfer and spread of resistance. Additionally, the 
effluents also contained antibiotics which would select for resistant strains and 
support the acquisition of resistance genes (Dolejska et al., 2011).
However, it is notable to mention that false-positive PCR products were amplified in 
50% (4/8) of the control E. coli isolates as sequencing revealed that these isolates did 
not contain the pabB SNP thereby suggesting a limitation in the reliability of this 
PCR method. In order to improve this experiement, all E. coli isolates with positive 
amplification products would need to be sequenced.
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Aside from allele-specific PCR, alternative rapid identification methodologies for the 
detection of the 025b-ST131 clone are available. Lau et al., (2009) and Pitout et al., 
(2009a) have both published data using the DiversiLab system. This is a semi­
automated method which utilises repetitive sequence based PCR (rep-PCR) to 
generate a fingerprint of the isolate in question. Both Lau et al., (2009) and Pitout et 
al., (2009a) successfully and accurately identified E. coli 025b-ST131 in 
concordance with MLST, but Lau et al., (2009) found it to be less discriminatory 
than PFGE. Additionally, both agree that this method could be adopted as a front­
line tool for the detection of clones as results are generated more quickly than by the 
use of PFGE and MLST. However, the cost implications of the DiversiLab system 
could potentially be an issue (Pitout et al., 2009a).
It was revealed that 18 K. pneumoniae isolates were clonally related by PFGE 
(Figure 5.8). There have been a number of studies reporting the incidence of K. 
pneumoniae clones harbouring genes for CTX-M-15 (Kamatchi et al., 2009, 
Damjanova et al., 2008, Dashti et al., 2010). Damjanova et al., (2008) described that 
the K. pneumoniae in their study were ciprofloxacin resistant, which posed a 
problem in Hungary and so an infection control strategy was adopted in hospitals.
In summary, E. coli and Klebsiella spp. isolates have been further characterised in 
order to identify clonal relatedness. The identification of clones, mechanisms and 
genes of resistance are important factors to consider for potential new antimicrobial 
agents and infection control procedures.
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Chapter 6: ESBLs and Antibiotics
6.1 Introduction
ESBLs are a widespread problem. Since the emergence of CTX-M in the UK in 
2000 (Alobwede et al., 2003), CTX-M genes have rapidly disseminated. ESBLs are 
now found in both hospital and community environments (Bonnet, 2004, Woodford 
et al., 2004).
With ESBLs, resistance is conferred to oxyimino-cephalosporins. These are ‘front 
line’ antibiotics prescribed for urinary-tract infections, respiratory-tract infections 
and intra-abdominal infections (Potz et al., 2006, Livermore, 1995). However, in 
addition to the aforementioned antibiotics, ESBL plasmids often harbour genes for 
resistance to other antibiotics including aminoglycosides (e.g. gentamicin and 
amikacin), quinolones and trimethoprim-sulfamethoxazole (TMP-SMX) thus 
causing strains to be multidrug resistant (Paterson et al., 2000). The clonal spread of 
resistance genes also poses a great problem. Data obtained by Cagnacci et al., (2008) 
revealed a correlation between ciprofloxacin resistance and E. coli clones 015: K52 
HI and 025: H4 ST131 (predominantly ESBL-producers) in urinary-tract infections. 
Therefore, the treatment of infections caused by ESBL-producers is challenging and 
the choice of antimicrobial agent is important as inappropriate treatment is linked to 
an increased mortality (Rodriguez-Bano et al., 2006). Also as the patterns of 
resistance change, the demand for new antimicrobial agents increases.
With this in mind, the following questions will be posed and answered in this 
chapter. How resistant are Enterobacteriaceae with ESBLs to aztreonam, 
ceftazidime and piperacillin/tazobactam? How active are ciprofloxacin, 
trimethoprim-sulfamethoxazole, gentamicin and amikacin against these organisms? 
Are carbapenems the only option against ESBL carriers? Are ‘newer’ antibiotics 
such as temocillin and tigecycline active against ESBLs and could they be suitable 
alternatives?
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6.1.1 Ceftazidime
Ceftazidime belongs to the 3rd generation cephalosporin class of antibiotics (Figure 
6.1). Information regarding 3rd generation cephalosporins can be found in Section 
1.3.2.3.
6.1.2 Aztreonam
Aztreonam is currently the only licensed monobactam antibiotic (Figure 6.1) and can 
be hydrolysed by ESBLs (Philippon et al., 1989, Paterson and Bonomo, 2005). 
Information regarding monobactams can be found in Section 1.3.4.
6.1.3 Piperacillin/tazobactam
Piperacillin/tazobactam is a combination antibiotic consisting of the penicillin-type 
antibiotic, piperacillin, along with the (3-lactamase inhibitor, tazobactam. Information 
regarding p-lactamase inhibitors can be found in Section 1.4.1.
6.1.4 Gentamicin and amikacin
Gentamicin and amikacin are both belong to the aminoglycoside family of 
antibiotics (Figure 1) and are active against Gram-positive and Gram negative 
organisms. Gentamicin was originally isolated from Micromonospora purpurea', 
whereas, amikacin is a semisynthetic derivative of kanamycin. The mode of action of 
aminoglycoside antibiotics involves the irreversible inhibition of protein synthesis. 
The antibiotic penetrates the cell wall by active transport and binds to receptors on 
the 3OS subunit of the bacterial ribosome thereby inhibiting ribosomal protein 
synthesis. By doing so, the ‘initiation complex’ of peptide formation is interfered 
thus causing the misreading of the mRNA template code. This allows the incorrect 
amino acid to be incorporated into the peptide. Aminoglycosides cause a breakup of 
polysomes into non-functional monosomes (Katzung, 1995).
6.1.5 Ciprofloxacin
Ciprofloxacin is a member of the quinolone family of antibiotics. It is a synthetic
fluorinated analogue of nalidixic acid (Figure 6.1) and is active against Gram-
positive and Gram-negative bacteria. Its mode of action is to block DNA synthesis
by inhibiting DNA gyrase. This inhibition prevents the relaxation of supercoiled
DNA, which is required for normal transcription and duplication (Katzung, 1995).
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6.1.6 Trimethoprim/sulfamethoxazole
Trimethoprim/sulfamethoxazole, or co-trimoxazole, is a combination antibiotic 
containing trimethoprim and sulfamethoxazole (Figure 6.1). Both are used in 
combination as they sequentially block the same pathway. They have a synergistic 
affect, which improves drug activity. Trimethoprim inhibits specific enzymes in 
bacteria known as dihydrofolic acid reductases. These enzymes convert dihydrofolic 
acid into tetrafolic acid, a component of purine synthesis and eventually involved in 
the formation of DNA. Sulfamethoxazole is a sulphonamide antibiotic, which is a 
structural analogue of />-aminobenzoic acid (required to form folic acid for the 
production of purines and nucleic acid). The mode of action involves the competition 
of the sulphonamide with the enzyme dihydropteroate synthesis and results in the 
formation of non-functional analogues of folic acid, which prevents the bacteria from 
further growth (Katzung, 1995). Trimethoprim/sulfamethoxazole is active against 
Gram-positive and Gram-negative bacteria and is often used in the prophylaxis of 
post-renal transplant patients (Johnson et al., 2010b).
6.1.7 Ertapenem
Ertapenem is a carbapenem antibiotic (Figure 6.1) marketed for the use in severe 
community-acquired infections (Livermore et al., 2005). Information regarding the 
carbapenems can be found in Section 1.3.5.
6.1.8 Temocillin
Temocillin was first introduced into the UK by Beecham Pharmaceuticals in the 
1980s but was later withdrawn due to poor commercial success (Livermore and 
Tulkens, 2009). It is a 6 -a-methoxy derivative of ticarcillin (Slocombe et al., 1981) 
which has the ability to prevent the activation of serine (by impeding the entry of 
water) and therefore blocking the chemical events which lead to the hydrolysis of the 
P-lactam ring (Figure 6.1) (Livermore and Tulkens, 2009). Temocillin is active 
against Gram-negative bacteria but has no activity against P. aeruginosa, 
Bacteroides fragilis, (Spencer, 1990) Campylobacter spp. or Acinetobacter spp. 
(Rodriguez-Villalobos et al., 2006). It also has low activity against Serratia spp. It 
has been shown to have activity towards ESBL and AmpC enzyme producers 
(Livermore et al., 2006).
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6.1.9 Tigecycline
Tigecycline was developed by Francis Tally (Projan, 2009) and is now marketed by 
Wyeth Pharmaceuticals. It belongs to a class of antibiotics known as the 
glycylcyclines, which were derived from tetracycline in order to overcome resistance 
(Pankey, 2005). It shares its 4 ring carbocyclic skeleton with the tetracyclines but has
iL
a substitution of N-alkyl-glycylamido on the D ring at the 9 position (Figure 6.1) 
which is said to achieve a broader spectrum of activity (Stein and Craig, 2006). 
Tigecycline has been shown to have activity in vitro against Gram-positive and 
Gram-negative bacteria (aerobic and anaerobic) including ESBL and AmpC- 
producing Enterobacteriaceae (Hope et al., 2006). However, tigecycline has been 
found to be less effective against P. aeruginosa and Proteus mirabilis (Gales and 
Jones, 2000, Livermore, 2005).
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6.2 Results
6.2.1 Antibiotic Susceptibility
ESBL-producing Enterobacteriaceae were tested against antibiotics of the BD 
Phoenix Gram-negative panel along with temocillin and tigecycline E-test strips. The 
Minimum Inhibitory Concentrations (MIC) were determined and using breakpoints 
supplied by societies/institutions such as BSAC and the Clinical and Laboratory 
Standards Institute (CLSI), susceptibility profiles were generated.
6.2.1.1 Antibiotic susceptibility profile generated by BD Phoenix
6.2.1.1.1 MIC Distributions of Aztreonam, Ceftazidime and 
Piperacillin/T azobactam
The activity of antibiotics against ESBL-producing strains was determined by the 
comparison of MIC values to breakpoints published by BSAC (BSAC, 2009) as 
outlined in table 6 .1 .
Table 6.1 BSAC MIC breakpoints of aztreonam, ceftazidime and 
piperacillin/tazobactam
BSAC MIC Breakpoints (pg/ml)
R I S
Aztreonam > 8 2 - 8 < 1
Ceftazidime > 8 2 - 8 < 1
Piperacill in/T azobactam >16 16 < 8
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MIC D is t r ibu t ion  of A z t re o n a m
■ Klebsie lla  spp.
MIC (M-g /m l)
Figure 6.2 MIC Distribution o f  aztreonam for ESBL-producing E. coli (n= 101) and 
Klebsiella spp. (n=32).
MIC D istr ibu t ion  of C eftaz id im e
•5 6°
■Q
1 f .  co li 
Klebsie lla spp.
M IC(|ig/m l)
Figure 6.3 MIC distribution o f  ceftazidime for ESBL-producing E. coli (n= 101) and
Klebsiella spp. (n=32).
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Figure 6.4 MIC distribution o f  piperacillin/tazobactam for ESBL-producing E. coli 
(n=!01) and Klebsiella spp. (n=32).
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6.2.1.1.2 Resistance Profile of aztreonam, ceftazidime and
piperacillin/tazobactam against ESBL-producing Enterobacteriaceae generated 
by BD Phoenix
Table 6.2 outlines the resistance profiles of ESBL-producing Enterobacteriaceae 
against aztreonam, ceftazidime and piperacillin/tazobactam. The BD Phoenix 
interprets MIC breakpoints according to BSAC guidelines. An initial MIC 
measurement by the BD Xpert system indicated that not all of the ESBL-producing 
Enterobacteriaceae were resistant to the aforementioned antibiotics. As outlined in 
Figures 6 .2-6.4, the MIC distrubitions for each antibiotic was not only confined to 
the resistant ranges. For aztreonam (Figure 6.2), the MIC range for E. coli and 
Klebsiella spp. was found between <1 and >16(ig/ml with a modal (most frequently 
occurring) MIC at >16pg/ml. For ceftazidime (Figure 6.3), the MIC range for E. coli 
was between lpg/ml and >16pg/ml with a modal MIC of <2pg/ml and for Klebsiella 
spp. the MIC range was between <2pg/ml and >16pg/ml with a modal MIC of 
>16pg/ml. For piperacillin/tazobactam (Figure 6.4), the MIC ranges for E. coli and 
Klebsiella spp. were between <4 and >32pg/ml. A modal MIC of 16pg/ml was 
demonstrated for E. coli, whereas, a modal MIC of <4pg/ml was demonstrated for 
Klebsiella spp.
The Xpert system of the BD Phoenix interprets these cephalosporin MIC readings 
according to the respective resistance mechanisms anticipated, in this case ESBL, 
and the vast majority of susceptible isolates were given a final MIC interpretation of 
resistant.
Overall, the percentages of ESBL-producers resistant to aztreonam and ceftazidime 
were, according to MIC 54% and 39% respectively, but reported as 99% and 98% 
respectively. The interpretations for piperacillin/tazobactam did not change as 
tazobactam is thought to effectively protect the piperacillin from ESBL activity.
The greatest disparity between resistance as measured by MIC and reported results 
was seen for E. coli. MICs for aztreonam and ceftazidime demonstrated resistance in 
40% and 25% of the strains respectively whereas the organisms were reported as 
resistant in 99% and 98% strains respectively. Within the Klebsiella spp., 84% had a 
resistant MIC to ceftazidime, which was then altered to resistant in 97% for the final
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interpretation. For Klebsiella spp., 94% had a resistant MIC to aztreonam, however, 
all were reported as resistant ( 1 0 0 %).
Those isolates which were not resistant by MIC measurement were split between 
‘susceptible’ and ‘intermediately resistant’. Using the initial BD Phoenix MIC 
measurement, 5% (6/101) of E. coli isolates were found to be susceptible to 
aztreonam by MIC whereas 55% (56/101) were found to be intermediately resistant. 
6 % (2/32) of Klebsiella spp. were initially found to be intermediately resistant to 
aztreonam according to MIC measurement before being reported as resistant. 60% 
(61/101) of E. coli isolates were found to be susceptible to ceftazidime. The reported 
value changed to 1% (2/101) susceptible after the Xpert system’s interpretation. 15% 
(15/101) of E. coli isolates were intermediately resistant. For Klebsiella spp., 16% 
(5/32) were intermediately resistant to ceftazidime by MIC. 60% (61/101) of E. coli 
and 41% (13/32) of Klebsiella spp. were susceptible to piperacillin/tazobactam, 
which is important as the antibiotic may eventually be used in non-life-threatening 
infection in these cases.
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6.2.1.3 Susceptibility profile of ciprofloxacin, trimethoprim-sulfamethoxazole, 
gentamicin, amikacin and ertapenem against ESBL-producing 
Enterobacteriaceae
The MIC values in this section were interpreted according to BSAC guidelines. 
These are outlined in table 6.3.
Table 6.3 BSAC MIC breakpoints for ciprofloxacin, trimethoprim-sulfamethoxazole, 
gentamicin, amikacin and ertapenem.
BSAC MIC Breakpoints (pg/ml)
R I S
Ciprofloxacin > 1 1 <0.5
Trimethoprim-
sulfamethoxazole
>4 4 < 2
Gentamicin >4 4 < 2
Amikacin >16 16 < 8
Ertapenem > 1 1 <0.5
The results outlined in table 6.4 give an overview of the susceptibility profile of 
ESBL-producing Enterobacteriaceae against the following antibiotics: 
ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin, amikacin and ertapenem. 
Ninety percent of all isolates were resistant to ciprofloxacin (90% of E. coli and 91% 
of Klebsiella spp.). The remaining E. coli (10%) were susceptible whereas 3% of the 
remaining Klebsiella spp. were resistant and 6 % were intermediately resistant.
Eighty-nine percent of all ESBL-producing Enterobacteriaceae were found to be 
resistant to trimethoprim-sulfamethoxazole with 94% of E. coli and 73% of 
Klebsiella spp. having MIC values of >4pg/ml. 6 % of Klebsiella spp. isolates were 
found to be intermediately resistant.
Gentamicin and amikacin are both aminoglycoside antibiotics. 67% of the isolates
were susceptible to gentamicin and 85% to amikacin. For gentamicin, 82% of E. coli
were susceptible, 16% were resistant and 2% were intermediately resistant. The
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Klebsiella spp. show a different profile as 21% were susceptible and 79% were 
resistant. For amikacin, 81% of E. coli were susceptible, 15% were resistant and 4% 
were intermediately resistant. With the Klebsiella spp., 97% of isolates were 
susceptible and 3% were intermediately resistant.
The carbapenems tested were meropenem, imipenem and ertapenem. 100% 
susceptibility was found for all isolates for meropenem and imipenem. However, the 
susceptibility for ertapenem was 99% as 1% (n=l) of E. coli was found to be 
resistant.
160
Ta
ble
 
6.4
 
Th
e 
Su
sc
ep
tib
ili
ty
 
pr
of
ile
s 
of 
ci
pr
of
lo
xa
ci
n,
 
pi
pe
ra
ci
lli
n/
ta
zo
ba
ct
am
, 
tri
m
et
ho
pr
im
-s
ul
fa
m
et
ho
xa
zo
le
, 
ge
nt
am
ic
in
, 
am
ik
ac
in
 
an
d 
ert
ap
en
em
 
in 
ES
BL
-p
ro
du
ci
ng
 
En
te
ro
ba
ct
er
ia
ce
ae
. 
MI
C 
va
lu
es
 
we
re 
m
ea
su
re
d 
by 
the
 
BD 
Ph
oe
nix
 
Xp
er
t 
sy
ste
m
. 
Im
ipe
ne
m 
and
 
m
er
op
en
em
 
we
re 
als
o 
tes
ted
 
and
 
1
0
0
% 
of 
all
 i
so
lat
es
 w
ere
 
su
sc
ep
tib
le
.
VO
£
a
•im
Bat•wa4»
o VI
i o
S Nau M ft- o0 -a
1  «
1 S a
£ ’s«>
oa*ocoua
C/5
X ®o '
VO X ®o '
X ®o '
X ®o '
OS
X ®o '
O C" c o
2% 2
%
2 % 0
%
2%
X ®
0 s
x ®
o '
X ®o '
x ®o ' X ®o '
C N 0 0 1-H !>•
OO O n l / S C N V O
X ®o '
X ®o '
O
X ®
O '
x ®o ' x ®O '
O c o O s
OS r - OO
x °o ' x ®O ' X ®o '
X ®o ' X ®o '
O O O VO
x ® V ®
X ®
o '
X ®o ' X ®O '
o ' o ' VO i -H ©
V O O O O C N
\ °
O '
x ®o '
O X ®o '
X ®o ' x °o '
O O V O «-H O
O n r- OS O n
0% 0% 0% 6%
X ®o '
X ®
O '
O N ®o '
X ®o ' X ®o ' X ®o '
O C N CO OO
vo
i".co
O
TC
-*-> c3
<£ z
VO vo
B S
CNro
•Si
r--*
Table 6.4 cont...The Susceptibility profiles of amikacin and ertapenem in ESBL- 
producing Enterobacteriaceae. MIC values were measured by the BD Phoenix Xpert 
system. Imipenem and meropenem were also tested and 100% of all isolates were 
susceptible.
Amikacin_______________ Ertapenem
S I R S R
E. coli (n=T01) 81% 4% 15% 99% 1%
E. coli IS26 Positive (n=64) 75% 19% 6 % 98% 2 %
E. coli IS26 Negative (n=37) 92% 0 % 8 % 1 0 0 % 0 %
Klebsiella spp. (n= 32) 97% 0 % 3% 1 0 0 % 0%
Total (n=133) 85% 4% 1 1 % 99% 1%
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6.3 Antibiotic Susceptibility Profile generated by E-test
E-test strips containing temocillin and tigecycline were used to test a total of 134 
molecularly-confirmed ESBL-producers, namely 99 E. coli isolates, 32 Klebsiella 
spp. (30 Klebsiella spp. were tested against tigecycline) and 3 other 
Enterobacteriaceae isolates (2 E. cloacae and 1 C.freundii).
A selection of control isolates - E. coli strains A-E, E. coli K12 and E. coli NCTC 
10418 - was also utilised. The method is described in Chapter 2 section 2.5.4.
MICs were interpreted using various breakpoint guidelines. For temocillin, BSAC 
UTI , BSAC systemic (BSAC, 2009) and Fuchs (Fuchs et al., 1985) breakpoints 
were used. BSAC UTI breakpoints have a specific stipulation associated with their 
usage. BSAC states: “UTI recommendations are fo r  organisms associated with 
uncomplicated urinary infections only. For complicated UTI systemic 
recommendations should be used. ” For this study, both breakpoint sets were 
analysed for comparison.
To interpret tigecycline MIC values, BSAC and CLSI breakpoints were followed 
(BSAC, 2009), (ABbioMerieux, 2009). Tables 6.5 and 6.5.1 outline the breakpoints 
used.
Table 6.5 BSAC UTI and BSAC Systemic guidelines for the interpretation of 
temocillin MIC values
Temocillin MIC 
(pg/ml)
Breakpoints
R S
BSAC UTI >32 <32
BSAC systemic > 8 < 8
Fuchs >32 <16
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Table 6.5.1 BSAC and CLSI (as stated by bioMerieux) breakpoints for the 
interpretation of tigecycline MIC values. EUCAST (European Committee 
Antimicrobial Susceptibility Testing) MIC values are the same as those outlined for 
BSAC.
Tigecycline Breakpoints (pg/ml)
R I S
BSAC > 2  2  < 1
CLSI
fNVI
■'3-00Al
6.3.1 Temocillin
6.3.1.1 MIC Distributions
The temocillin E-test strips utilised had a concentration range of 0.125pg/ml - 
256pg/ml (Figure 6 .6 ). For all ESBL-producing E. coli isolates tested (n=99), the 
M I C  values were within a concentration range of 2-32pg/ml (Table 6 .6 ). 36% of E. 
coli isolates (n=36) had an M I C  >12pg/ml of which 8 % (n=3) had M I C  values at the 
top end of the E. coli range (32pg/ml). 24% of E. coli isolates (n=24) had an M I C  
value of < 6  pg/ml of which 12.5% (n=3) had an M I C  of 2pg/ml. 38% of E. coli 
isolates (n=38) were found to have a modal (most frequently occurring) M I C  of 
8 pg/ml (Figure 6.5). The M I C 5o and M IC 9 0  values represent the M I C  at which 50% 
and 90% of organisms are inhibited, respectively. The values were calculated by 
cumulating the number of isolates inhibited and finding the M I C  value at the 
respective percentage (Hamilton-Miller, 1991). The M IC 5 0  value for E. coli was 
8 pg/ml whereas the M IC 9 0  value was 16pg/ml. However, differences do occur 
within E. coli when isolates are analysed according to the presence of absence of an 
insertion element 26 (ZS26). The modal M I C  for E. coli containing IS26 was 8 pg/ml 
(52%) whereas for E. coli IS26 negative isolates, the modal M I C  was 12pg/ml 
(25%). The M IC 5 0  and M IC 9 0  values also differ as E. coli IS26 negative isolates have 
an M IC 5 0  of 12|ig/ml and M IC 9 0  value of 24pg/ml. The M IC 5 0  value for E. coli IS26 
positive isolates was 8 pg/ml whereas the M IC 9 0  value was 1 2 pg/ml.
Additionally, temocillin was tested against epidemic E. coli strains A-E, E. coli K12
and NCTC 10418. Within the 5 epidemic E. coli strains, the MIC distribution for
temocillin was bimodal with values at 8 pg/ml (strain A and C) and 12pg/ml (strain
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D and E). Strain B had an MIC value of 24|ig/ml. These MIC values were different 
from those measured for E. coli K12 and E. coli NCTC 10418, which had lower 
MIC values of 6 pg/ml and 2pg/ml, respectively.
The M I C  concentration range for Klebsiella spp. (n=30) was found to be 3-256pg/ml 
(Figure 6.5). 43% of Klebsiella spp. (n=l 3) had M I C  values of >12pg/ml and of 
which, 1 K  pneumoniae isolate had an M I C  value of 256pg/ml -  the highest 
concentration found on the temocillin E-test strip. 30% of isolates (n=9) had an M I C  
of <6 pg/ml. The modal M I C  for temocillin within the Klebsiella spp. was found to 
be 8 pg/ml (27%). The M IC 5 0  value for Klebsiella spp. was 8 pg/ml and the M IC 9 0  
value was 24pg/ml.
Two E. cloacae and 1 C. freundii isolate were tested against temocillin. The MIC 
range was found to be 2-12jig/ml. The MIC values of the two E. cloacae were 3 and 
12|ig/ml whereas C. freundii had the lowest MIC value of 2pg/ml.
Table 6 .6  MIC distribution of temocillin against ESBL-producing
Enterobacteriaceae.
Temocillin
Range (pg/ml) M IC 5 0  (pg/ml) M IC 9 0  (pg/ml)
E. coli (n=99) 2-32 8 16
E. coli IS26 positive (n=63) 2-32 8 1 2
E. coli IS26 negative (n=36) 2-32 1 2 24
Klebsiella spp. (n=30) 3-256 8 24
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Figure 6.5 MIC distribution o f  E. coli and Klebsiella spp. for temocillin.
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3|ig/m l
Figure 6.6 Temocillin E-test. E-test to determine the MIC o f  ESBL-producing 
isolates against temocillin.
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6.3.1.2 Susceptibility profile of temocillin
100% (n=99) of E. coli and other Enterobacteriaceae (n=3) isolates tested against 
temocillin and interpreted using BSAC UTI breakpoints were found to be 
susceptible. 93% (n=28) of Klebsiella spp. were found to be susceptible whereas 7% 
(n=2) were found to be resistant. Therefore, in total temocillin was effective against 
98% (n=130) of ESBL-producing Enterobacteriaceae using BSAC UTI breakpoints.
However, the susceptibility profile changes when interpreted using BSAC systemic 
breakpoints. The number of resistant isolates increased, with 37% of E. coli, 47% of 
Klebsiella spp. and 33% of other isolates being called resistant. Using these 
breakpoints, temocillin was only effective against 61% (n=81) of ESBL-producing 
Enterobacteriaceae with an approximately 25-fold increase in the number of 
resistant isolates (n=51).
Using Fuchs’ breakpoints to interpret MIC, the susceptibility profile generated for 
temocillin is altered once more. Fuchs’ guidelines share a similarity to BSAC UTI 
guidelines as they have the same breakpoint for determining resistance (>32 for 
BSAC UTI and >32 pg/ml for Fuchs). With Fuchs’ breakpoints, the threshold for 
susceptible isolates is set between the susceptible breakpoints of BSAC UTI and 
BSAC systemic guidelines, at <16 pg/ml. Therefore, fewer susceptible isolates are 
found with Fuchs’ guidelines than with BSAC UTI. Ninety-one percent of E. coli 
isolates and 80% of Klebsiella spp. were found to be susceptible to temocillin when 
using Fuchs’ guidelines. Overall, Fuchs’ guidelines identified 8 8 % of all isolates as 
susceptible (Table 6.7).
Using BSAC UTI breakpoints, all seven of the control isolates used in this section of 
study were found to be susceptible to temocillin (Table 6 .8 ). However, using the 
BSAC systemic breakpoints 43% (n=3) of isolates were found to be resistant.
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Table 6.7 Susceptibility profile to temocillin amongst ESBL-producing 
Enterobacteriaceae.
Temocillin 
BSAC UTI
Temocillin 
BSAC systemic
Temocillin
Fuchs’
S R S R S I R
E. coli (n=99) 100% 0% 63% 37% 91% 5% 4%
E. coli IS26 positive (n=63) 100% 0% 75% 25% 96% 2 % 2 %
E. coli IS26 negative (n=36) 100% 0% 41% 59% 83% 11% 6 %
Klebsiella spp. (n=32) 93% 7% 53% 47% 80% 13% 7%
Other (n=3) 100% 0% 67% 33% 100% 0% 0 %
Total (n=134) 98% 2 % 61% 39% 8 8 % 7% 5%
The MIC values were interpreted into susceptible (S) or resistant (R) using BSAC 
UTI, BSAC systemic and Fuchs’ breakpoints.
Table 6 . 8  Resistance profile of temocillin for epidemic E. coli strains A-E, E. coli 
K12 and NCTC 10418 using BSAC UTI and BSAC systemic breakpoints.
Controls Temocillin BSAC UTI Temocillin BSAC systemic
E. coli Strain A Susceptible Susceptible
E. coli Strain B Susceptible Resistant
E. coli Strain C Susceptible Susceptible
E. coli Strain D Susceptible Resistant
E. coli Strain E Susceptible Resistant
E. coli K12 Susceptible Susceptible
E. coli NCTC 10418 Susceptible Susceptible
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6.3.2 Tigecycline
6.3.2.1 MIC Distributions
Tigecycline E-test strips have an M IC  range of 0.64-256jig/ml (Figure 6 .8 ). The 
M IC  range for E. coli (n=99) was between 0.125 and 2pg/ml with 53% (n=53) of 
isolates being predominantly found at the lower end of the concentration scale 
(<0.5pg/ml). 27% (n=27) of isolates had an M IC  of >1 pg/ml (Table 6.9). The modal 
M IC  was 0.75pg/ml with 19% (n=19) of E. coli with this value (Figure 6.7). The 
MIC50 and MIC90 for E. coli were 0.5pg/ml and lpg/ml respectively. However as 
with temocillin, differences occur when E. coli is categorised according to the 
presence or absence of IS26 . E. coli IS26 positive isolates had an increased lower 
range from 0.125pg/ml to 0.19pg/ml whereas the MIC50 and MIC90 values for E. coli 
IS26 negative isolates were 0.38pg/ml and 1.5pg/ml respectively (Table 6.9).
Tigecycline was tested against epidemic E. coli strains A-E, E. coli K12 and NCTC 
10418. The range of activity was 0.64|ig/ml - lpg/ml and the modal MIC was at 
0.5pg/ml (43%). Once more, the MIC of E. coli K12 and E. coli NCTC 10418 were 
found at the lower end of the scale with values of 0.19pg/ml and 0.64pg/ml 
respectively.
The M IC  range for Klebsiella spp. tested against tigecycline was found to be at a 
higher portion of the concentration gradient in comparison to E. coli with values 
between 0.5pg/ml - 8 pg/ml with 40% (n=13) of isolates with an M IC  of >2pg/ml 
and 38% (n=12) with an M IC  of <l|ig/ml. The modal M IC  was 1.5pg/ml (22%). 
MIC50 and MIC90 values for Klebsiella spp. were 1.5pg/ml and 4pg/ml respectively. 
M IC  values of 1.5pg/ml, lpg/ml and 0.25pg/ml were found for the 2 E.cloacae and 
1 C. freundii.
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Table 6.9 MIC distribution o f  tigecycline against ESBL-producing
Enterobacteriaceae.
Tigecycline
Range (pg/ml) M IC5o (pg/ml) M IC 90 (pg/m l)
E. coli (n=99) 0.125-2 0.5 1
E. coli IS26 positive (n=63) 0.19-2 0.5 1
E. coli IS26 negative (n=36) 0.125-2 0.38 1.5
Klebsiella spp. (n=32) 0.5-8 1.5 4
o
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Figure 6.7 MIC distribution o f  E. coli and Klebsiella spp. for tigecycline.
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0.75ng/ml
Figure 6.8 Tigecycline E-test. E-test to determine the MIC o f  tigecycline against 
ESBL-producing isolates.
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6.3.2.2 Susceptibility profile of tigecycline
Using BSAC guidelines, 98% (n=97) of E. coli isolates were susceptible to 
tigecycline, 2% (n=2) were intermediate (Table 6.10). This varies slightly when 
divided between 7526 positive and negative strains as E. coli IS26 negative isolates 
are 97% (n=35) susceptible and 3% (n=l) intermediate. Using CLSI breakpoints, 
100% (n=99) of E. coli isolates were found to be susceptible.
56% (n=18) o f Klebsiella spp. were susceptible using BSAC breakpoints, 19% (n=6 ) 
were intermediate and 25% (n=8) were resistant. In comparison, using CLSI 
breakpoints generated more susceptible MIC values than BSAC breakpoints with 
88% (n=28) of Klebsiella spp. being susceptible, 3% (n=l) intermediate and 9% 
(n=3) resistant. 100% of other Enterobacteriaceae species were found to be 
susceptible using both BSAC and CLSI breakpoints.
In total, tigecycline was effective against 89% of all Enterobacteriaceae using 
BSAC breakpoints and 97% effective using CLSI breakpoints. However, despite the 
higher number of susceptible MIC values, the CLSI breakpoints reveal more 
resistant values (5%) than the BSAC breakpoints (2%). BSAC breakpoints have a 
greater number o f intermediate MIC values (6%) than CLSI (1%).
Using both BSAC and CLSI breakpoint to interpret results, all seven control isolates 
were found to be susceptible to tigecycline.
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Table 6.10 Susceptibility profile o f tigecycline against ESBL-producing 
Enterobacteriaceae. The MIC values were interpreted as susceptible (S), 
intermediate (I) or resistant (R) using BSAC and CLSI (as provided by bioMerieux) 
breakpoints.
Tigecycline BSAC Tigecycline CLSI
S I R S I R
E. coli (n=99) 98% 2% 0% 100% 0% 0%
E. coli IS26 positive (n=63) 98% 2% 0% 100% 0% 0%
E. coli IS26 negative (n=36) 97% 3% 0% 100% 0% 0%
Klebsiella spp. (n=32) 56% 19% 25% 88% 3% 9%
Other (n=3) 100% 0% 0% 100% 0% 0%
Total (n=134) 89% 6% 2% 97% 1% 5%
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6.4 Discussion
This chapter has evaluated the susceptibility of ESBL-producing Enterobacteriaceae 
to various antibiotics. Clinically, ESBL-producers are considered to be resistant to 
aztreonam and ceftazidime (Paterson and Bonomo, 2005). However, from this study 
it is clear to see that, according to measurement o f MIC, this is not the case for all 
ESBL-producing Enterobacteriaceae. Within the E. coli population, only 40% of  
isolates have resistant MIC values to aztreonam and only 25% of isolates were 
resistant to ceftazidime. This highlights the importance o f detection o f the ESBL 
resistance mechanisms, as these antibiotics would otherwise eventually be 
recommended for therapy.
Resistance to front line antibiotics poses a great limitation from the perspective of 
treatment options (Paterson et al., 2000). Ciprofloxacin is commonly used to treat 
urinary-tract infections. In this study, 90% of all Enterobacteriaceae were resistant 
to ciprofloxacin. Breaking this down into species level, 90% o f E. coli and 91% of 
Klebsiella spp. were resistant. A study conducted by Hwang et al., (2009) observed 
52% and 50% resistance with ESBL-producing E. coli and Klebsiella spp., 
respectively. Cagancci et al., (2008) carried out a study on non ESBL-producing E. 
coli associated with urinary-tract infections, showing that only 10% were resistant to 
ciprofloxacin. Paterson et al., (2000) described a correlation between ciprofloxacin 
resistance and ESBL production, stating that 60% of isolates in the study were in fact 
ESBL-producing.
Piperacillin/tazobactam is a combination antibiotic containing the broad-spectrum 
penicillin piperacillin and the p-lactamase inhibitor tazobactam. In theory, owing to 
the presence of a p-lactamase inhibitor, the large majority o f isolates should be 
susceptible. However, it was only effective against 56% of isolates: 60% of E. coli 
and 42% Klebsiella spp. were susceptible. This result appears to be at odds once 
more with the findings o f by Hwang et al., (2009) who observed that 90% of ESBL- 
producing E. coli and 73% of ESBL-producing Klebsiella spp. were susceptible. 
However, CLSI guidelines were followed in their study.
As stated in the introduction to this chapter (section 6.1), plasmids encoding ESBL 
genes often harbour genes for other resistance mechanisms e.g. aminoglycosides and
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trimethoprim-sulfamethoxazole. In this study, the effectiveness o f gentamicin, 
amikacin and trimethoprim-sulfamethoxazole was analysed. 31% of all isolates were 
resistant to gentamicin whereas 11% were resistant to amikacin. 89% of all 
Enterobacteriaceae isolates were found to be resistant to trimethoprim- 
sulfamethoxazole of which 94% were E. coli. A study by Cagnacci et al., (2008) on a 
population of non-ESBL-producing E. coli stated that only 30.2% were resistant.
The carbapenems are active against Gram-negative organisms and are reserved 
primarily for severe infections with organisms producing ESBL and high level 
AmpC (Woodford et al., 2007a). In this study, 100% of isolates were fully 
susceptible to meropenem and imipenem. When evaluating the use o f ertapenem 
only one E. coli (n=101) isolate was found to be resistant with an MIC value of  
4pg/ml. The E. coli isolate in question carried CTX-M-15. Comparing the results to 
those o f Hwang et al., (2009), all isolates in their study were susceptible.
Temocillin has been shown to have an increased stability to ESBL- and AmpC- 
producing Enterobacteriaceae. In this study, using BSAC UTI breakpoints, 
temocillin was effective against 98% of all isolates tested. This is comparable with 
the sensitivity rate (99%) obtained by Livermore et al., (2006) in the South East of 
England.
Rodriguez-Villalobos et al., (2006) Rodriguez-Villalobos et al., (2009) and 
Glupczynski et al., (2007) used Fuchs’ guidelines (Fuchs et al., 1985) to interpret 
temocillin MIC breakpoints. Rodriguez-Villalobos et al., (2006) demonstrated that 
92% of E. coli were susceptible to temocillin and Rodriguez-Villalobos et al., (2009) 
found that 95.4% of E. coli were susceptible to temocillin. Glupczynski et al.,
(2007) stated that 97.5% of E. coli were susceptible. In this thesis, 97% of E. coli 
strains were susceptible using Fuchs’ breakpoints. Glupczynski et al., (2007) also 
stated that 88% of ESBL-producing Klebsiella spp. were susceptible to temocillin 
whereas in this study, 93% were found to be susceptible. The percentage of 
susceptible isolates decreases when BSAC systemic breakpoints are used. Using 
these guidelines, temocillin was effective against 61% of all isolates including 63% 
E. coli, 53% Klebsiella spp. and 67% of other Enterobacteriaceae. This is interesting 
to note as community-acquired bacteraemia can be associated with localised
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infections such as those found in the urinary tract (Hwang et al., 2009). However, 
temocillin has high activity in urinary-tract infections against most ESBL-producing 
organisms.
Tigecycline has generally exhibited good in vitro activity against Enterobacteriaceae 
in previous studies (Hope et al., 2006, Morosini et al., 2006, Lu et al., 2008, Jones et 
al., 2009). A study carried out by Hope et al., (2006) in the South East o f England 
demonstrated 100% sensitivity when testing tigecycline against ESBL-producing E. 
coli and 52% sensitivity against ESBL-producing Klebsiella spp. The results shown 
in this study are comparable as 98% of ESBL-producing E. coli and 56% of  
Klebsiella spp. were susceptible when using BSAC guidelines. However, these 
results contrast with those obtained by Naesens et al., (2009) who found that only 
65% of ESBL-producing E. coli and 0% of ESBL-producing Klebsiella spp. were 
susceptible to tigecycline. In this chapter, using CLSI guidelines increased the 
percentage of susceptible E. coli isolates to 100% and Klebsiella spp. to 88% giving 
an overall susceptibility of 97%. This result exactly supports the findings o f Jones et 
al., (2009) and is also comparable to the results (99% susceptible) o f Lu et al.,
(2008).
In summary, resistance is commonly found against the most established antibiotics. 
In this study amikacin (11% of isolates resistant) and the carbapenems (ertapenem 
1% of isolates resistant) have proved to be the most active o f the established 
antibiotics against ESBL-producing Enterobacteriaceae. Also the ‘new’ alternatives 
temocillin and tigecycline have demonstrated good in vitro activity. However with 
temocillin, considerations need to be made when choosing the most suitable MIC 
breakpoint guidelines and type o f infection involved, as the susceptibility profile 
varies between each considerably.
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Chapter 7: Identification of Enterobacteriaceae isolates by matrix- 
assisted laser desorption ionization time-of-flight (MALDI-TOF) 
mass spectrometry
7.1 Introduction
Within the clinical laboratory, bacteria are identified using conventional phenotypic 
methods such as growth on various media, colony morphology, Gram stain and other 
biochemical tests. However, although accurate, these typical tests are often time 
consuming and costly (Bizzini et al., 2003). As bacterial identification can take 
between 24 and 36 hours (Cherkaoui et al., 2010), the correct treatment o f patients 
by empirical antibiotic therapy is often hampered (Seng et al., 2009). In order to 
improve patient care, the need for a rapid and accurate identification o f bacteria is 
essential (Carbonnelle et al., 2011, Seng et al., 2009). Molecular and genotypic 
methods e.g. PCR and nucleotide analysis have been developed but they are often 
technically demanding and expensive (Conway et al., 2001). The use o f matrix- 
assisted laser desorption ionization time-of-flight mass spectrometry (MALDI- 
TOF/MS) has been demonstrated by a number of studies to have the capability of 
rapidly identifying bacteria to species level e.g. enterobacteria (Lynn et al., 1999, 
Conway et al., 2001), staphylococci (Carbonnelle et al., 2007), listeria (Barbuddhe et 
al., 2008) and clostridia (Grosse-Herrenthey et al., 2008).
MALDI-TOF/MS utilises a ‘proteomic’ approach to bacterial identification by 
creating a protein ‘fingerprint’ which can be compared to a database (Carbonnelle et 
al., 2011, Bizzini et al., 2003). Sample preparation for MALDI-TOF is relatively 
simplistic. Intact cells can be directly applied (smear method) to a target plate or 
alternatively, an extraction procedure can be adopted to disrupt the cell (particularly 
the cell wall) thus causing the release o f protein markers. The samples are overlaid 
with a matrix, before being subjected to laser radiation. Protein and peptide ions, 
mainly from ribosomal proteins, enter a time o f flight tube where they can be 
separated dependent on their mass to charge ratio (m/z) (Stults, 1995). The mass to 
charge ratio values form mass spectral peaks which indicate the respective 
components detected in the sample (Cherkaoui et al., 2010). In this study the Bruker 
Daltonics Microflex LT Benchtop MALDI Mass Spectrometer (Bruker Daltonics,
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Germany) was utilised and spectra were analysed using MALDI Biotyper 2.0 
software.
MALDI-TOF/MS was first utilised in the 1990s for the identification o f bacteria 
(Holland et al., 1996, Krishnamurthy and Ross, 1996). However, its usage in the 
clinical setting has only been investigated in recent years. MALDI-TOF/MS methods 
capable o f directly detecting bacteria from the source sample e.g. blood (La Scola 
and Raoult, 2009, Stevenson et al., 2010) and urine (Ferreira et al., 2010) are being 
established to reduce time and maximise efficiency.
Additionally, as well as bacterial identification, MALDI-TOF/MS has been utilised 
in studies for the detection o f methicillin-resistant Staphylococcus aureus, MRSA 
versus methicillin sensitive S. aureus, MSSA (Edwards-Jones et al., 2000). MALDI- 
TOF/MS has also been used to subtype clonal lineages o f MRSA (Wolters et al., 
2010) and Staphylococcus epidermidis (Harris et al., 2010). It has also been shown 
to have the capability to differentiate E. coli 0157: H7 from wild type E. coli strains 
(Parisi et al., 2008).
In this chapter, the aim was to rapidly identify 160 Enterobacteriaceae isolates and 
to compare the findings with the BD Phoenix Automated system which is already 
established as an automated identification tool within the clinical laboratory.
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7.2 Results
7.2.1 Identification of bacterial isolates by the Bruker Daltonics MALDI- 
Biotyper
Mass spectra o f Enterobacteriaceae were analysed by the MALDI Biotyper 2.0 
software (Bruker Daltonik, Bremen,Germany). Figure 7.1 and 7.2 demonstrate 
spectra of E. coli and K. pneumoniae, respectively. The spectra demonstrate mass ion 
intensity over a mass to charge ratio (m/z) range o f 2000 to 20000. Differences 
between the spectra are clearly distinguished, which support this instrument’s 
capability in the identification o f bacteria. For each sample tested, the mass ion 
peaks were compared to the spectra contained within MALDI Biotyper 2.0 database. 
The Bruker MALDI Biotyper generated the ‘Best Match’ identification along with a 
‘Score Value’. It also gave a ‘Second Best Match’ option and ‘Score Value’. The 
score value is a number generated to give an indication o f how successful and 
effective the identification process had been. The score value scale ranged from 0 
(no reliable identification) to 3 (highly probably species identification). Overall, 
there are four score value groups as outlined in Table 7.2.
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Figure 7 .1 Mass spectra o f  three replicates o f  an E. coli isolate.
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Figure 7.2 Mass spectra o f  three replicates o f  a K. pneumoniae isolate.
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7.2.1.1 The use of the smear method versus extraction method in the 
preparation of samples
Two approaches were utilised in the preparation of samples for MALDI-TOF/MS. 
The direct smear method and the extraction method were both used on 4 isolates o f  
E. coli and Klebsiella spp. and 6 replicates of each were carried out. All had a score 
value o f >2.0 and 42/48 (88%) had a score value o f >2.3.
Using the smear method, 19/24 (79%) of E. coli isolates were found to have a score 
value of >2.3. 5/24 (21%) o f isolates had a score value o f 2.2. Within the Klebsiella 
spp., 23/24 (96%) isolates had a score value of >2.3.
Using the extraction method, 23/24 (96%) of E. coli isolates had a score value o f  
>2.3 and 1/24 (4%) of isolates had a score value o f 2.2. Within the Klebsiella spp., 
24/24 (100%) isolates had a score value of >2.3.
The extraction method was utilised as the score values were generally higher. It was 
also suggested by the manufacturer that the extraction method generated more 
detailed spectra.
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7.2.2 The identification of bacterial isolates using the extraction preparation 
method for MALDI-TOF/MS
One hundred and sixty isolates were identified using Bruker Daltonics MALDI- 
Biotyper. The methodology employed is described in Chapter 2 (2.4.2). 
Unfortunately, four of the original 164 isolates could not be revived for testing at this 
point.
As outlined in table 7.1, the MALDI Biotyper identified 114 E. coli (71.25%), 34 
Klebsiella pneumoniae (21.25%), 4 Klebsiella oxytoca (2.5%), 4 Enterobacter 
cloacae (2.5%), 1 Enterobacter aerogenes (0.625%), 1 Citrobacter freundii 
(0.625%), Citrobacter koseri (0.625%) and 1 Morganella morganii (0.625%).
97% (111/114) of all E. coli isolates were identified with a score value of greater 
than 2.3. 3% (3/114) had a score o f less than 2.3. However, those isolates with a 
score value o f less 2.3 all had a score value of >2.2, which still suggests that the 
correct identification had been achieved as a secure genus and probable species 
identification.
All Klebsiella spp. were identified with a score value o f greater than 2.3. 89% (8/9) 
of all other Enterobacteriaceae were identified with a score value o f greater than 2.3 
and only one isolate {E. cloacae) had a score value o f less than 2.3 with a value of 
2 . 1.
Using the MALDI Biotyper 2.0 software, a dendrogram of all samples identified was 
generated. This allowed for Enterobacteriaceae to be clustered according to species. 
The MALDI Biotyper 2.0 software correctly grouped isolates o f the same species 
together (Figure 7.3).
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Table 7.1 Bacterial identification using Bruker MALDI Biotyper
Score Value
Identification with MALDI Biotyper <2.3 >2.3
E. coli (n=l 14) 3 111
Klebsiella pneumoniae (n=34) 34
Klebsiella oxytoca (n=4) 4
Enterobacter cloacae (n=4) 1 3
Enterobacter aerogenes (n=l) 1
Citrobacter freundii (n=l) 1
Citrobacter koseri (n=l) 1
Morganella morganii (n=l) 1
Table 7.2 Score Value groupings and interpretations using Bruker MALDI Biotyper 
software for the identification o f organisms
Range Description
2.300 - 3.000 Highly probable species identification
2.000 - 2.299 Secure genus identification, probable species identification
1.700- 1.999 Probable genus identification
0.000- 1.699 No reliable identification
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Figure 7.3 Species dendrogram produced by Bruker M ALDI Biotyper. Selections o f  
isolates o f  different species were analysed with the M ALDI BioTyper software in 
order to create a dendrogram. Isolates o f  the same species were grouped together.
7.3 Concordance of MALDI-TOF identification with BD Phoenix
The bacterial identifications provided by the Bruker M ALDI Biotyper were 
compared to the bacterial identifications achieved via the use o f  the BD Phoenix 
(data outlined in Chapter 4). Between the two methods, there is a 97%  agreement 
between bacterial identification.
Discrepancies occurred between the two instruments as the BD Phoenix 
identification o f  K. pneumoniae ssp. ozaenae (n=4) differed to the Bruker M ALDI 
Biotyper. The Bruker MALDI Biotyper identified these isolates as ju s t  being K. 
pneumoniae with no further sub-speciation. Another discrepancy occurred with an 
Enterobacter spp. The BD Phoenix defined this isolate as E. cloacae whereas the 
Bruker MALDI Biotyper identified it as E. aerogenes.
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7.4 Discussion
Preliminary experiments were set up using a selection of 8 isolates, 4 E. coli and 4 
Klebsiella spp. (6 replicate tests of each), to determine which preparation method 
(smear versus extract) was most suitable using the Bruker Daltonics Microflex LT 
Benchtop MALDI Mass Spectrometer. Using the smear method 19/24 (79%) o f E. 
coli and 23/24 (96%) o f Klebsiella spp. had a score value o f >2.3. However, upon 
using the extract method, 23/24 (96%) E. coli isolates and 24/24 (100%) of 
Klebsiella spp. had a score value o f >2.3. The smear method was very simple and 
easy and had a very quick preparation time. Minimal consumables were used 
meaning it had very low consumable costs. The extraction method took slightly 
longer to prepare the samples as there are 2 centrifugation steps and 2 incubation 
steps (waiting for pellet to dry and for cell lysis after the addition o f formic acid). 
Additionally, more reagents were used in this method suggesting it may be slightly 
more expensive not only due to the longer hands on time but also for the used 
consumables. However, it is thought that more detailed spectra are achieved through 
the extract method which could in turn lead to more accurate and reliable 
identifications (Bohme et al., 2010).
In this study, 160 Enterobacteriaceae isolates were identified by MALDI-TOF/MS. 
These isolates had previously been identified using the BD Phoenix Automated 
System. Overall, the MALDI Biotyper generated a score value reading of 2.3 for 
98% of all isolates tested. The remaining 2% o f isolates had score values o f >2.0. A 
score value of 2.0 is recommended by the manufacturers as cut-off for probable 
species identification and this suggests that the MALDI Biotyper is a reliable tool for 
genus and species level identification within Enterobacteriaceae tested in this study.
A concordance of 97% was found between the use of the Bruker MALDI Biotyper 
and the BD Phoenix Automated System as 5 discrepant results were obtained. 
Discrepancies in identification have been found in other studies. In a study by Seng 
et al., (2009) a large number of samples were identified (n=1660) and 95.4% were 
found to be correctly identified. A number o f isolates could not be correctly 
identified due to limitations in the database. This was also found by Bessede et al., 
(2010) who achieved 98% identification and suggested that the database should be
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expanded to include a greater range of organisms. A study by van Veen et al., (2010) 
demonstrated correct identification for 97.8% of all bacteria and yeast tested (n=980) 
and their results show that 96.6% of Enterobacteriaceae were correctly identified to 
species level using MALDI Biotyper whereas 100% were correctly identified to 
genus level. 81.8% of non-fermentative Gram-negative bacteria were identified to 
genus level and of which, 74.5% were also identified to species level.
An explanation for the discrepancies found within the identification o f Klebsiella 
spp. could be attributed to the Klebsiella spp. classification systems. As outlined in 
Chapter 1 (section 1.1.2), there are 3 main classification systems for Klebsiella spp. 
The 0rskov system (used in the USA and parts of Europe) identifies K  ozaenae to 
be a subspecies o f K  pneumoniae whereas the Cowan (used in the UK) and 
Bascomb systems list them as individual species (Podschun and Ullmann, 1998). 
However despite database issues, the MALDI Biotyper proved to be a much more 
rapid identification tool when compared to the BD Phoenix Automated System as 
bacteria on a 96 well plate could be identified in approximately 90 minutes-2 hours.
Aside from bacterial identification, MALDI-TOF/MS has been shown to be a rapid 
alternative to current typing methods e.g. PFGE, spa typing, MLST as well as other 
biochemical typing methods (Barbuddhe et al., 2008, Dieckmann et al., 2008, Harris 
et al., 2010, Wolters et al., 2010). In 2000, Edwards-Jones et al., demonstrated that 
some MRSA strains could be discriminated from MSSA strains (Edwards-Jones et 
al., 2000) and this has been developed further so that five major MRSA clonal 
lineages can now be discriminated using MALDI-TOF/MS (Wolters et al., 2010). 
Dubois et al., (2009) and Harris et al., (2010) also demonstrated this principle for S. 
epidermidis. Dubois et al., (2009) showed that clinical S. epidermidis could be 
discriminated from environmental S. epidermidis whereas Harris et al., (2010) found 
that isogenic mutants of S. epidermidis could be paired to their respective parent 
strain using the Bruker Daltonics MALDI Biotyper 2.0 software.
The use of MALDI-TOF/MS as a typing tool has been applied to other bacterial
species besides staphylococci. For instance, Dieckmann et al., (2008) found that
Salmonella spp. could be rapidly typed using MALDI-TOF/MS. Usually, isolates o f
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Salmonella spp. have to undertake long incubation periods through biochemical 
typing tests and so the result is often delayed as well as being limited by subjectivity 
and specificity. However, the MALDI-TOF/MS approach was found to resolve these 
issues and provide results comparable to DNA-sequence methods (Dieckmann et al., 
2008). Another example is outlined by the subtyping o f Listeria spp. Clonal lineages 
were discriminated due to spectral peak differences therefore allowing various 
serotypes to be identified (Barbuddhe et al., 2008). In addition, MALDI-TOF/MS 
has been able to discriminate strains of E. coli 0157: H7 due to differences in mass 
spectra peaks (Parisi et al., 2008).
Clonal dissemination of an E. coli clone, 025b-ST131 has been reported 
internationally (Clermont et al., 2009, Lau et al., 2009, Lau et al., 2008a, Pitout et al., 
2009a, Rogers et al., 2011, Johnson et al., 2010a, Peirano and Pitout, 2010). The use 
of MALDI-TOF/MS in the rapid discrimination o f this clone could be potentially 
adopted. A current literature search yielded one result whereby MALDI-TOF/MS 
had been used to identify clonal relatedness. Using MALDI Biotyper software, 2 
ST131 positive E. coli isolates originating from poultry (n=l) and calf (n=l) were 
found to be related and it was found that ST131 positive E. coli isolates obtained 
from humans were unrelated (Kmet et al., 2011). The development o f such a method 
would allow epidemiologically relevant and related strains to be identified rapidly 
(within 2 hours) and in doing so improvements could be made with regards to 
clinical decisions and outbreak management to prevent further clonal dissemination 
(Harris et al., 2010, Wolters et al., 2010).
The use o f MALDI-TOF/MS could one day replace current time consuming 
phenotypic testing (Carbonnelle et al., 2011) as it has been demonstrated to be a 
robust and successful identification tool within this study and others. The potential 
for MALDI-TOF/MS to be implemented as a typing tool appears promising. It has 
been suggested that further studies using more clonally related strains, along with an 
assessment of laboratory reproducibility should be carried out (Wolters et al., 2010). 
However current literature suggests that it has good discriminatory power akin to 
current typing methods, which could potentially be developed for the identification 
of clonal lineages in other species.
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Chapter 8: Biofilm formation in Escherichia coli isolates
8.1 Introduction
Costerton et a l , (1999) defines a bacteria biofilm as “a structured community o f  
bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert 
or living surface”.
Biofilms are formed over five different stages (Van Houdt and Michiels, 2005) 
(Figure 8.1).
1. Attachment of planktonic bacteria (reversible)
2. Irreversible attachment by the production o f extracellular polymers or 
adhesins.
3. Development o f biofilm structure by formation o f microcolonies.
4. Development o f mature biofilm with water channels and pores from 
microcolonies. Extracellular polymeric matrix is produced for adhesion and 
to trap nutrients for continuing growth.
5. Dispersion o f bacteria from the biofilm into the environment (return to 
planktonic form).
There are many surface determinants associated with E. coli biofilm formation and 
some examples are outlined below.
The flagella play a role in the motility o f bacteria (Cooke, 1974). There are four
main rationales linking flagella to biofilm formation. Firstly, it is thought that
flagella play a role in the attachment o f the cell to a surface (Pratt and Kolter, 1998).
Flagella are believed to facilitate the movement of the bacteria to the surface and to
also play a role in the motility o f bacteria along the surface in order to allow for
growth and spread during the developing stages (Pratt and Kolter, 1998). Lastly,
flagella are associated with chemotaxis whereby bacteria move towards nutrients that
are situated at the biofilm surface (Pratt and Kolter, 1998). However, experiments
associated with flagella mutants have been carried out by Pratt and Kolter, (1998). It
was found that bacteria lacking flagella or with flagella with insufficient motility
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were defective in forming a biofilm as the initial stages of biofilm formation were 
hindered. Interestingly, it was also found that non-chemotactic bacteria still formed a 
biofilm (Pratt and Kolter, 1998).
Type I pili, also known as fimbriae, are associated with host tissue adhesion in 
pathogenic bacteria strains (Finlay and Falkow, 1997). In E. coli, the fim  gene 
operon is associated with encoding type I pili. Within the fim  operon,fimA encodes 
for the major fimbrin subunit, fim H  encodes the mannose specific adhesin and fimC  
and fimD  are associated with assembly (Fernandez and Berenguer, 2000). Mutations 
in these fim  genes are associated with isolates whereby pili do not attach to surfaces 
(Pratt and Kolter, 1998). More specifically, it has been shown that mutations in fimH  
alter the structure o f pili, which therefore leads to the interference of normal 
attachment (Pratt and Kolter, 1998). Type 3 fimbriae have also been shown to be 
involved with biofilm formation in uropathogenic E. coli (Ong et al., 2008).
Antigen 43 is an outer membrane protein found in E. coli (Owen et al., 1987), which 
is important for cell to cell and cell to surface attachment. It is encoded by the agn43 
gene and mutations of this gene can affect the autoaggregation o f E. coli in liquid 
media. Cells deficient in antigen 43 were found to be defective at forming mature 
biofilms. However, these mutants are capable o f forming closely packed cell clusters 
(Danese et al., 2000a).
Curli are important for surface attachment and colonisation (Vidal et al., 1998). The 
csgA gene is associated with encoding curli subunits. It has been demonstrated that 
no biofilm formation occurs in bacteria whereby a csgA null mutation has occurred. 
Curli formation is regulated by the OmpR protein. Biofilm formation is hindered in 
bacteria with an ompR null mutation, as adhesion is suppressed (Vidal et al., 1998).
Exopolysaccharide production e.g. colanic acid or M antigen was found to play a 
role in giving the biofilm its protective outer capsule. Colanic acid was not found to 
play a role in initial attachment but it is associated with the formation o f the three- 
dimensional structure (Danese et al., 2000b, Prigent-Combaret et al., 2000). Another 
form of exopolysaccharide is poly-p-1, 6 -N-acetyl-D-glucosamine (PGA), which is 
involved with the attachment of cells to abiotic surfaces, intercellular adhesion and 
biofilm formation (Wang et al., 2004).
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Biofilms are a part o f  bacterial survival (Hall-Stoodley and Stoodley, 2009) and are 
often difficult to eradicate (Lewis, 2001). In medicine biofilms can complicate 
infections which are chronic or difficult to treat for example prostatitis (Kanamaru et 
al., 2006) and urinary catheter cystitis caused by E. coli (Costerton et al., 1999, 
Jackson et al., 2002). Biofilms have a protective phenotype (Costerton et al., 1999). 
Antimicrobial agents often fail to penetrate the complex biofilm structure (Jefferson 
et al., 2005) and also, due to nutrient limitations some bacteria exist in a slow- 
growing state (Brown et al., 1988).
As well as aiding to medical problems, biofilms are also present in nature and are 
able to cause environmental problems (Costerton et al., 1999).
Figure 8.1 The development o f  a bacterial biofilm encompassing the 5 stages o f  
formation. Adapted from (Van Houdt and Michiels, 2005).
8.1.1 Significance of the pgaABCD  gene locus
Wang et al., (2004) identified a gene locus in E. coli known as pgaABCD. This 
locus, which can be horizontally transferred, was found to be associated with the 
promotion o f  surface binding, intercellular adhesion through the production o f  poly- 
p-1, 6-N-acetyl-D-glucosamine (PGA) (known as polysaccharide intercellular 
adhesin (PIA) in Staphylococcus epidermidis (Mack et al., 1996)) and biofilm 
formation.
The transcription o f  pgaABCD is activated by NhaR (D N A  binding protein) 
belonging to the LysR family o f  transcriptional regulators (Goller et al., 2006). 
pgaABCD was found to have homology to the hmsHFRS locus found in Y. pestis
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(Hare and McDonough, 1999) and the icaADBC gene locus found in S. epidermidis 
(Heilmann et al., 2006). Each gene within the locus has a specific function (Wang et 
al., 2004).
PgaC is a glycosyltransferase and is homologous to IcaA found in 
S. epidermidis.
PgaB is a lipoprotein with homology to IcaB from S. epidermidis.
PgaA is an outer membrane protein associated with the translocation and docking o f  
PGA to the cell surface. It has no homologue in staphylococci.
PgaD is an inner membrane protein which is a potential functional (not sequence) 
homologue of IcaD of S. epidermidis.
Each gene is involved with the production and function of PGA. pgaC  and pgaD  are 
involved in PGA synthesis whereas pgaA and pgaB  have a function in the export of  
PGA (Itoh et al., 2008).
8.1.2 Biofilms and ESBLs
Bacterial conjugation is a mechanism by which genetic information can spread. Gene 
transfer occurs frequently in biofilms as their complex network o f communities is 
ideally suited to the role (Hausner and Wuertz, 1999). However owing to the 
connection of conjugation and biofilm, medically relevant plasmid-bearing strains 
could potentially form biofilms thus increasing the chance o f virulence spread and 
biofilm related infection. Conjugation also plays a role in the horizontal transfer of 
antibiotic resistance and virulence factors. It has been suggested that a consequence 
of using antimicrobial agents in medicine and the environment may have been a 
selection of plasmid bearing-strains capable of biofilm formation (Ghigo, 2001).
With this information in mind, it was interesting to investigate whether ESBL- 
producing E. coli isolates in this study had a greater likelihood o f forming biofilms.
The aim of this chapter was to identify the prevalence o f pgaABCD  locus in 3 
different E. coli populations, to establish biofilm production phenotypically and to 
identify any correlation between biofilm formation and ESBL production.
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8.2 Results
8.2.1 Screening ESBL and AmpC-producing E. coli isolates for pgaABCD
Using primers specific for amplifying pgaA and pgaC  of the pgaABCD  gene locus 
(Cerca et al., 2007), 105 (100%) ESBL and AmpC-producing E. coli (largely 
belonging to phylogenetic subgroup B2), were found to give positive amplification 
products (Table 8.1, Figure 8.2). As a control, E. coli strain A and E. coli K12 were 
used and both possessed the target genes. Additionally, several isolates o f Klebsiella 
spp. were screened. No amplification products were generated. Therefore, in positive 
strains, both targets were consistently found.
8.2.1.1 Screening control E. coli isolates for pgaABCD
Forty cefpodoxime sensitive E. coli isolates obtained from urine specimens were 
screened for the pgaABCD locus to serve as a control population. 33/40 (83%) were 
found to be positive (Table 8.1).
8.2.1.2 Screening bovine E. coli isolates for pgaABCD
As E. coli isolates in this thesis were found to be largely related to one clonal type, 
characterised bovine E. coli isolates were used to act as a non-human control 
population. Therefore, 124 E. coli isolates obtained from bovine endometrium were 
also used in this experiment. Of these 124 bovine E. coli isolates, 114 had previously 
been characterised by Triplex PCR into phylogenetic groups; 37/114 (32%) were 
group A, 51/114 (45%) were group B l, 3/114 (3%) were group B2 and 23/114 
(20%) were group D. MLST revealed that many of these isolates belonged to 4 
distinct clonal clusters (Sheldon et al., 2010).
Using the pgaABCD PCR, 114/124 (92%) were found to be positive for pgaA and 
pgaC  whereas 10/124 (8%) were negative (Table 8.1). These isolates had 
additionally been screened for ESBL genes by multiplex PCR as described in chapter 
3; however no positive amplification was generated.
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Figure 8.2 Amplification o f  pgaA and pgaC. M, lOObp molecular ladder; Lanes 1-3 
E. coli isolates positive for the gene locus.
Table 8.1 Prevalence o f  pgaABCD locus amongst E. coli isolates from various 
sources
Human E. coli ESBL Human E. coli
and AmpC (n=105) control (n=40) Bovine E. coli (n=124)
+ + +
pgaABCD 105 (100%) 0 (0%) 33 (83%) 7 (1 7 % ) 1 1 4 (9 2 % )  10(8% )
8.3 Detection of biofilms in E. coli isolates using a biofilm assay 
Although the prevalence o f the pgaABCD locus was established, isolates were 
phenotypically screened for the capability to produce a biofilm using a semi- 
quantitative microtitre plate biofilm assay (Chapter 2) for Staphylococcus spp. 
(Mack et al., 1996, Christensen et al., 1985). S. epidermidis 1457 grown in TSB 
media was used as a positive control.
8.3.1 Method optimisation
The standard protocol did not yield a significant level o f biofilm formation o f E. coli 
when compared to the absorbance values generated by S. epidermidis so a number o f  
variables including medium, time of incubation, etc. were varied in order to optimise 
the experiment for E. coli isolates. All optimisation experiments were carried out on 
E. coli K12; E. coli isolates 35 and 231 (CTX-M-15 ZS26 positive and negative, 
respectively) and S. epidermidis 1457. As a negative control and to establish 
background absorbance values for biofilm positive isolates, wells were also 
incubated with medium without the addition of bacteria. This generally yielded 
background absorbance values of approximately 0.048-0.056.
8.3.1.1 Time
Using LB media for E. coli, the time of incubation of the 96-well plate at 37°C was 
varied (24 hours, 48 hours and 72 hours) to determine any effect on biofilm 
formation.
It is clear to see that an incubation time o f 24 hours yields an increase in biofilm 
formation when compared to 48 hours and 72 hours (Figure 8.3) as absorbance value 
for E. coli K12 was approximately 0.13 ± 0.008. The ability to form biofilm appears 
to decrease using longer times. However, using the student t-test, no statistically 
significant difference was observed between 48 and 72 hours (p-0.6622)
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Figure 8.3 Effect o f  time (24, 48 and 72 hours respectively) on biofilm formation 
using LB medium and E. coli K12; E. coli isolates 35 and 231 (CTX -M -15 IS26 
positive and negative respectively).
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8.3.1.2 Temperature
Using LB media for E. coii, the incubation temperature was lowered to 19°C (using a 
19°C incubator to maintain a constant temperature) and 30°C for 24 hours was 
altered to determine any effect on biofilm production. From the data for
S. epidermidis, it can be determined that by using a higher temperature o f  30°C, 
absorbance values o f  approximately 0.55 ±0.018 were generated whereas with a 
temperature o f  19°C, an absorbance value o f  less than 0.1 ±0.0087 was achieved. 
Absorbance values were much lower for the E. coli K12 and the clinical E. coli 
isolates (less than 0.1) using both temperatures (Figure 8.4).
T e m p e r a t u r e
Figure 8.4 Effect o f  temperature (19°C and 30°C) on biofilm formation using E. coli 
K12; E. coli isolates 35 and 231 (CTX-M -15 IS26 positive and negative 
respectively) and S epidermidis 1457.
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8.3.1.3 Media
As all the previous experiments were carried out in LB broth, another variable to 
consider was to supplement the media and also to test how well biofilms form in 
different media. Supplementing media with glucose, ethanol and NaCl has been 
shown to increase PGA production (Cerca and Jefferson, 2008) therefore a series of 
experiments were set up using LB supplemented with 1% glucose, 2% glucose, 1% 
sucrose, 2% sucrose, 1% glucose and sucrose, 4% NaCl and 4% ethanol. Also, TSB, 
BHI (brain heart infusion) media and EC broth were used as alternative media to aid 
in the determination o f which media best supported biofilm production.
From the experiment carried out with LB, it was clearly seen that 2%  sucrose had the 
greatest positive effect as the absorbance value for E. coli K12 is approximately 0.2 
±0.39. The use o f 4% ethanol and 4%  NaCl appeared to have a negative effect on 
biofilm formation as absorbance values are below 0.1 for E. coli K12 (±0.009 and 
±0.008, respectively). However, the most significant increase in biofilm formation 
could be seen with the use o f EC broth. Absorbance values o f approximately 0.275 
±0.08 were obtained with E. coli K12 whereas for the clinical isolates, values 
exceeded 0.15 (±0.01, ±0.05 and ±0.007, respectively).
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0.35
LB with 1% LB w ith 2% LB with 1% LB with 2% LB w ith 1% LB with 4% LB w ith 4%  TSB BHI EC b ro th
g lucose g lucose  su c ro se  su c ro se  glucose and  e th a n o l NaCl
su c ro se
M edia
Figure 8.5 Effects o f  different m edia and m edia supplem ents including varying 
concentrations o f  glucose, sucrose, ethanol and NaCl on biofilm  form ation using E. 
coli K12; E. coli isolates 35 and 231 (C TX -M -15 IS26 positive and negative 
respectively).
200
8.3.1.3.1 EC broth
As EC broth stimulated significantly higher absorbance readings for the clinical 
E. coli isolates which had not been achieved with any other media, further work was 
carried out to elucidate optimal conditions. EC broth was supplemented with 1% 
glucose, 2 % glucose, and 1% glucose and 1% sucrose to elucidate any affect on 
biofilm formation. It is clear that supplementing the media had a positive effect on 
biofilm formation (Figure 8 .6 ). In the case of E. coli K12, a significant difference 
was found with the addition of 1% glucose, 2 % glucose, and 1% glucose and 1% 
sucrose as it was clear to see the absorbance values increase from approximately 0.3 
±0.08 with EC broth alone to 1.625 ±0.5 with EC plus 1% glucose and 1% sucrose. 
However, when statistical analysis was applied using student t test, no significant 
difference was found on biofilm formation when using 2 % glucose or 1% glucose 
and 1% sucrose for the clinical E. coli isolates.
8.3.1.3.2 EC broth without bile salts
The ingredients of EC broth list bile salts no. 3 as a component. However, the 
literature suggests that bile salts are associated with biofilm formation in Bacteroides 
fragilis (Pumbwe et al., 2007). Therefore a second batch of EC broth was made 
without bile salts to see if there was any effect on biofilm formation with E. coli 
isolates from this collection. Clearly absorbance values were lower when bile salts 
were removed. For instance, values for E. coli K12 decreased from approximately 
0.275 ±0.08 to below 0.1 ±0.003 when comparing EC broth with bile salts and EC 
broth without bile salts (Figure 8 .6 ).
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I K12 
231
l% g lu co se  2% glucose  1% glucose and  EC w ithou t bile l% g lu c o se  2% glucose
su c ro se  salts
EC broth w ith  and w ith out bile sa lts  + /-  su p p lem en ts
l% g lu c o se  and  
su c ro se
Figure 8.6 Effect o f  EC broths with and w ithout bile salts on biofilm  form ation. EC 
broths with and w ithout bile salts were also supplem ented with glucose and sucrose. 
E. coli K12 and E. coli isolate 231 (CTX -M -15 IS26 negative) was used.
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8.3.2 Prevalence of phenotypic biofilm production in human and bovine isolates
Using the optimised phenotypic biofilm assay consisting of EC broth (with and 
without 1% glucose) along with an incubation temperature of 24 hours at 37°C, 105 
ESBL and AmpC-producing E. coli were screened. Of these, 38% (40/105) were 
found to produce biofilm with an absorbance reading of >0.1. 62% (65/105) were 
found have an absorbance reading of <0.1 and were deemed biofilm negative (Table 
8.2). Notably, epidemic E. coli strain A is a successful biofilm producer with an 
absorbance value of 1 .1 .
From the non-ESBL producing E. coli control collection (n=40), 44% (15/40) were 
found to be positive for a phenotypic biofilm with an absorbance reading of >0 .1  
whereas 56% (19/40) were negative.
Analysis of the bovine E. coli isolates show that 53% (66/124) were phenotypic 
biofilm producers whereas 47% (58/124) were not.
Figure 8.7 outlines a box plot of all biofilm positive isolates (absorbance values 
>0.1) and biofilm negative isolates (absorbance vales <0.1) within the three E. coli 
populations. It is interesting to note that the ESBL and AmpC-producing E. coli 
population has a greater range of absorbance values (approximately 0.1-0.75) than 
the non-ESBL E. coli human and bovine populations which demonstrated ranges of 
approximately 0.1-0.65 and 0.1-0.325, respectively. However, the box size of the 
ESBL and AmpC-producing E. coli population demonstrated that the majority of 
biofilm positive isolates had absorbance values within that range whereas the box 
sizes were larger for the other two populations.
Table 8.2 Phenotypic biofilm production within E. coli isolates.
Human E. coli 
ESBL and Human E. coli Bovine E. coli
AmpC (n=105) control (n=40) (n=124)
+ + +
Biofilm 40 65 15 19 6 6  58
(Abs >0.1) (38%) (62%) (44%) (56%) (53%) (47%)
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Figure 8.7 A box plot representation of biofilm positive isolates (absorbance values 
>0.1) and biofilm negative isolates (absorbance values <0.1) for 3 different E. coli 
populations. 1 represents the ESBL and AmpC biofilm positive E. coli isolates, 2 
represents the ESBL and AmpC biofilm negative E. coli isolates, 3 represents the 
biofilm positive bovine E. coli isolates, 4 represents the biofilm negative E. coli 
bovine isolates, 5 represents the non-ESBL control biofilm positive E. coli isolates 
and 6  represents the non-ESBL control biofilm negative E. coli isolates.
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8.4 Discussion
Biofilms are complex microbial communities that form to enhance survival under 
hostile conditions (Wang et al., 2004). Infections associated with biofilms are often 
complicated as they are not easily eradicated (Lewis, 2001). In this study, E. coli 
isolates were screened for the pgaABCD gene locus and assessed for phenotypic 
biofilm formation.
In ESBL and AmpC producing isolates (n=105), all E. coli isolates were found to 
possess the pgaABCD gene locus. However, in the non-ESBL producing control E. 
coli isolates and the uterine bovine E. coli isolates not all isolates gave positive 
amplification products (7/40 and 10/124, respectively) and so these negative isolates 
were reconfirmed as being E. coli using API 20E strips. In a study conducted by 
Cerca et al., (2007), 30 clinical E. coli isolates obtained from urinary tract and 
neonatal blood stream infections were screened for the pgaABCD locus. Of which 26 
out of 30 possessed pgaABCD. The remaining 4 were negative and were found not to 
produce PGA (Cerca et al., 2007). In this thesis, isolates that did not amplify pgaA  
and pgaC did not form a biofilm under the optimal conditions of EC broth 
supplemented with and without 1% glucose.
To elucidate whether the E. coli isolates produced a biofilm, a phenotypic biofilm
assay was carried out. However, in order to increase the absorbance values obtained
so that the identification of a positive biofilm could be achieved, a number of
variables were altered to identify optimal in vitro conditions. An initial experiment
involved increasing the time of incubation at 37°C from 24 hours to 48 hours and 72
hours. In doing so, it can be clearly seen that biofilm formation decreases with time.
A suggestion for this is that the biofilm is in its maturation stage whereby bacterial
cells are dispersing and planktonic status is returned. The next variable to be altered
was incubation temperature. Lower temperatures of 19°C, 30°C were used and were
found to not support biofilm formation and thus generate absorbance values as high
as those found when using 37°C. This agrees with the fact that 37°C is the optimum
temperature for bacterial growth and biofilm formation. So once establishing the
optimum time and temperature for biofilm formation, different media types were
sought and tested for their capacity to support biofilm formation in E. coli. All the
previous work had been carried out using LB broth (Sambrook et al., 1989) and so
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the LB media was supplemented with glucose, sucrose, ethanol and NaCl. Cerca et 
al., (2008) had established that PGA production significantly increased in the 
presence of glucose whereas there was a slight increase with the addition of ethanol 
and NaCl. Statistical analysis was used for E. coli K12 (as this generally produced 
higher absorbance readings when compared to clinical isolates tested) to determine 
significant differences using different media supplemens. Using the student t-test no 
significant difference was found in this study when using LB supplemented with 1 % 
glucose (p=0.2247) or 2% glucose (p=0.2253). A negative impact was found with 
the addition of ethanol and NaCl. The addition of 4% ethanol or 4% NaCl had a 
statistically significantly (p=0.0134 and p=0.0188, respectively) affect, as biofilm 
formation decreased.
Alongside LB; TSB, BHI and EC broth were also utilised. EC broth was found to 
generate absorbance values which were consistently higher and a significant 
difference was found when compared to LB (p=0.0418). It was therefore chosen as 
the optimal media to support biofilm formation. In parallel, the addition of 1% 
glucose, 2% glucose and 1 % glucose and sucrose supplemented the EC broth based 
upon the findings that glucose increased PGA production (Cerca and Jefferson, 
2008). It was found that the use of 1% glucose had a significant difference 
(p=0.0041) on biofilm formation when supplementing EC broth.
The contents of EC broth were investigated and the addition of bile salts no. 3 was 
observed. Bile salts, particularly bile salt stress had been associated with the 
enhanced adhesion in enteropathogenic E. coli isolates (de Jesus et al., 2005, Torres 
et al., 2007). Bile salts have also been implicated in biofilm formation in Bacteroides 
fragilis (Pumbwe et al., 2007). Therefore in order to deduce whether bile salts had 
any effect on E. coli isolates in this study, EC broth was made without bile salts. It 
was observed that the removal of bile salts greatly reduced biofilm formation. The 
average absorbance value for EC broth was 0.145, when bile salts were removed this 
value decreased to 0.07. Thus the removal of bile salts generated a statistically 
significant difference (p=0.0205).
In this study, biofilm formation was found in 38% (n=40) of ESBL and AmpC- 
producing E. coli, 44% (n=15) of non-ESBL control E. coli isolates and 53% (n=6 6 )
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of uterine bovine E. coli isolates. Potential rationales for this could be due to the fact 
that E. coli biofilms are more difficult to achieve in vitro or that the conditions in this 
study were not ideal for doing so in clinical isolates. Another suggestion to consider 
as to why not all pgaABCD positive isolates express a phenotypic biofilm could be 
related to other factors associated with E. coli biofilm formation e.g. surface 
determinants such as flagella, fimbriae (Pratt and Kolter, 1998), autotransporter 
proteins e.g. antigen 43 (Danese et al., 2000a), curli and pili (Pratt and Kolter, 1998). 
In addition, monoculture biofilms are rarely found in the natural environment; 
therefore, biofilm production and development may depend on interactions from 
other organisms (Blaschek et al., 2007).
With regards to investigating the link between ESBL and biofilm formation, it can 
be noted that all ESBL E. coli isolates possessed the pgaABCD gene locus but not all 
produced a phenotypic biofilm. Clermont et al., (2008) reports of a CTX-M-15 clone 
prevalent in Europe and Africa having biofilm formation ability but stipulates that 
the CTX-M plasmid does not support biofilm formation. However, biofilm 
formation could aid in the persistence of clones (Clermont et al., 2008, Ghigo, 2001). 
Yang et al., (2008) published data indicating that biofilm forming K. pneumoniae 
strains in their collection had an increased likelihood of also possessing ESBL 
enzymes.
The bovine E. coli isolates used in this chapter were additionally screened for ESBL 
genes. No positive amplification products were generated. However, ESBL- 
producing organisms have been associated with cattle. A study by Madec et al., 
(2008) detected CTX-M-1, CTX-M-16, CTX-M-14 and TEM-126 in the faeces of 
sick cattle. ESBL genes have been found in cattle in the UK. Liebana et al., (2006) 
reported CTX-M genes associated with cattle at a dairy farm.
In summary, the pgaABCD gene locus was found in all ESBL and AmpC-producing 
E. coli but not in all other E. coli. In total, 10 isolates were found to be negative. 
pgaABCD negative isolates did not form a phenotypic biofilm. However, biofilm 
formation was demonstrated in approximately 45% of all E. coli isolates using 
optimum conditions i.e. a 24 hour incubation time at 37°C using EC broth (with and 
without 1% glucose).
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Chapter 9: Clinical epidemiology of ESBL-producing
Enterobacteriaceae isolated from the PHW Microbiology ABM 
Swansea laboratory
9.1 Introduction
Located in the gut of humans and animals, E. coli is an opportunistic pathogen which 
is commonly associated with urinary-tract infections, wound infections following 
surgery, hospital-acquired pneumonia, infections of the gastrointestinal tract 
(diarrheal disease), neonatal meningitis and septicaemia (Mims, 1998, Nataro and 
Kaper, 1998). As the name suggests, UTIs are bacterial infections that affect any part 
of the urinary tract. Urine is the most commonly received specimen in the clinical 
laboratory with a large number of routine antimicrobial sensitivity testing and results 
being prepared and issued each day (Barrett et al., 1999). Therefore UTIs are one of 
the most common infections encountered in clinical practice. It is thought that E. coli 
is the causative bacteria in 70-95% of community-acquired cases and 50% of 
nosocomial cases (Chomarat, 2000, Kucheria et al., 2005).
UTIs can be divided up into uncomplicated and complicated infections. A 
complicated UTI is an infection associated with a condition that increases the risk of 
treatment failure. Factors associated with complicated UTI include: abnormalities of 
the urinary-tract e.g. renal stone, foreign bodies e.g. catheters, immunosuppression 
and the presence of multidrug resistant bacteria. An example of complicated UTI is 
pyelonephritis. Uncomplicated UTI are infections which can be diagnosed and 
treated more readily e.g. acute cystitis (Hooton, 2000). In the UK, complicated UTIs 
are often treated with parenteral cephalosporins and aminoglycosides whereas 
uncomplicated UTIs are treated frequently with trimethoprim or nitrofurantoin (Bean 
et al., 2008).
UTIs are associated with both the community and hospital setting and in recent years 
antibiotic resistance has become problematic (Chomarat, 2000). There has been an 
increase in the occurrence of cephalosporin-resistant E. coli which cause UTI and 
invasive infection. These are also often resistant to fluroquinolones and trimethoprim 
and therefore the treatment of this type of UTI is limited (Paterson and Bonomo,
2005).
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UTIs due to E. coli can progress to bacteraemia, which can often be linked to a 
higher mortality (Lau et al., 2009, Melzer and Petersen, 2007). Data from the HPA 
demonstrates an increasing number of reports of bacteraemias caused by Klebsiella 
spp., as in 2005; there were 5150 reports of Klebsiella spp. bacteraemia whereas in 
2009 there were 6160 reports
(http://www.hpa.org.uk/web/HPAwebFile/HPAweb C/1287142531496T
Cephalosporins and fluoroquinolones are typically recommended in the front-line 
treatment of both community and hospital-associated bacteraemia (Rodriguez-Bano 
et al., 2006).
The aim of this chapter is to deduce the clinical epidemiology of ESBL-producing 
Enterobacteriaceae, primarily in isolates obtained from urine samples.
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9.2 Results
9.2.1 Clinical epidemiology
In this section, the clinical epidemiology of isolates was analysed. This included the 
source of sample, distribution of hospital and community-associated isolates, gender 
distribution and average age. All isolates were analysed, including those that did not 
have ESBL or AmpC genotypes.
9.2.1.1 All isolates
71.2% (117/164) of all isolates obtained were E. coli. Of which, 69% (81/117) were 
isolated from patients who had been admitted into hospital. The remaining 31% 
(36/117) of E. coli were isolated from samples that were submitted by a GP 
(community-associated). Of the 117 E. coli isolates, 90% (105/117) were found to 
possess ESBL/AmpC genes. 69% (72/105) were hospital associated and the 
remaining 31% (33/105) were community associated.
Within the hospital-associated E. coli population, 33% of isolates were isolated from 
males with an average age of 72.8 years whereas 67% were isolated from females 
with an average age of 65.6 years. For the ESBL and AmpC E. coli isolates, 35% 
were from males with an average age of 73.1 and 65% were females with an average 
age of 62.3. Amongst the community-associated E. coli isolates, 19% of isolates 
were obtained from males with an average age of 73.5 years whereas 81% were 
isolated from females with an average age of 53.9 years. For the ESBL and AmpC E. 
coli isolates, 21% were from males with an average age of 73.3 and 79% were from 
females with an average age of 53.9 (Table 9.1).
In total, 87% (102/117) E. coli were isolated from urine samples and of which, 24% 
were isolated from males with an average age of 73.5 years. 76% were isolated from 
females with an average age of 62.8 years. 8 8 % (72/81) of these urinary isolates 
were obtained from hospital-associated E. coli isolates and 42% (34/81) were urine 
E. coli isolated from the community. For the ESBL and AmpC E. coli isolates, 8 8 % 
(90/102) were obtained from urine samples and of which, 26% were from males with 
an average age of 73.9 years and 74% were from females with an average age of
60.4 years.
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Blood culture isolates accounted for 13% (9/117) of all E. coli isolates and of these 
67% were obtained from males with an average age of 76.2 years and 33% were 
obtained from females with an average age of 32.7 years. 5% (6/117) of all E. coli 
were obtained from other sources including wounds (3/6, 50%) and faeces (3/6, 
50%). 60% (3/5) of these samples were obtained from males with an average age of 
61.3 years. 40% (2/5) were from females with an average age of 35.5 years. Of these 
‘other’ samples, 6 % (3/4 wound and 1/4 faeces samples) were hospital-associated 
and 3% (2 faeces samples) were community-associated (Tables 9.2 and 9.3). All of 
these non-urine related isolates were found to be ESBL/AmpC-producing. For one 
isolate, no information could be obtained.
After E. coli, the next largest strain population in this study were Klebsiella spp. 
accounting for 23% (38/164) of all isolates. 6 8 % (26/38) were hospital-associated. 
Of which, 38% (10/26) were obtained from males with an average age of 62.2 years 
whereas 62% (16/26) were from females with an average age of 69.5 years. 32% 
(12/38) of Klebsiella spp. were community-associated and 58% (7/12) of these were 
from males with an average age of 70.3 years whereas 42% (5/12) were obtained 
from females with an average age of 84.6 years (Table 9.1). For the ESBL and 
AmpC Klebsiella spp., 69% (22/32) were hospital-associated, of which, 40% (9/22) 
were obtained from males with an average age of 60.4 years whereas 60% (13/22) 
were from females with an average age of 76.5 years. 31% (10/32) of Klebsiella spp. 
were community-associated and 60% (6 / 1 0 ) were from males with an average age of
70.5 years and 40% (4/10) were obtained from females with an average age of 8 8  
years (Table 9.1).
As with the E. coli population, the majority (33/38 -  87%) of Klebsiella ssp. isolates 
were obtained from urine samples. All 12 (100%) community-associated 
Klebsiella spp. were isolated from urine. 44% (15/33) of Klebsiella spp. obtained 
from urine samples were isolated from males with an average age of 65.7 years and 
56% (18/33) were isolated from females with an average age of 73.3 years. For the 
ESBL-producing Klebsiella spp., 8 8 % (28/32) were obtained from urine samples, of 
which, 85% (18/22) were hospital-associated whereas 100% (10/10) were 
community associated. 50% (14/28) of Klebsiella spp. urine isolates were isolated 
from males with an average age of 65.5 years whereas the other half (14/28) were
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isolated from females with an average age of 80.5 years. Three Klebsiella spp. (8 %) 
were isolated from blood cultures taken in hospital. Of which, 67% (2/3) were 
isolated from males with an average age of 64 years and these were both ESBL- 
producing. The remaining Klebsiella spp. (1/3 -  33%) was isolated from the blood of 
an 82 year old female. Aside from urine and blood cultures, two Klebsiella spp. (5%) 
were isolated from wound related sources. Both were hospital-associated and 
isolated from females with an average age of 48.5 years (Tables 9.2 and 9.3).
Nine other Enterobacteriaceae i.e. not E. coli and Klebsiella spp. were isolated. 
These included 6  E. cloacae, 1 C. freundii, 1 C. koseri and 1 M. morganii. 67% (6/9) 
were hospital-associated and 33% (3/9) were community-associated. Of the hospital- 
associated isolates, 67% (4/6) were isolated from males with an average age of 74 
years and 33% were isolated from females with an average age of 78 years. Of the 3 
community-associated isolates, one was isolated from a male aged 56 years and 67% 
(2/3) were isolated from females with an average age of 28.5 years (Table 9.1). As 
demonstrated by the E. coli and Klebsiella spp. populations, the most frequent source 
for these other isolates were urine samples (56% - 5/9). 60% (3/5) of the urine 
samples were obtained from males with an average age of 73 and 40% (2/5) were 
from females with an average age of 67.5 years. One E. cloacae isolate (11%) was 
from a blood culture. This was isolated from a 77 year old male. Three E. cloacae 
(33%) were isolated from wound samples. Of which, 33% (1/3) was isolated from a 
56 year old male and 67% (2/3) were isolated from females with an average age of 
39 years (Tables 9.1.1 and 9.1.2). 56% (5/9) were found to be ESBL-producing 
Enterobacteriaceae. For these ESBL-producing isolates, 67% (4/6) were found to 
hospital-associated and of which, 75% were from males with an average age of 77 
years and 25% were from females with an average age of 78 years. The remaining 1 
isolate was community-associated and isolated from a female with an age of 57 
years. In total, 4 isolates were obtained from urine samples and 50% were obtained 
from males with an average age of 73 years and 50% were from females with an 
average age of 67.5 years. 1 isolate was obtained from other sources and was isolated 
from a female with an average age of 78 years.
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Table 9.2 Distribution of hospital and community based isolates amongst varying 
infection sources.
Isolate Source
Urine Blood O ther
All Hospital E. coli (n=81)
Hospital ESBL and AmpC E. coli (n=72)
All Community E. coli (n=36)
Community ESBL and AmpC E. coli (n=33)
6 8  (84%) 
59 (81%) 
34 (94%) 
31 (94%)
9(11%) 
9(13%) 
0  (0 %)
0  (0 %)
4 (5%) 
4 (6 %) 
2  (6 %) 
2  (6 %)
All Hospital Klebsiella spp. (n=26)
Hospital ESBL Klebsiella spp. (n=22)
All Community Klebsiella spp. (n=12) 
Community ESBL Klebsiella spp. (n=10)
2 1  (81%) 
18(82%) 
1 2  ( 1 0 0 %) 
1 0 ( 1 0 0 %)
3 (12%) 
2 (9%)
0  (0 %)
0  (0 %)
2 (7%) 
2 (9%) 
0  (0 %) 
0  (0 %)
All Hospital Other Enterobacteriaceae (n=6 ) 
Hospital ESBL Other Enterobacteriaceae (n=4) 
All Community Other Enterobacteriaceae (n=3) 
Community ESBL Other Enterobacteriaceae 
(n=l)
4 (6 6 %) 
3 (75%) 
1 (33%) 
1 1 0 0 %)
1 (17%) 
0  (0 %)
0  (0 %)
0  (0 %)
1 (17%)
1 (25%)
2 (67%) 
0  (0 %)
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9.2.2 Epidemiology of urine isolates
As urine isolates predominated the strain collection this section focuses on isolates 
obtained from urine specimens to avoid selection bias. Table 9.3 demonstrates that 
122 ESBL/AmpC-producing Enterobacteriaceae were isolated from urine samples. 
Of which, 80 (6 6 %) isolates were found to be hospital-associated whereas 42 (34%) 
were community-associated. Of these, 28/37 (76%) were hospitalised males and 
52/85 (61%) hospitalised females. 9/37 (24%) of isolates were from males in the 
community and 33/85 (39%) from females in the community. It is interesting to note 
in table 9.4, that E. coli are predominately isolated from women whereas amongst 
the Klebsiella spp., the numbers are more evenly distributed.
9.2.2.1 Hospital-associated isolates
Of the 80 hospital-associated Enterobacteriaceae isolates, 59 (74%) isolates were 
E. coli, 18 (23%) were Klebsiella spp. and 3 (3%) were other Enterobacteriaceae. 
Fifty-six (94%) E. coli isolates contained a CTX-M group 1 gene, 2 (3%) isolates 
had a CTX-M group 9 gene and 2 (3%) isolates harboured a TEM gene (TEM-116 
and TEM 52). It must be noted that the isolate harbouring TEM-116 also carries a 
CTX-M group 1 gene. It was demonstrated that 18/59 (31%) hospital-associated E. 
coli isolates were obtained from males and 41/59 (69%) from females. Within the 
male population, 17/18 (94%) E. coli isolates contained a CTX-M group 1 gene and 
1 (6 %) isolates had a CTX-M group 9 gene. Within the female population, 39/41 
(95%) E. coli isolates contained a CTX-M group 1 gene, 1 (2%) isolates had a CTX- 
M group 9 gene and 2 (2%) isolates harboured a TEM gene.
Sixteen (89%) Klebsiella spp. isolates contained a CTX-M group 1 gene and 1 (5%) 
isolates harboured an SHV gene. It was demonstrated that 8/18 (44%) hospital- 
associated Klebsiella spp. isolates were obtained from males and 10/18 (56%) from 
females. Within the male population, 8 /8  (100%) Klebsiella spp. isolates contained a 
CTX-M group 1 gene. Within the female population, 9/10 (90%) Klebsiella spp. 
isolates contained a CTX-M group 1 gene, and 1 (10%) isolates harboured a SHV 
gene.
1/3 other Enterobacteriaceae isolates (E. cloacae) contained a CTX-M group 1 gene 
and an SHV-2 gene, 1/3 (C. freundii) had a TEM-116 gene. 2/3 harboured ampC
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genes. It was demonstrated that 2/3 hospital-associated Klebsiella spp. isolates were 
obtained from males and 1/3 from females. Within the male population (n=2), 1 
other Enterobacteriaceae isolate (E. cloacae) contained a CTX-M group 1 gene, 1 E. 
cloacae isolate harboured an SHV-2 gene and had an ampC gene. Within the female 
population, one isolate harboured a TEM-116 and ampC gene (C. Jreundii).
9.2.2.2 Community-associated isolates
Within the 42 community-associated Enterobacteriaceae isolates, 31 (74%) E. coli, 
10 (24%) Klebsiella spp., and 1 (2%) other Enterobacteriaceae were found. Twenty- 
seven (87%) E. coli isolates contained a CTX-M group 1 gene, 3 (10%) isolates had 
a CTX-M group 9 gene and 3 (10%) isolates harboured a TEM gene (2 TEM-116 
and 1 TEM-52). One E. coli isolate was found to harbour an ampC gene. It was 
demonstrated that 5/31 (16%) community-associated E. coli isolates were obtained 
from males and 26/31 (84%) from females. Within the male population, 4/5 (80%) E. 
coli isolates contained a CTX-M group 1 gene and 1 (20%) isolates had a CTX-M 
group 9 gene. Within the female population, 23/26 (8 8 %) E. coli isolates contained a 
CTX-M group 1 gene, 2 (8 %) isolates had a CTX-M group 9 gene, 3 (11%) isolates 
harboured a TEM gene and 1 (4%) isolate had an ampC gene.
8/10 (80%) Klebsiella spp. isolates associated with the community contained a CTX- 
M group 1 gene, 2 (20%) isolates had a TEM gene (TEM-116) and 1 (10%) isolate 
harboured an SHV-2 gene. A higher proportion 6/10 (60%) community-associated 
Klebsiella spp. isolates were obtained from males and 4/10 (40%) from females. 
Within the male population, all 6  Klebsiella spp. isolates contained a CTX-M group 
1 gene and 1 contained a CTX-M group 9 gene. Within the female population, 3/4 
(75%) Klebsiella spp. isolates contained a CTX-M group 1 gene and 1 isolate 
harboured a TEM (TEM-116) gene and a SHV-2 gene.
One community associated E. cloacae isolate was found. This was isolated from a 
female patient and exhibited a CTX-M group 1 gene.
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9.2.3 The clinical epidemiology of E. coli isolates in relation to CTX-M-15 IS26
Table 9.5 outlines the distribution of CTX-M-15 IS26 (see Chapter 5) amongst 
hospital and community-associated E. coli isolates. By PCR, 64% (66/103) E. coli 
isolates were found to obtain CTX-M-15 IS26. Of these positive E. coli isolates, 
6 6 % were found to be hospital associated and 34% were associated with a GP 
practice. 31% were obtained from males and 69% from females. 36% of E. coli 
isolates did not yield a positive amplification for CTX-M-15 IS26 and were so 
named IS26 negative. Of these IS26 negative isolates, 72% were hospital associated 
and 28% were community associated. 34% were obtained from males and 72% were 
from females.
To coincide with section 9.2.2, isolates obtained from urine specimens were analysed 
independently to avoid selection bias. In total, 8 8  ESBL-producing E. coli isolates 
were obtained from urine specimens and of these, (59/88) 67% were positive for 
CTX-M-15 IS26 and 33% were negative for CTX-M-15 IS26. Within the CTX-M- 
15 IS26 positive isolates obtained from urine specimens, 62% were hospital 
associated and 38% were community associated. 26% were obtained from males and 
74% were from females. Of the 33% of E. coli isolates negative for CTX-M-15 IS26, 
72% were hospital-associated and 28% were community-associated. Of which, 28% 
were obtained from males and 72% from females.
Table 9.5 Distribution of CTX-M-15 IS26 amongst hospital and community- 
associated ESBL E. coli isolates
Source Gender
Age Range 
(Years)
Hospital Community Male Female Male Female
All E. coli CTX-M-15 6 6 % 34% 31% 69% 34-90 3-90
IS26 positive (n=6 6 )
E. coli CTX-M-15 IS26 62% 38% 26% 74% 34-90 3-90
positive urine (n=59)
All E. coli CTX-M-15 72% 28% 34% 6 6 % 41-89 4-90
ZS26 negative (n=37)
E. coli CTX-M-15 IS16 72% 28% 28% 72% 54-89 4-90
negative urine (n=29)
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9.2.4 The clinical epidemiology of E. coli isolates in relation to 025b-ST131
Table 9.6 outlines the distribution of the 025b-ST131 clone (see Chapter 5) within 
E. coli isolates. In total, 80 E. coli isolates were found to possess a SNP in the pabB  
gene which is indicative of the 025b-ST131 clone (Clermont et al., 2009). Of these 
isolates, 70% were hospital-associated and 30% were community-associated. 8 8 % 
(70/80) of the pabB positive E. coli isolates were obtained from urine specimens. 
Within these E. coli isolates isolated from urine specimens, 67% were hospital- 
associated and 33% were found to be community-associated, of which, 23% were 
obtained from males and 77% from females.
To further evaluate the epidemiology of the 025b-ST131 clone, the distribution of 
025b-ST131 with and without CTX-M-15 IS26 was analysed. Unfortunately, only 
63/66 of the E. coli CTX-M-15 IS26 positive could be revived for testing with the 
025b-ST131 allele specific PCR. Results for E. coli CTX-M-15 IS26 with the SNP 
in the pabB gene can be seen in table 9.6.
46% of isolates positive for the 025b-ST131 clone were CTX-M-15 IS26 positive 
and 82% were hospital-associated, whereas 18% were community-associated. 29% 
were obtained from males and 71% from females. 38% (14/37) of these isolates were 
obtained from urine specimens. Within these pabB positive CTX-M-15 IS26 
negative E. coli, 8 6 % were hospital-associated and 14% community-associated. 21% 
were obtained from males and 79% from females. This differs to distribution seen by 
E. coli CTX-M-15 IS26 negative 025b-ST131 negative, as 60% were hospital 
associated and 40% were community associated. 35% were obtained from males and 
65% were from females.
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Table 9.6 Distribution of 025b-ST131 amongst hospital and community-associated 
E. coli isolates.
Hospital Community Male Female
All pabB positive E. coli (n=80) 70% 30% 31% 69%
All pabB positive E. coli from urine 
(n=70)
67% 33% 26% 77%
pabB positive CTX-M-15 IS26 
positive E. coli (n=63)
67% 33% 32% 6 8 %
pabB positive CTX-M-15 IS26 
positive E. coli from urine (n=56)
63% 38% 27% 73%
pabB positive CTX-M-15 IS26 
negative E. coli (n=17)
82% 18% 29% 71%
pabB positive CTX-M-15 IS26 
negative E. coli from urine (n=14)
8 6 % 14% 2 1 % 79%
*pabB positive isolates are those whereby a SNP has been detected in the pabB  gene.
This SNP is characteristic of the intercontinental clone, 025b-ST131 (see chapter 5).
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9.3 Discussion
The aim of this chapter was to identify the clinical epidemiology associated with 
ESBL-producing Enterobacteriaceae. It is clearly demonstrated in this study, E. coli 
followed by Klebsiella spp. were the most common types of isolates containing 
ESBL and AmpC genes. These isolates were most commonly isolated from urine 
samples from females with an average age of 60 years. This is not an unexpected 
result as UTIs are most commonly associated with women. There are several factors 
that predispose women to UTIs including: urethra length and shorter distance 
between urethra and the anus, which is the source of microorganisms capable of 
causing UTIs (Hooton, 2000). It is also thought that the reduced levels of the 
hormone oestrogen in postmenopausal women contributes to the occurrence of UTIs 
(Hooton, 2000).
As the number of isolates collected from urine samples exceeded others, the urine 
population was analysed independently. 6 6 % of all ESBL and AmpC-producing 
Enterobacteriaceae in the urine collection were hospital-associated and 34% were 
community-associated. CTX-M group 1 was found to be the most prevalent ESBL 
type found, as 92% gave positive amplification by PCR and of which, 6 6 % were 
hospital-associated and 33% were community-associated. In total, CTX-M group 1 
was found in 93% (74/80) of hospital-associated and 90% (37/42) of community- 
associated Enterobacteriaceae. ESBLs, particularly CTX-M, have been increasingly 
prevalent in the community. A study conducted by Woodford et al., (2004), 
demonstrated that 25% of CTX-M-producing isolates were obtained from the 
community. This result is similar to the 21% of community associated ESBL 
infection found by Kang et al., (2004). Rodriguez-Bano et al., (2006) demonstrated 
that 19% of bacteraemia due to ESBL-producing E. coli was community-associated. 
However, Melzer and Peterson, (2007) and Bean et al., (2008) observed lower values 
for ESBLs associated with the community. Melzer and Peterson, (2007) found that 
6 .6 % of isolates in their ESBL bacteraemia study were community-acquired and 
Bean et al., (2008) demonstrated that 5.7% of their isolates which were ESBL- 
producing E. coli from UTIs were obtained from the community.
The prevalence of CTX-M-15 7526 E. coli from the community in this isolate
collection was evaluated. It was found that 6 6 % of isolates were hospital-associated
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w hereas 34%  w ere com m unity-associated  and in isolates ob tained from  urine 
specim ens, these values change to 62%  hospital-associated  and 38%  com m unity  
associated.
T h e  dissem ination o f  ESBLs, particularly  C TX -M , into the com m unity  could  be 
associated with the presence o f  m obile genetic elem ents. C T X -M  genes are often 
found alongside \SEcpl or type 1 integrons (P itout et al., 2005b, Poirel et al., 2003). 
It has also been im plied that due to  the p resence o f  isolates carry ing  C T X -M  in 
anim als, that food-producing anim als and dom estic pets could  act as a reservoir 
(P itout et al., 2005b).
A dditionally, the prevalence o f  the international clone, 025b-S T 131  w as also 
analysed. This clone w as present in 70%  o f  E. coli w hich w ere hospital-associa ted  
and  30%  com m unity-associated. A gain, these num bers change to 67%  and 33% , 
respectively in E. coli isolates isolated from  urine specim ens. A  study by Lau et al., 
(2008b) found that 84%  o f  hospital infection and 64%  and com m unity  infection w as 
associated with ST131. The dissem ination o f  such clones could also  p lay  a  role in 
facilitating the spread o f  ESBLs in the com m unity.
W ith the spread o f  C TX -M , particularly  C TX -M -15 into the com m unity  setting, 
treatm ent options are lim ited (W oodford et al., 2004). Isolates harbouring  C TX -M  
genes often harbour resistance genes for o ther types o f  antib io tics e.g. trim ethoprim - 
sulfam ethoxazole, am inoglycosides and fluoroquinolones (R odriguez-B ano et al.,
2006). Therefore, nitrofurantoin or fosfom ycin (not currently  m arketed  in the U K ) 
have been recom m ended as trea tm ent options. H ow ever, it has been  suggested  that 
these are not ideal (W oodford et al., 2004).
UTIs caused by E. coli often progress to bacteraem ia (L au et al., 2009, M elzer and 
Petersen, 2007). A  recent report by the H ealth P ro tection  A gency (H PA ) 
dem onstrated that the rate o f  bacteraem ia caused by E. coli has increased from  
18,593 in 2005 to 25,532 in 2009. The report also stated th a t a  reduction  in the 
prevalence o f  CTX -M  in E. coli w as noted by B SA C  (H PA , 2010). H ow ever, in the 
instance that the bacteraem ia is due to E S B L -producing E. coli, p roblem s w ith 
treatm ent options could be faced. A  study by R odriguez-B ano et al., (2006) found 
that em pirical therapy w ith cephalosporins or fluoroquinolones w as associa ted  w ith a
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higher mortality rate and found that 4/10 patients who received therapy with a 
cephalosporin died. Therefore it was suggested that carbapenems are the most 
appropriate option for treating bacteraemia caused by ESBL-producing E. coli 
(Rodriguez-Bano et al., 2006).
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Chapter 10: Discussion
10.1 General discussion
ESBLs can be defined as p-lactamase enzymes capable of hydrolysing the 
penicillins, 1st, 2nd and 3rd generation cephalosporins and the monobactam 
aztreonam. They are unable to hydrolyze cephamycins and carbapenems. ESBLs are 
inhibited in vitro by the p-lactamase inhibitor clavulanic acid (Philippon et al., 1989, 
Paterson and Bonomo, 2005). ESBLs were first reported in 1983 (Paterson and 
Bonomo, 2005) and until 2001 with the emergence of CTX-M, ESBLs in the UK 
were mostly mutants of TEM and SHV which were predominantly found in 
Klebsiella spp. (Potz et al., 2006). Resistance to front line antibiotics poses a great 
limitation from the perspective of treatment options (Paterson et al., 2000). The 
choice of antimicrobial agent is important as inappropriate treatment is linked to an 
increased mortality (Rodriguez-Bano et al., 2006). Therefore it is imperative to 
correctly and accurately identify ESBL-producing organisms to ensure that the 
appropriate antimicrobial therapy is delivered to the patient.
The rationale of this study was to establish the molecular epidemiology of ESBL- 
producing Enterobacteriaceae within the Abertawe Bro Morgannwg (ABM) 
University Health Board. Enterobacteriaceae were collected from the Public Health 
Wales (PHW) Microbiology ABM Swansea laboratory based upon resistance to 
cefpodoxime. With a selection of molecularly confirmed ESBL-producing 
Enterobacteriaceae, it was possible to analyse the sensitivity of current phenotypic 
laboratory ESBL detection procedures thus allowing suggestions to be made where 
relevant. Isolates were then further characterised and typed in order to identify clonal 
relationships. In doing so, a greater understanding of ESBLs types within the ABM 
University Health Board could be achieved. The activity of well established and 
‘newer’ antibiotics towards ESBLs, and subsequently, ESBLs which were associated 
with clones that often harbour multidrug resistances could be analysed. The 
evaluation of this information could potentially contribute to decisions made 
regarding treatment options. Alongside the identification of clones, a hypothesis 
regarding a link between the spread of ESBL genes and E. coli biofilm formation 
was also investigated.
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The three main UK ESBL types; TEM, SHV and CTX-M were detected by PCR and 
identified using DNA sequencing. The predominant ESBL genotype identified was 
CTX-M group 1, which was found in 92% of isolates. Sequence analysis revealed 
that CTX-M-15 was found to be the most common ESBL genotype with 92% of all 
E. coli and Klebsiella spp. analysed possessing this gene. CTX-M-15 enzymes are 
now the most commonly reported ESBL in Europe (Peirano and Pitout, 2010) and 
have also been reported in Canada (Pitout et al., 2007, Pitout et al., 2005a, Boyd et 
al., 2004), Asia (Ensor et al., 2006, Hawkey, 2008), Africa (Gangoue-Pieboji et al., 
2005), South America (Villegas et al., 2008) and Australia (Zong et al., 2008).
ESBLs, particularly CTX-M, have been increasingly prevalent in the community 
owing to urinary-tract infections which may progress to bacteraemia. The HPA 
recently released a report stating that the number of reported bacteraemias in 
England, Wales and Northern Ireland caused by E. coli has increased from 18,593 in 
2005 to 25,532 in 2009 (HPA, 2010). A study conducted by Woodford et al., (2004), 
demonstrated that 25% of CTX-M-producing isolates were obtained from the 
community. In this study, CTX-M group 1 was found in 93% (74/80) of hospital- 
associated and 90% (37/42) of community-associated Enterobacteriaceae. In 
contrast, while the rate of E. coli bacteraemia has increased, efforts to decrease 
hospital-acquired infections caused by methicilin-resistant Staphylococcus aureus 
(MRSA) and Clostridium difficile have resulted in a significant decrease in those 
infections in this time period. In 2003, approximately 6000 cases of MRSA 
bacteraemia were reported and in 2 0 1 0 , less than 2 0 0 0  cases were reported 
(http7/www.hpa.org.uk/hpr/infections/bacteraemia.htm#saurL For C. difficile 
infections, the baseline quarterly average number of reported cases has decreased 
from approximately 13,000 in 2008 to 4827 cases in 2011 
(http://www.hpa.org.uk/web/HPAwebFile/HPAweb C/1284473407318). This 
implies that measures successful in reducing MRSA bacteraemia in the UK do not 
affect E. coli bacteraemia, which may be related to the increasing number of ESBL 
carrying E. coli in the community, which resist empiric front-line treatment and 
therefore cause bacteraemia as a complication of community- and hospital-acquired 
urinary tract infection with increasing frequency. Consequently the Wales Healthcare 
Associated Infection Programme (WHAIP) has introduced new mandatory
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surveillance of E. coli community and hospital acquired bacteraemias, with the first 
data to be published in October 2011, in addition to its existing requirements on C. 
difficile infection and S. aureus bacteraemias.
The further characterisation and typing of isolates allows for a better understanding 
of the genetic variability and pathogenicity of bacterial isolates and allows changes 
in epidemiology to be monitored. Strain A was first reported in the UK in 2003 after 
an epidemic E. coli outbreak in Shropshire and was found to have a characteristic 
CTX-M-15 ZS26 link region (Woodford et al., 2004). As shown in Chapter 3, upon 
screening all CTX-M group 1 Enterobacteriaceae isolates by PCR for this link 
region, 51% generated positive amplification products and all of which were found 
to be E. coli. It was found by PFGE that the isolates containing the CTX-M-15 IS26 
link region were ‘closely related’ and ‘possibly related’ to epidemic E. coli strain A. 
The prevalence of CTX-M-15 ZS26 E. coli in the community was evaluated and it 
was found that 6 6 % of isolates were hospital-associated whereas 34% were 
community-associated. However, Lau et al., (2008a) found that the UK’s epidemic 
E. coli strains A-E belonged to an international clone, 025b-ST131. As outlined in 
Chapter 5, all isolates positive for the CTX-M-15 IS26 link region along with a 
number of isolates that did not possess this region, were also found to be positive by 
PCR for 025b-ST131. It was revealed in Chapter 9 that genes associated with the 
international clone 025b-ST131 were found to be present in 70% of E. coli which 
was hospital-associated and 30% which was community-associated.
The clonal spread of resistance genes, especially within the community, poses an 
increased problem with regards to treatment options. A report by Cagnacci et al., 
(2008) revealed a correlation between ciprofloxacin resistance and E. coli clones 
015: K52 HI and 025b-ST131 in urinary-tract infections. In Chapter 6 , it can be 
seen that 90% of all Enterobacteriaceae were resistant to ciprofloxacin whereas 
100% of CTX-M-15 IS26 E. coli were resistant and as mentioned previously all of 
which were found to be associated with 025b-ST131.
ESBL plasmids often harbour genes for other mechanisms of resistance including 
aminoglycosides (e.g. gentamicin and amikacin), quinolones and Trimethoprim- 
sulfamethoxazole (TMP-SMX) thus causing strains to be mutidrug resistant
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(Paterson et al., 2000). As demonstrated in Chapter 6, 31% of all isolates were 
resistant to gentamicin whereas, 11% were resistant to amikacin. 89% of all 
Enterobacteriaceae isolates were found to be resistant to trimethoprim- 
sulfamethoxazole. With such an increase in CTX-M prevalence especially in the 
community, the pressure posed on treatment options is greatened further, as the 
choices are limited. Therefore, serious infections would require the use of 
carbapenems (Livermore and Hawkey, 2005, Peirano and Pitout, 2010, Dhillon and 
Clark, 2011). However, the use o f carbapenems could alter the selection pressure 
which could thereby increase the prevalence o f the carbapenem resistant bacteria, 
which would limit antimicrobial treatment to a greater extent (Livermore, 2009). The 
most recent major public health concern regarding carbapenemases has been the 
emergence of the New Delhi Metallo-p-lactamase 1 (NDM-1), a metallo-p-lactamase 
which is associated with a transmissible mobile element. NDM-1 was originally 
isolated from K. pneumoniae in India and has now spread to other 
Enterobacteriaceae. It has been isolated in many countries around the world 
including the UK. Infections with NDM-1 are problematic to treat, as bacteria 
harbouring this type o f p-lactamase are resistant to all antimicrobial agents except 
the polymyxins i.e. colistin (Yong et al., 2009, Moellering, 2010, Kumarasamy et al., 
2010).
As well as analysing the susceptibility o f currently administered antibiotics, the 
susceptibility o f temocillin and tigecycline were also evaluated. Temocillin and 
tigecycline have been shown to have an improved stability to ESBL and AmpC- 
producing Enterobacteriaceae. In this study, using BSAC MIC breakpoints, 
temocillin was effective against 98% of all isolates and tigecycline was effective 
against 89% of all isolates tested. However, despite temocillin being 98% effective, 
the most active antibiotics tested in this study were the carbapenems. All isolates 
were 100% susceptible except for ertapenem, for which 1% of isolates were 
resistant.
With the molecular epidemiology o f ESBLs established, the laboratory detection of 
ESBLs could be evaluated. As well as utilising commercial and automated ESBL 
and AmpC detection methods, improvements to the current detection system could 
be suggested. Currently, ESBL detection in the laboratory involves a two-step
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procedure whereby Enterobacteriaceae are firstly screened for ESBL production and 
then confirmed as ESBL producers. BSAC recommends that cefpodoxime is used as 
an indicator of choice (BSAC, 2007, BSAC, 2009) as variable resistance to 
cefotaxime and ceftazidime are seen (Livermore and Brown, 2001). With regards to 
ESBL screening, the addition o f ceftazidime, as outlined in the HPA QSOP 51 
guidelines, would be advisable to achieve a greater sensitivity. As for ESBL 
confirmation, cefpodoxime is also the indicator cephalosporin of choice stipulated by 
BSAC. However, in this study cefpodoxime had a sensitivity o f 96% for the 
confirmation of ESBL in molecularly confirmed isolates. The addition o f cefotaxime 
or ceftazidime would increase the sensitivity of the Synergy Test to 98%. A 
combination of all three cephalosporin discs would achieve a sensitivity of 99%. 
However, the laboratory detection o f ESBL can often be problematic due to the 
presence o f AmpC enzymes. In this study, one C. freundii isolate was found to 
possess TEM-116 and an ampC gene. Unfortunately, the isolate was negative to all 
phenotypic ESBL tests and would have therefore been overlooked in the clinical 
setting.
A commercial AmpC and ESBL detection kit (Mast® AmpC and ESBL Detection 
Set) was shown to be 98% sensitive overall and proved to be an adequate detection 
system for AmpC with a sensitivity of 100%. However, an increased number of 
ESBL and AmpC producing Enterobacteriaceae would need to be evaluated. As for 
the use of automated systems to detect ESBL in E. coli and Klebsiella spp., the BD 
Phoenix™ Automated System was found to have 99% sensitivity.
Another aim in this study was to investigate the use of the BD Phoenix automated 
system and Bruker Daltonics MALDI Biotyper for bacterial identification. In order 
to improve patient care, the need for a rapid and accurate identification o f bacteria is 
essential (Carbonnelle et al., 2011, Seng et al., 2009). Typically within the clinical 
laboratory, bacteria are identified using conventional phenotypic methods such as 
growth on various media, colony morphology, Gram stain and other biochemical 
tests. Using these methods, bacterial identification can take between 24 and 36 hours 
(Cherkaoui et al., 2010) therefore the correct treatment o f patients by empirical 
antibiotic therapy can be delayed (Seng et al., 2009). Using these two systems, a
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concordance of 97% was noted. However, the length of time to identify bacteria 
using the BD Phoenix automated system is significantly longer than the Bruker 
Daltonics MALDI Biotyper. The Bruker Daltonics MALDI Biotyper is a rapid 
identification tool capable of identifying a bacterial isolate in minutes (90 minutes to 
2 hours to complete a 96 well plate) as opposed to approximately 16 hours. 
However, the BD Phoenix automated system has the added capability o f producing 
MIC information, which allows the BD Xpert system to deduce ESBL production.
The final aim in this study was to investigate whether ESBL-producing E. coli 
isolates had a greater likelihood o f forming biofilms. Bacterial conjugation is a 
mechanism by which genetic information can spread and gene transfers often occur 
in biofilms, as their complex network o f communities is ideally suited to the role 
(Hausner and Wuertz, 1999). Wang et al., (2004) identified a gene locus in E. coli 
known as pgaABCD. This locus, which can be horizontally transferred, was found to 
be associated with the promotion of surface binding and intercellular adhesion 
through the production o f poly-p-1, 6-N-acetyl-D-glucosamine (PGA) (Wang et al., 
2004). As shown in Chapter 8, all ESBL and AmpC-producing E. coli isolates 
possessed the pgaABCD gene locus but not all produced a phenotypic biofilm. Aside 
from growth conditions and surface determinants, another explanation to postulate 
why isolates possess the pgaABCD locus but not produce a phenotypic biofilm could 
be due to a link between pgaABCD and CsrA. pgaABCD expression can be repressed 
by CsrA (carbon storage regulator) (Wang et al., 2005). CsrA is a RNA binding 
protein that negatively regulates several metabolic pathways e.g. glycogen 
biosynthesis, gluconeogenesis, and glycogen catabolism (Liu and Romeo, 1997). 
CsrA also serves as an activator o f biofilm dispersal under certain conditions 
(Jackson et al., 2002).
In summary, this study contributes to an understanding o f the molecular 
epidemiology and prevalence o f ESBLs in Enterobacteriaceae isolated within the 
ABM Bro Morgannwg University Health Board. The results were comparable to the 
current UK epidemiology whereby CTX-M group 1, particularly CTX-M-15 were 
the most prevalent. Clonail relationships were observed between E. coli isolates in 
this study, UK epidemic E. coli strain A and subsequently the international clone, 
025b-ST131. With changes in molecular epidemiology and the emergence o f new
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enzyme types, it is vital that continuous monitoring o f current detection methods and 
antibiotics sensitivity is undertaken to avoid the misidentification o f ESBLs and 
therefore, the use o f ineffective agents to treat patients.
10.2 Future work
In order to further to support and further the findings o f this thesis a number of 
experiements could be carried out. As illustrated in Chapter 3, a number o f isolates 
which were phenotypically ESBL positive were found to be molecularly ESBL 
negative using TEM, SHV and CTX-M primers. This finding was attributed to the 
possibility o f rarer/atypical or even novel ESBL genes being present. In order to 
investigate this further, primers specific for other ESBL genotypes could be used. 
Additionally, the use of isoelectric focusing (IEF) could be used to provide 
information on isoelectric point values and inhibitor profiles in order to characterise 
the p-lactamase enzyme present (Wiegand et al., 2007).
A second collection o f Enterobacteriaceae isolates could be be collected and 
screened for ESBL and carbapenemase production in order for the molecular 
epidemiology at two different timepoints to be compared. The presence o f ST131 
and clonal relatedness could also be investigated. This would be a relevant study as 
the National electronic Library for Medicines (NeLM) announced in February 2012 
that the Department of Health was making £500,000 available for further research 
into ESBLs (http://www.nelm.nhs.uk/en/NeLM-Area/News/2012—
February/09/Department-of-Health-announces-funding-for-new-research-into- 
antibiotic-resistance-bacteria-/).
Another theme that could be investigated further would be the potential o f using 
MALDI-TOF/MS to deduce the clonal relatedness o f 025b-ST131 isolates. At the 
time of writing, only one study investigating this could be found. Using MALDI 
biotyper software, Kmet et al. (2011) identified that ST131 positive E. coli isolates 
obtained from humans were unrelated to 2 related ST131 positive E. coli isolates 
originating from poultry (n=l) and calf (n=l). The use o f MALDI-TOF/MS would 
detect the relatedness o f epidemiologically relevant rapidly.
In this thesis, biofilm formation in ESBL-producing E. coli was investigated. E. coli
obtained from cow endometrium was used as a non-human control population. A
231
large number of these isolates were found to be positive for the pgaABCD  locus and 
a number also expressed a phenotypic biofilm in vitro. However, from the box-plot 
featured in Chapter 8 Figure 8.7, it can be noted that a range o f absorbance readings 
were obtained. The isolates could be ranked into groups based on absorbance 
readings so that a correlation could be investigated between biofilm production and 
severity of disease to determine how severe the original disease was. This would 
provide information on whether the more adherent isolates i.e. those with a higher 
absorbance reading were associated with more severe infection in the cow 
endometrium. Additionally, epithelial cells could be grown and E. coli (with a range 
of different absorbance readings) could be applied to each cell culture to investigate 
invasiveness.
Experiments to investigate the virulence of the bovine isolates would also be an 
interesting future work perspective. Isolates could be exposed to monocytes and 
levels o f cytokine production could be measured. Karlsson et al. (2004) stimulated 
monocytes with E. coli isolates with or without human recombinant gamma 
interferon (rIFNY). Cytokines were determined by ELISA. It was revealed that 
increased levels of interleukin (IL)-12p70, IL-10, IL-6 and tumour necrosis factor 
(TNF) was measured in response to E. coli (Karlsson et al., 2004). Another study by 
Agace et al. (1993) exposed a urinary tract model and monocytes to E. coli. The 
urinary tract model expressed increased levels o f IL-6, IL-la and IL-8, whereas, the 
monocytes expressed increased levels of IL-la, IL-ip, IL-6, IL-8 and TNFa (Agace 
et al., 1993).
In addition, the isolates could be also be exposed to neutrophils in order to study 
their ability to resist killing. Aarestrup et al. (1994) carried out this experiment in S. 
aureus isolates, which had been isolated from cows with mastitis. In their study, 
bacteria were grown overnight and cells were washed and resuspended to give a
Q
concentration o f 10 CFU before being opsonised and exposed to neutrophils. 
Bacteria killing by neutrophils was measured by a colorimetric assay (Aarestrup et 
al., 1994). However, the comparision of CFU before and after exposure to 
neutrophils could be a simpler approach.
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